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Ab tract 
The pre\ alen e of diab te mel l itu 
\'1 
. . 
mcreasmg at an alarming rate 
\\ orldwide. Cardiova cular ( ) di ease i the major cause of morbidity and 
mortal ity in diabet ic patients. The search for new treatments has led to developing 
altemative in ul in-independent treatment trategies such as sodium/glucose co-
tran pOIier ( GLT) inhibitor . Inhibition of intestinal SGLTI impairs dietary glucose 
ab orption, w hi le  inhibition of renal GLT2 promotes glucose excretion leading to 
calori loss and improved glycemic contro l .  In this study, we hypothesized that 
i nhibiting cardiac GL T may alter Ca2+ mobi l i zation in myocytes. The effects of 
Phlorizin ( PHLOR) (non-selecti e SG LT I and 2 inhibitor), Quercetin-3 -0-g1ucoside 
(Q ER-3-G) ( selective SGLT I inhibitor), Dapagliflozin ( DAPA) ( selective GLT2 
inhibitor) on ventricular myocyte shortening and intracel lular Ca2+ have been 
investigated in streptozotocin ( STZ)-induced diabetic rats and age-matched Controls. 
Experiments were performed at 3S -36°C after 2 months of STZ treatment. Myocyte 
shortening, intracel lu lar Ca2+ and L-type Ca2+ current were measured by video edge 
detection in electrical ly-stimulated ( 1  Hz) myocytes, by fluorescence photometry in 
Fura-2 loaded myocytes and by whole-ce l l  patch c lamp, respectively before and after 
a 5 minute appl ication of the SGLT i nhibitor ( 1 0.6 M) tested. The ampli tude (AMP) of 
shortenin g  was significantly (P<O.OS) reduced by PHLOR in STZ ( 84. 76±2.9 1 %, 
n=20)  myocytes and Controls ( 83 .72±2 .6S%, n=23), by QUER-3-G in STZ 
( 79 . 1 2±2 .28%, n=20) myocytes and Controls ( 76 .69± 1 .92%, n=30) and by DAPA in 
STZ ( 76 .S8± 1 .89%, n=42) myocytes and Controls ( 76.68±2.28%, 17=3 7) .  The AMP 
of the Ca:2+ transient was significantly reduced by PHLOR in STZ ( 82 . 37±3 . l 6%, 
\'11 
n= 1 6) myocyte and Control (73 .94±5 .22%, n=2 1 ) and by QUER-3-G in TZ 
(73 .62±5. 83%. 17= 1 8 ) myocyte and Controls (78 .32±3 .54%, n=4 1 ). DAPA reduced 
the MP of the Ca2.,.. tran ient ignificantly in TZ (7] .45±5.35%. 11= 1 6) myocytes 
and mode tly in Controls (92.0]±2.72%, n= 1 7) .  The AMP of L-type Ca2+ current was 
ignificantl. reduced in myocytes from TZ compared to Control rats across a range 
of test potent ial and was additional ly reduced by DAP A. Myofilament sensitivity to 
Ca:!+ and R a2+ were not significantly altered by PHLOR, QUER-3 -G or DAPA. 
The reduction in L-type Ca2+ current in the presence of DAPA may partly underlie its 
negat ive i notropic effects. However, fmther studies are required to i nvest igate the 
mechanism(s)  behind the negati e inotropic effects of PH LOR and QUER-3-G. 
Keywords :  Diabetes mel l i tu ; SGLT inhibitors; Phlorizin; Quercetin-3 -0-glucoside; 
Dapagl i flozin; Ventricular myocytes 
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Chapter 1 :  I ntroduction 
1 . 1 .  D iabete Mel l i tu  
Diabete Mell i tus ( DM)  is a chronic progressIve metabolic disease 
characterized by impaired metaboli m of carbohydrate, fat and protein accompanied 
by persi tent hyperglycemia due to ab olute or relative deficiency of insul in secretion 
and/or decrea ed sensiti i ty to insul in effect [ 1 0] .  Several acute and chronic 
complication affect a variet of organs including the eyes, nerves, kidneys and the 
cardio\'ascular (CV) system, by damage, fai lure or dysfunction owing to chronic 
expo ure to hyperglycemia [ 1 0; 43 ] . 
1 . 1 . 1 .  Types and Classification o f  Diabetes Mel l i tus  
Despite the fact that DM is  commonly c lassified into two etiopathogenic 
type ; type 1 diabete mell itus ( T I DM) and type 2 diabetes mel l i tus (T2DM). this 
c lassification does not accurately reflect the range of DM [284 ] .  Besides, categorizing 
the type of D M  for some patients i s  not always simple [ 1 0] .  Therefore, thi s 
c lassification has been expanded into further subdivisions based on pathogenesis ( Fig. 




Figure 1 - 1 : Classification of diabetes mel l i tus 
T 1 D M :  type 1 diabetes mel l i tus; T2 DM:  type 2 diabetes mel l i tus; T 1 AD M :  type l A  
diabetes mel l itus; T 1 B D M :  type 1 B diabetes mel l i tus; DD:  double diabetes; LADY: 
latent autoimmune diabetes in the young; LA DA: latent autoimm une diabetes in 
adults MODY:  maturjty onset diabetes of the young 
1 . 1 . 1 . 1 .  Type 1 Diabetes Mel l i tus 
A. Au toim mune Diabetes M el l itus  
A. 1 .  Type 1 A  Diabetes Mel l i tus  
I t  i s  bel ieved that type 1 A diabetes mell i tus ( T l  ADM) occurs due to exposure 
of genetical ly  susceptible individuals to an environmental trigger resulting in the 
development of humoral autoimmuillty over a period of months or years [ 1 38 ] .  T-
3 
l ; mphoc;1e-mediated autoimmune responses destroy the pancreatic �-cel ls  [290] . 
The rate of �-cell de truction d iffer according to age. It is fast in infants and chi ldren 
and it i low in adult [ 1 0] .  utoimmune destruction can be detected b y  the presence 
of auto-antibodie to �-cel l - pecific antigens uch as insul in  and proinsul in ,  and 
n uro ndocrine antigens uch as glutamjc acid decarboxylase 65 (GAD65 ) and 
insul inoma-associated protein-2 ( IA-2 ) [ 1 3 8 ] .  
The detection of  auto-antibodies can be done years before the disease i s  
c l inical ly diagno ed  as  shown in F igure 1 -2 [ 1 02 ] .  The late stage is  characterized by 
the presence of hypoinsul inemia, which is indicated by low or undetectable C-
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Figu re 1 -2 :  Model showing the stages of development of type l A  diabetes mel l itus 
Adapted from [ 8 1 ;  1 02 ]  
4 
A.2.  Double Dia bete M el l i tu 
The term double diabetes (DD) imply refers to the presence of both T I DM 
and T2DM characteri tic in  the patient . Other names used to de cribe DD include 
hy brid diabetes and type 1 . 5 DM. It has tv 0 versions: latent autoimmune diabetes in 
the young ( LADY),  affecting chi ldren, and latent autoimmune diabetes in adults 
( LADA), affecting adults [225 ] .  
A.2 . 1 .  Latent Autoi m m une  Dia betes in  t h e  Young 
Chi ldren and youths affected are obese with insul in resistance ( as T2DM) and 
have p-cell specific auto-antibodies in their sera ( as T I DM) [225 ] .  
Reinehr and col leagues showed that 36% of  the chi ldren used in this study, 
who were diagnosed with T2DM, had p-cel l  specific auto-antibodies indicating that 
they have DD and were misdiagnosed with T2DM [230] . Another study also reported 
that 33% of the chi ldren were also misdiagnosed with T2DM due to the presence of 
auto-anti bodies [ 1 03 ] .  Although. auto-antibodies were detected i n  chi ldren 
previously diagnosed with T2DM. the did not need insul in  for more than a year 
[230] . I t  was also shown that. l ike LADA in adults some chi ldren original ly 
diagnosed with DD or i nit ia l ly misdiagnosed with T2DM switched from oral anti ­
d iabetic medications to insulin [ 1 03 ] .  The detection of single or more auto-antibodies 
including anti- insul in.  anti-GAD, ant i- IA-2 and is let cel l auto-antibodies ( lCA) 
indicates DD in  chi ldren [ 1 03 ] .  It is suggested that the progression of p-cel l 
destruction in  DD is  slower than that in  T I ADM which is  indicated by the detection 
of onl a ingle auto-antibody [225 ] .  Figur 1 -3 ho the number of detected t pe 
of auto-antibodi type in  T l  DM and DD. 
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Figu re 1 -3 :  The percentage of subjects diagnosed ith type 1 diabetes mell itus 
( T 1 DM) and double-diabetes ( DD)  according to the number of detected types of auto­
antibodies 
Adapted from [ 1 03 ]  
Subjects include chi ldren aged between 8- 1 8  years, from different ethnicities o f  the 
U nited States population, who were newly diagnosed with diabetes mell itus. 
A.2.2. Latent Autoi m m u n e  Diabetes in Adu lts  
LADA is  a slowly progressive autoimm une disease [92] . During the early 
stages of the d isease, patients with LADA are often misdiagnosed with T2DM 
because they are not dependent on insul in  [92 ] .  Some studies also reported the 
presence of T2DM insulin resi stance in  LADA patients [63 ] ,  whi le others disagree 
[2 1 ] . However. LADA is characterized by the presence of auto-antibodies to insul in,  
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G D, IA-2 and other [ 92 J .  the disease progresse to  i t  late tage, the patients 
experienc weight 10 s, usceptibi l i t  to DKA, undetectable C-peptide levels and 
insul in dependence [ 209) .  
Diagno is  o f  L DA rel ies on three factors including the age o f  the patient 
(about � - -40 year ). pre ence of auto-ant ibodie with ant i-GAD and ICA being the 
1110 t common ant ibodies. and lack of insul in dependence for at least 6 months after 
diagno is [92; 209J . The treatment changes as the disease progresses st311ing with diet 
control. then oral anti -diabetic medications and eventual ly insul in [209) . 
B. I d iopathic Diabetes M el l i tus 
B. t .  Type I B  Diabetes M el l itus  
Being characterized as an idiopathic di sease, the actual pathogenesis is sti l l  
not c lear. I t  occurs due to p-ce l l  destruction resulting in hypoinsul inemia and DKA 
[ 1 0) .  This disease does not show any signs of autoimmuruty or genetic relation to 
human leukocyte antigen ( H LA) genes [ 1 0) .  I t  i s  bel ieved to be an inherited disease 
as it only affects specific races (Africans 311d Asians) [ 1 0) .  
B.2. Fulminant  Diabetes M el l itus  
This  is  an idiopath.ic rapidly progressmg DM that involves nearly total 
destruction of p-cel ls  and consequent ly absolute insul in deficiency, hyperglycemia 
and DKA [ 1 29J . It was first reported in  2000 in Japan [ 1 30) .  The population affected 
is mainly from east Asian countries l ike Japan, Korea, China, Taiw311, the Phi l ippines 
and Malaysia [28 1 J .  Cases were also reported in the Caucasian population in France 
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[202] and the Hispanic population in the United tate [ 1 92 ) .  I t also affects pregnant 
\\ omen, e pec iall in the third trime ter or right after del ivery [ 1 1 7) .  Unl ike the 
autoimmune DM where progre ion take year , fulminant DM progression only 
take a fe\\ da s and in rare cases ma exceed one week ( Fig. 1 -4 )  [ 1 1 7) .  
The c l inical featmes o f  fulminant D M  include the abrupt onset of 
hypergl cemia accompanied by weight loss, polyuria and polydipsia, rapid 
development of DKA (one \ eek after the onset of symptoms), almost nonnal levels 
of glycated (or gl cosylated) hemoglobin ( HbA lc) ,  undetectable or low C-peptide 
le\'els. ele\'ated levels of serum pancreatic enzyme ( such as amylase and l ipase) and 
usua l ly absence of auto-antibodies [ 1 29; 1 3 1 ) . However it was reported that some 
patients diagnosed with fulminant DM were positive for ant i-GAD but none were 
positi\'e for anti - IA-2 [ 1 3 1 ] . Flu- l ike symptoms such as rhinorrhea, fever, sore throat 
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Figure 1 -4 :  Duration of �-cel l  mass destruction in fulminant diabetes mel l i tus versus 
autoimmune diabetes mel l itus 
Retrieved from [ 1 1 7] 
Pathogenesis i s  belie ed to be viral-mediated owing to the abrupt onset of the 
disease and the presence of flu- l ike symptoms [ 1 27 ] .  A study reported high ti ters of 
immunoglobulin A antibodies to enterovirus in the sera of fulminant diabetics 
suggesting recurrence of enterovi rus infection and high susceptibi l ity of these patients 
to this v irus [ 1 27 ] .  Moreover. other studies showed a relat ionship between the disease 
and some genetic  factors such as disease-susceptible H LA alleles [ 1 28 ;  1 54;  28 1 ] . 
A lthough it is c lassified as an idiopathic type of DM, some studies reported evidence 
for the i nvolvement of autoimmunity in the pathogenesis of this disease [ 1 67; 208 ] .  
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1 . 1 . 1 .2 .  Type 2 Dia bete M el l i tus 
About 90-95% of diabetic pat ient ha e thi type of DM v;hich makes i t  the 
mo t c mmon type of DM [ 1 0] .  Unl ike T I DM. T2DM is characterized by relative 
in ul in deficiency that is ometimes accompanied b in u l in re istance [ 1 0] .  
Therefore. patient with T2DM are not insul in dependent. and rarely develop DKA 
[ 1 0] .  There are ri k factors for T2DM. however, its exact etiology is sti l l  unclear 
[ 1 " 2 ] .  The ri k factors include en  ironmental factors such a s  obesity or increased 
percentage of body fat especial ly abdominal fat, low physical inact ivity and increased 
age, and genet ic factors uch as etlu1ici ty and fami ly hi story [ 1 0; 1 32 ] .  
1 . 1 . 1 .3. Monogen ic Diabetes M el l i tus 
This occur as a result of spontaneous de no 0 mutation(s) or the inheritance 
of dominant or recessive mutation(s) in one single gene ( thus, cal led monogenic )  
which is i nvolved i n  maintaining glucose homeostasis [254] .  Monogenic DM arises 
as a result of reduced �-cell functions or number, pancreatic transcription factors or 
insu l in  receptor sensitivity, depending on the gene involved [254] . Mutations 
affecting �-cel l  functions or number lead to defects in glucose sensing. or insul in 
synthesis. packaging or secretion [254 ] .  Mutations affecting pancreatic transcription 
factors can also impair insul in synthesis, reduce pancreatic growth or cause agenesis 
[254] . Moreover, mutations affecting T-lymphocytes result in  the generation of an 
autoimmune response against �-cel l s  [254] . Since mutations can lead to the 
development of an autoimmune response. as wel l  as, insul in sensitivity and 
resi stance, monogenic  DM can be neither c lassified under T 1 DM nor T2DM . 
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Monogenic  DM can be further c la sified to neonatal DM, maturity onset 
diabete of the yOWlg ( MODy) and mitochondrial DM [ 1 1 8 ] (Fig. 1 - 1 ) . eonatal DM 
i general ly defined as insulin-dependent hyperglycemia. It occurs during the first 
three month of age [68] and it has been extended to include six to nine months of age 
[238 ] .  Insul in secretion mutations are more commonly the cause of neonatal DM 
compared to insul in en it ivi ty mutations [238 ] .  MODY has been initial ly  
characterized by  three cri teria which include being considered as  non-insul in 
dependent DM, affecting indi idual s below 25 years of age and showing autosomal 
dominant inheritance [99] . However, nowadays identifying MODY is based on its 
genetic etiology which clearly dist inguishes between d ifferent genetic subgroups and 
d ifferentiates i t  from T2DM in young individuals [68 ] .  So far, mutations of nine 
genes have been found to produce different genetic subgroups of MODY ( MODY l ­
MODY9) [99] . Mitochondrial DM involves the transmission of mutated 
mitochondrial deoxyribonucleic acid C D  A)  from the mother t o  the fetus resulting i n  
development o f  non-autoimmune �-cell dysfunction [68 ] .  Organs having a high 
energy requirement, such as the brain,  pancreatic  �-cel l s, sensory organs and skeletal 
musc le, can also be impaired resulting in  various syndromes such as deafness [68;  
1 1 8 ]  . 
Molecular studies involving genetic testing provide a highly sensitive and 
specific diagnostic  tool for monogenic DM [238] . However, they are not widely 
appl icable owing to the high cost and long time consumption [238] . 
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1 . 1 . 1 .4 .  G e  tat ional  Diabete M el l i tu 
Ge tational DM i the type of DM or gluco e intolerance that i diagnosed for 
the first t ime during pregnanc (ge tation) [ 1 0] .  Gestational DM occurs 
approximately at the 24th week of pregnancy where insul in resistance contributes to 
it OCCUlT nce [ 1 32 ] .  ince the h perglycemia can badl affect the health of  the 
mother and fetus/neonate. diagnosis of DM by plasma glucose tests (See diagnosi s 
section) hould be done at the 24_28th weeks of pregnancy.  Fortunately. the 
hyperglycemia is u ual ly  reversed after deliver [ 1 0] .  
1 . 1 . 1 .5. Secondary Diabete M el l i tus  
Secondary DM is  a d isease that develops as a result of secondary factors such 
as pancreatic disea e. autoimmune diseases. infections. genet ic syndromes. drugs or 
chemicals [ 1 0 : 305 ] .  Impairment of either the exocrine or endocrine functions of the 
pancreas can cause DM. Exocrine dysfunction can result from pancreatit is. cancer, 
trauma/pancreatectomy and cyst ic fibrosis. however these factors, excluding cancer. 
must cau e greatl y  pronounced pancreatic damage before DM can develop [305 ] .  On 
the other hand. endocrine dysfunction may result from endocrine diseases such as 
Cushing' s Syndrome, glucagonoma, acromegaly, hyperthyroidism and 
pheochromocytoma. that involve the secretion of insulin-antagonizing hormones 
including cortisoL glucagon, growth hormone, thyroid hom10ne and catecholan1ines 
[305 ] .  In addition. autoimmune diseases such as lupus erythematosus and sti ff-man 
syndrome can cause the generation of auto-antibodies against insulin receptors [ 1 0J .  
V iral infections such as congenital rubel la and cytomegalovirus can also lead to DM. 
Moreo\ r. admini tration of orne drug such as nicotinic acid, thiazide and �­
adrenergic agoni t . or hormones such as glucocorticoid and th roid hormone can 
di turb in ul in function and induce DM [ 1 0] .  Patients with genet ic syndromes such as 
Down yndrome. Kl inefelter S ndrome and Twner yndrome ha e a high 
susceptibi l ity to DM and tho e with Wolfram Syndrome have no �-cel ls  and 
con equent ly i nsulin defic ienc [ 1 0] .  
1 . 1 .2.  Diagno i o f  Diabetes Mel l i tus  
It i estimated that about 46% of the patients with DM worldwide are 
undiagnosed and unaware of being diabetic [ 1 32 ] .  Since DM is a progressive di sease 
that can cause development of serious compl ications if left uncontrol led. a correct 
diagnosis is crucial . 
DM has wel l -established c l inical symptoms including polyuria. polydipsia, 
polyphagia, fat igue. unexplained weight loss, b lurred vi sion, slow heal ing of wounds, 
and h igher susceptabi l i ty to infection [ 1 3 3 ] .  eve11heless, some diabetic patients can 
be asymptomatic [ 1 33 ] .  Therefore. d iagnosis does not solely rely  on the existance of 
symptoms, rather there are tests for measuring plasma glucose levels as an indication 
for the presence of DM. Table 1 - 1  shows the latest updated diagnostic criteria used 
for D M  according to the World Health Organization (WHO) and American Diabetes 
Association (ADA). 
H bA1c  ( % )  
Fast ing  p ia  rna 
gl uco e 
( rn m ol/l)  
75 g OGTT 
post-load 
plasma gluco e 
( m m olll ) 
Ra ndom 
gl uco e 
( m mol/l ) 
1 3  
Diabetes IFG IGT Prediabetic 
(WHO and (WHO)* (WHO) * (ADA) * 
ADA)* 
� 6 .5% § A NA � 5 .7% to 6.4% 
� 7.0 � 6. 1 to 6.9 < 7.0 � 5 .6 to 6.9 
(� 1 26 mg/d l )  § (� 1 1 0 mg/d l to « 1 26 mg/dl )  (� 1 00 mg/d l to 1 25 
1 25 mg/d l )  mg/d l )  
211. � 1 1 . 1  2h, < 7 . 8  2 h .  � 7 .8  t o  J 1 .0 2 h � 7 .8  to 1 1 .0 
(� 200 mg/d l )  § « 1 40 mg/d l )  ( �  1 40 mg/d l to ( �  1 40 mg/dl to 
1 99 mg/d J )  1 99 mg/d l )  
� I l . l  A N A  N A  
( �  2 0 0  m g/d l )  
" i t h  c lassic 
s mptoms 
Table 1 - 1 : Diagno tic criteria of diabetes mel l i tus 
Adapted from [2 1 2 : 306] 
W HO: World Health Organization; ADA:  American Diabetes Association: I FG :  
impaired fasting glucose: I GT: impaired glucose tolerance; H bA 1 c :  glycated 
haemoglobin A l e; NA: not appl icable;  OGTT: oral glucose tolerance test 
* WHO and ADA ha e identical diagnostic criteria for diabetes, whi le they have 
different terms and approaches in defining and diagnosing intermediate 
hypergl caemia or prediabetes .  
§ If  the results are equivocaL retesting should be done for confirmation. 
The diagnosis of DM should be done using venous plasma as a universal 
standard. It has been stated that venous and capi l l ary samples are identical when 
measuring fasting plasma glucose (FPG).  however, capi l lary samples gives higher 
non-fasting glucose levels compared to venous ones [306] .  In  addition, glucose levels 
should be measured in  plasma separated from blood samples rather than the whole 
blood because approximately 1 1  % higher glucose is  measured in  plasma samples than 
that in whole b lood samples [306] . 
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Impai red fasting glucose ( l FG )  and impaired gluco e tolerance ( IGT) have the 
an1e definition. They represent the region that l ies between the upper borderl ine of 
normal gluco e and the lower borderl ine of diabetic glucose in the fasting and fed 
tate . respectively [ 1 32 ;  306] . I f  a pati nt was diagnosed with I FG, this indicates 
impaired in ul in ecret ion and impaired inhibition of hepatic glycolysis and 
gluconeogen is [306) . IGT provides e idence for an increa ed risk of developing 
DM, howeyer. not al l i nvdividuals with IGT wi l l  develop DM [306) . If IGT is 
detected, this indicates impaired insul in secret ion and the presence of insul in 
resi tance. Both IFG and IGT provide a predict ive measure for DM development 
[306 ] .  
Mea  uring HbA 1 c  gives an  indication of the average plasma glucose levels 
during the past 2-3 months ( 8- 1 2  weeks) [307] . HbA [ c  i s  considered as the gold 
standard for monitoring glycemic control during treatment of diabetic patients [ 306) . 
At least 3 days before the test, the patient should eat nonnally (an unrestricted 
carbohydrate diet that involves ingesting above 1 50 g carbohydrate) and maintain his  
usual ph sical activity [305 ) .  FPG involves measuring the plasma gl ucose level after 
fasting overnight for 8- 1 4  hours where drink ing is pennitted [305] . Then, oral glucose 
tolerance test ( OGTT) requires ingestion of 75 g of anhydrous glucose (or any 
equivalent carhohydrate content) dissolved in 250-300 ml of water, where blood 
glucose is measured after 2 hours from the beginning of the glucose drink [305 ] ,  or at 
30 m inute interval s for 2 hours. Random (casua l )  glucose involves measuring plasma 
glucose at any time of the day regardless the t ime of the last meal [68) .  
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In  2009. diagnosis u ing the HbA le  test wa recommended by the ADA, the 
International Diabet Federation ( IDF) ,  and the European ssociation for the tudy 
of Diabete ( EA D) [ 1 1 ] . Hb Ie overcomes many disad antages of FPG and OGTT 
becau e it is more convenient for the patient a it does not require fasting or any prior 
dietr) preparation and it avoid the problem of day-to-day fluctauations of blood 
glucose levels ( BGL)  as a result of i l lness or stre s [ 1 1 ;  307] .  On the other hand, 
HbAl c ha ome disadvantage inc luding high cost. unavailabi l ty in  some developing 
countrie , lack of standardization in some countries and variation among races and 
ethnicit ies ( i t is higher in African-American ) [ 1 1 ;  307] . In addition, it is influnenced 
by everal factors such as genet ic background and i l lness especial ly 
hemoglobinopathies such as certain anemias and malaria [307] . I f  a patient was 
shown to be diabetic according to the diagnostic results, the patient should confirm 
the e results by repeat ing the test [ 1 1 ] . This is appl icable especial ly  for asymptomatic 
patients but not appl icable for patients with D KA (hyperglycemic crisis) or random 
plasma glucose exceeding 200mg/d l .  accompanying the known DM symptoms [ 1 1 ;  
307] .  Using the same test i s  recommended for a higher chance of consistent results 
[ 1 1 ] . Two d ifferent diagnostic tests ( such as HbA l e and FBG) can also be used in 
v,hich the diagnosis of DM is  confirmed if the results from both tests are above the 
diagnostic threshold. I f  one test only was above the threshold whi le the other was 
below it, the test above the threshold should be repeated [ 1 1 ] . 
After DM is  confirmed in  a patient, f1ll1her tests and fol low-ups should be 
perfonned to identify the type of DM.  A simple schematic diagram on identification 
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Figure 1 -5 :  Simple schematic  diagram for identifying the type of diabetes mell itus 
T I ADM: type l A  diabetes mel l itus· T I BDM : type I B  diabetes mell itus; DD:  
double-diabetes; T2DM: type 2 diabetes mell itus 
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1 . 1 .3. Epidemiology of Dia bete Mel l i tu  
1 . 1 .3. 1 .  Preva lence 
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DM i one of the non-communicable diseases which poses a global threat 
[308 ] .  Worldwide, DM affected about 328 mi l l ion individuals in 20 1 3  and this is 
expected to increase b. 55% to reach 592 mi l l ion in 203 5 ( Fig. 1 -6) [ 1 32 ] .  In the 
Middle Ea t and orth Africa (ME ) region ( Fig. 1 -6), t o  which the Uni ted Arab 
Emirates (UAE) belongs. there are about 35 mi l l ion diabetic patients [ 1 32 ] .  The UAE 
was reported in  10 1 3  to have one of the highest age-standardized comparative 
prevalences ( 1 8 .98%) worldvride and a global comparative prevalence of 8 .3%, with 
Abu-Dhabi having the most elevated rates of DM among the other emirates [ 37 ] .  The 
prevalence of IGT in the UAE was also ranked among the top ten worldwide reachi ng 
1 6.6°,0 ( 3
rd) in  .:..0 1 3  and is  expected to rise to 1 7 .0% (4th ) by 2035 [ 1 32 ] .  Among the 
UAE population in 2005, the prevalence was reported to be 25% below the age of 55 
year and 40% above i t  [ 1 90 ] .  Moreover. in 2007, a study in the UAE national 
citizens in AI-Am, Abu Dhabi reported a prevalence of 1 0 .5% for diagnosed diabetic 
patients, 6.6% for undiagnosed diabetic patients and 20.2% for pre-diabetic patients 
[239] . 
1 . 1 .3 .2 .  Regional  Va riat ion 
According to the regional c lassification of the I DF ( Fig. 1 -6 ), the ME A 
region has the highest prevalence ( 1 0.9%) among other world regions [ 1 32 ] .  The 
orth America and Caribbean region has the second highest (9 .6%) prevalence 
fol lowed by the South and Central America region ( 8 .2%) [ 1 32 ] .  When comparing 
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urban and rural regIons. it ha been shown that urban populations ha e a higher 
pre\alence of DM than rural populations [ 1 32 ] .  
Figu re 1 -6 :  The world regional c lassification of  the Intemational Diabetes Federation 
howing the number of diabetic population in each region 
Retrie\ed from [ 1 32]  
1 . 1 .3.3. Age a t  Onset 
As mentioned earl ier, DM can develop at any age from birth in  neonates unti l  
senescence in  adults. The age range to  which 50% of adult diabetic patients belong i s  
from 40 to  59 years [ 1 32 ] .  Several studies showed a significant increase in  the 
incidence of T I DM in chi ldren with age [ 1 50;  275 ] .  Simi larly in  T2DM. there was a 
positi\e correlation between the prevalence of DM and age in Asian and European 
populations, but it was more pronounced in the Asian population [273 ; 274] .  
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1 . 1 .3.4. Male-to- Female Variat ion 
General l . there are more diabetic males than female worldwide, with a total 
d ifferenc of 1 .+  mi l l ion [ 1 32 ] .  In chi ldren aged from 0- 1 4  ears. the incidence of 
T I D  1 \va not shO\\11 to be different between males and females [275] .  I t was shown 
previou Iy that ethnicitie at high risk of T I DM incidence such as Caucasians 
( represented by Europeans) have a higher male-to-female ratio, while ethn icities at 
low ri k uch as African and A ians have higher female-to-male ratios [ 1 50] .  Two 
large studies on T2DM prevalence in Asian and European populations showed a 
higher prevalence of I FG in males from China. Japan and Europe and in females from 
India. There was a higher prevalence of I GT in females from China, Japan and 
Europe and in male from I ndia [273 ;  274 ] .  Undiagnosed DM was more common in 
A ian females and European males [273 ;  274 ] .  T2DM affects females more than 
males in the United States population and the same was seen among chi ldren with 
T2DM [8 ] .  
The global d ifference i n  DM-causing mortal i ty between males and females i s  
very l ittle [ 1 32 ] . But i f  each region is  considered individual ly there are differences 
seen in a l l  the world regions. except for M ENA and Western Pacific regions, in which 
diabetic females have h igher mortal i ty rates than males [ 1 32] . 
1 . 1 .3.5. Associat ion w it h  Pregnancy 
During pregnancy, women are prone to two types of DM:  fulminant DM and 
gestational DM.  Fulminant DM was recently  discovered in Japan and it is not specific 
to pregnant women as i t  can also affect males and non-pregnant females [ 1 30] . I t  can 
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affect pregnant women during the third trimester or after delivery leading to a poor 
progno is for the fetu [ 1  1 7] .  
About 2 1 .4 mi l l ion \: om n had ge tational DM in 20 1 3  [ 1 32 ] .  As the age of a 
pregnant \" oman inc rea es. he ha a higher chance of getting gestational DM 
reaching i t  highest chance at the age of 45 ears [ 1 32 ] .  
1 . 1 04.  Pathophy iology of Diabetes Mel J i tus 
In  order to ful ly understand the pathophysiology of DM it  is impOliant to 
understand normal glucose homeostasis  ( Fig. 1 -7 ) .  During fasting, there is 
simultaneou endogenous glucose production and glucose ut i l ization [2 1 2] .  
Endogenous glucose production i s  carried out by the l iver via glycogenolysis and 
gluconeogenesis. whereas its uti l ization is done by insul in-independent t issues l ike 
the brain. Endogenous glucose production via glycogenolysis and gluconeogenesis is 
carried out by the l iver ( 85%) and k idneys ( 1 5%) to match basal glucose ut i l ization (:::::: 
2 .0 mglkg/min)  [ 73 ] .  The endogenous glucose produced is  then mainly uti l ized by 
insul in-independent t issues including the brain ( 50%). and l iver and gastrointestinal 
t issues (cal led splanchnic area) (25%) which are solely dependent on glucose, unl ike 
insul in-sensit ive t issues (25%) such as the heart, skeletal muscles and adipose tissue 
which can make use of other energy sources rather than glucose such as non­
esterified fatty acids produced via adipose tissue l ipolysis [73 ;  2 1 2] .  The interaction 
between these two processes prevents hypoglycemia during fasting [2 1 2 ] . On the 
other hand after carbohydrate intake ( fed state ), dietary glucose is absorbed in the 
smal l  intestine by the b loodstream thereby rai sing the BGL [2 1 2] .  Elevated BGL 
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induce p-cel l  to ecrete in ul in and inhibits a-cel ls from ecreting glucagon [2 1 2] .  
Glucagon-l ike peptide 1 (GLP 1 )  amplifies the effects of the elevated BGL on insul in 
ecret ion and gl ucagon suppres ion [2 1 2 ] .  The secreted insul in then works on 
decreasing the BGL via three proce ses incl uding promotion of glucose uptake in 
insul in- en it i\'e ti ue (heart, skeletal musc les and ad ipose tissue) and in splanchnic 
area . inhibition of endogenous glucose production by hepatocytes and i nh ibition of 
adipo e tissue l ipolysis [ 73 :  2 1 2] .  Decrea ing postprandial BGL usual ly  takes about 2 
hour to reach fasting levels [2 1 2 ] .  The uptake of dietary glucose in insul in-sensitive 
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Figu re 1 -7 :  ormal glucose homeostasis in  fasting ( upper pane l )  and fed ( lower 
panel )  states 
Retrieved from [2 1 2] 
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The pathophysiology of T I DM is  characterized by complete insul in  
deficiency and consequent hyperglycemia and DKA. Deficiency of insul in secretion 
leads to a disturbance in  the secretion of other hormones such as lept in  whose 
secretion, from adipose t issue, is reduced [ 1 98 ] .  Glucagon secretion, which is  
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n rmal ly control led b) in  ul in and leptin, i s  then increa ed [ 1 98 ] .  I t  has been hown 
recently that leptin deficiency, in diabetic rat , increases the pituitar gland secretion 
of adrenoc rt icotrpin homl0ne ( CTH) [ 1 98 ] .  ACTH increases the adrenal gland 
ecretion of corticosterone which lead to increasing l ipolysis, and production of free 
fatty acids ( FF ) and glycerol from triglycerides [ 1 98 ] .  Glycerol and FF A are then 
carried by the b loodstream to the l iver where they are con erted to glucose and 
ketone bodies, respectively [ 1 98 ] .  Moreover, oxidation of FAA produces acetyl -CoA 
which leads to glucose production from pyruvate [ 1 98 ] .  Collectively, these events 
result in hyperglycemia and DKA [ 1 98 ] .  Figure 1 -8 shows the pathophysiology of 
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Figu re 1 -8 :  Pathophysiology of type 1 diabetes mel l itus 
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The pathophysiology of T2DM is  shown in Figure 1 -9. T2DM occurs due to 
lack of responsiveness of insu l in-sensit ive tissues to insul in  effects ( insul in 
resistance) resulting in �-ce l l  dysfunction [ 1 1 5 ; 1 45 ] .  Besides, i t  is  associated with 
accelerated production of endogenous glucose [262 ] .  A lack of response of target 
ti ue to in ulin. due to in ul in re i tance, dri es the �-ce l ls  to produce more insul in 
at early or intel111ediate tage of DM [ 1 45 :  262 ] .  Insulin resistance causes the �-ce l l  
to eventual ly  become irre pon ive to ele ated BGL [ 1 45 ] .  Moreo er, insul in 
re i tance el iminate insulin effect on target tissues including glucose uptake b 
in ul in-sen i t ive ti sues (heart, skeletal mu c les and adipose t issue) and splanchnic 
area. inhib i t ing endogenous glucose production and inh ibi ting l ipolysis in adipose 
t i  ue [ 262 ] .  Thi result in the persistence of hyperglycemia and product ion of FF A 
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stated b. the I OF, " OM i the leading cause of CV di ease. bl indne s, 
kidney fai lure. and lov" er- l imb amputat ion" [ J  32 ] .  The persistent hyperglycemia of 
OM cau e damage to blood ve els, known as angiopathy. In small  blood essels, 
inc luding capi l larie , this result in ' micro ascular complications' and in large blood 
vessel , inc luding arterie and veins. this results in ' macrovascular complications' 
[39: 9 1 ] . The e compl ications are what make DM a dangerous progressive di sease as 
they repre ent the main cause of morbidity and mortal ity in al l  types of OM [93 ] .  
Microva cular complications affect the eyes ( retinopathy) ,  neurons (neuropathy) and 
kidneys ( nephropathy). while macrovascular compl ications affect the heart arteries 
(CV di ease) ,  brain arteries ( cerebrovascular disease) and peripheral arteries (Fig. l ­
I O) [9 L 93 ] .  The presence of more than one macrovascular compl ication can 
sometime be cal led polyvascular disease [22 1 ] . Moreover. persistent hyperglycemia 
can lead to other chronic complications such as depression, dementia. impaired oral 
health ( gingivit is and tooth loss). h igh suscept ibi l i ty to infection, sleep apnea and 
sexual dysfunction [9 1 :  1 32 ] .  
Eye ( t'etinopathy) ----!. 
Oral health ----­
(ginghitis & tooth los ) 
Heart and coronarY---":'!';'!.<:.......j1ilil 
c irc u la tion 
(coronary heart di  ea e) 
Kidney--,;....+��4-\ 
(nephropat hy) 
Lower Limbs ----I 
(peripheral vascular di ease) 
'\--- B rain and cerebral 
c ircu lation 
(cerebrovascular disease) 
;--- Peripheral nervous system 
(neuropathy) 
.---- Diabetic foot 
( u lceration and amputat ion) 
Figu re 1 - 1 0 : Compl ications of diabetes mel l i tus 
Adapted from [ 1 32] 
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1 . 1 .5. 1 .  1 icrova cular Com plication 
The development of micro\'a cular compl ications depends on the duration and 
e\'erity of hypergl cemia [93 ] .  
A .  Diabetic Retinopathy 
Diabetic retinopathy in 01  es impaired retinal blood flow, and blockage and 
danlage of the retinal vess Is which can lead to hypoxia and ret inal damage [39] . 
tudie ha\'e shovm that diabetic retinopathy is more prevalent in T I DM patients and 
Ie s prevalent in T2DM patients diagnosed after the age of 30 [39] . After 20 years of 
being diagnosed with DM. nearly all T I DM patients and most of T2DM have some 
igns of retinopathy [9 1 ] .  Development of retinopathy may begin  7 years before DM 
is diagno ed in type 2 patients [93 ] .  The first sign of retinopathy is microaneurysms 
which are smal l  retinal vascular di latations and are c l inical ly indicated by red dots 
(bal loon-l ike sacs) during ret inal examination ( Fig. 1 - 1 1 )  [39 ;  93 ] .  Microaneurysms 
occur due to loss of pericytes which are elongated contracti le cel ls surrounding the 
smal l  vessel s  to control the vessel constriction and di latation ( tone) ,  control vessel 
gro\v1:h and provide protection against reactive oxygen species ( ROS) [39] . There are 
five grades of diabetic  retinopathy including ( i )  background reti nopathy. ( i i )  
background reti nopathy with maculopathy. ( i i i )  pre-prol iferat ive ret inopathy, ( iv)  
prol iferative ret inopathy and (v)  advanced diabetic  eye disease which differ in  the 
progression and prognosis of DM [78 ] .  Background reti nopathy is  characterized by 
the presence of dot hemorrhages with marginal l ipid deposition (hard exudates) in  the 
middle retinal layers, microaneurysm and grayish retinal areas indicating retinal 
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edema [ 78 :  93 ] .  Background retinopathy with maculopathy exhibit hard exudates. 
capi l lary occlusion and leakage in the macu lar region accompanied by central i sual 
10 s ( uch a reading difficulty) [ 78 ] .  Pre-prol iferati retinopathy is characterized by 
the pre nce of white areas on the retina resembling ' cotton wool spots' and large 
hemorrhages. Prol iferati e retinopath sho\ s abnormal growth of new retinal vessels 
and ma cau e visual lo s [ 78 ] .  Advanced diabetic eye disease is the most dangerous 
and exhibit vitreous hemorrhage. retinal detac1unent and thrombotic glaucoma 
re ulting in partial or total vi ual loss [39;  78 ] .  
Figure 1 - 1 1 :  Microaneur sm manifested by  bal loon-l ike sacs (arrow) during ret inal 
examination 
Adapted from [62] 
B. D iabetic Neu ropathy 
Diabetic neuropathy is  the damage of peripheral nerves resulting from extreme 
hyperglycemia along with hypertension [ 1 32 ] .  There are two types of diabetic 
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peripheral neuropathie focal neuropathie (mononeuropathies) and sen orimotor 
pol) neuropathy w hich more common [ 76] . Peripheral polyneuropathies affect 
motor and en ory nerve e pecial l  in  the feet causing pain, tingl ing and loss of 
en ation \\ hich can consequent ly lead to unnoticed inj urie , infections. ulcerations 
and amputat ion [ 76: 1 32 ] .  Foot ulceration or injury. associated with diabetic 
neuropathy, accounts for more than 80% of amputations [93 ] .  Long nerve fibers are 
th fir t to be affected . Lo of nerve terminals and nerve conduction velocity are first 
manife ted in the feet and then affect other areas, mainly the hands, giving a pattern 
of . glove and stocking' ( Fig.  1 - 1 2A) [9 1 ] . The systems affected by autonomic 
neuropathy include the CV. gastrointestinal , urogenital, sudomotor and pupi l lomotor 
systems ( Fig.  1 - 1 28)  [95 ] .  Cardiac autonomic neuropathy can be manifested as 
resting tachycardia, exercise intolerance, variable resting HR, slow HR reco ery after 
exercise. orthostatic hypotension, prolonged QT intervals, ' si lent' myocardial 
infarction ( M I )  and increased mortal ity  [39:  76] . Other autonomic neuropathies 
include gastroparesis, vomiting. diarrhea, const ipation, bladder paresis, sweating 
abnormal ities ( anhidrosis), impaired wow1d healing, impaired l ight reflex and erecti le  
dysfunction [76; 9 1 ;  93 ] .  Whereas in  addit ion to sensorimotor neuropathy, sensory 
neuropathy (without motor neuropathy) can also be found in some diabetic patients 
but i t  i s  relatively rare [93 ] .  Mononeuropathies commonly affect median, ulnar and 
radial  ner es but can also affect any other nerves ( Fig. 1 - 1 2C)  [93 ] .  They can also be 
manifested by severe pain,  weakness and atrophy of large muscles ( thigh muscles), a 
condition known as diabetic amyotrophy [93 ] .  
Figu re 1 - 1 2 :  Different pattems of diabetic neuropathy distribution 
dapted from [4 1 ]  
(A)  Polyneuropathy (glove and stocking) 
( B) Autonomic neuropathy 
(C)  Mononeuropathy 
C. D iabetic Nephropathy 
3 1  
Diabetic nephropathy invol es damage to small renal blood vessels resulting 
in kidney dysfunction or even fai lure [ 1 32 ] .  The risk factors for diabetic nephropathy 
include hyperglycemia. hypertension, obesity, dysl ipidemia and smoking tobacco 
[39] . Before development of the overt diabet ic nephropathy, a stage cal led ' inc ipient 
nephropathy' occurs. which is characterized by microalbuminuria (20-200 flg/min or 
20-300 mg/24h) [78 ] . Overt diabetic nephropathy develops, in  the maj ority of cases, 
as a result of uncontrol led hyperglycemia and hypertension, however, it can also 
develop with good glycemic control and normal blood pressure [9 1 ] . I t  is manifested 
by proteinuria in which albumin is the main protein excreted, elevated blood pressure 
and progressive reduction of the glomerular fi ltration rate over a period of 1 0-20 
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y ear [ 78 :  9 1 ] . During the earl tage of DM, an increa e in renal ize takes place 
due to hyperpla ia and h pertrophy and consequent ly the glomerular fi ltration rate 
lncrea 1 ading to fi ltration of more glucose, proteins and fatt acids [9 1 ] . 
Proteinuria indicate al terations in the glomerular fi ltration barriec vascular damage 
and ub equent end stage renal disease [78 :  9 1 ] . The end stage renal disease is the 
mo t evere stag in which hemodialysis or a renal transplant is a necessity [78 ] .  
Diabetic nephropathy predispo es  the development of macrovascular compl icat ions 
[9 1 ] . 
1 . 1 .5.2. M acrovascu lar  Compl ication 
Macrova cular complications are the most dangerous and are the major cause 
of morbidity and mortal i ty in  diabetic pat ients [ 1 32 ] .  The risk factors for 
macrovascular complications, aside from hyperglycemia, include hypertension and 
hypercholesterolemia [ 1 32 ] . Atherosclerosis is the principle pathological process that 
results in the development of macrovascular complications [93 ] .  Chronic 
inflanunation and inj ury to the coronar and peripheral arteries lead to accumulation 
of oxidized low-density l ipoprotein-cholesterol (LDL-C),  which may be oxidized by 
angiotensin It in  the arterial wal l [93 ] .  Oxidation of LDL-C particles changes their 
properties and makes them antigenic causing stimulation of the immune system [ 75 ] . 
The arterial wal l i s  then infiltrated by macrophages (d ifferentiated from monocytes), 
which together with oxidized LDL-C. result in the fonnation of foam cel ls due to 
engulfing LDL-C partic les by the macrophages [75 ;  93 ] .  Macrophages then 
pro l iferate and attract T - lymphocytes which stimulate pro l iferation of endothel ial  
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cel l  and arterial mooth muscle . plus the accumulation of col lagen [75;  93 ] .  This 
erie of e nts eventual ly re ult in the fonnation of athero c 1erot ic plaque. These 
plaques are l ipid-rich in content and are covered with a fibrous cap [93 ] .  When the 
plaque rupture , acute vascular infarction occurs [93 ] .  
A .  Card iova cu lar  Di  ease 
Diabetic patient . particularly those with T2DM, have a 2 to 6-fold higher risk 
of developing CV disease compared to non-diabetic individuals [ 1 32 ] .  CV disease is  
one of the most common causes of death in diabetic pat ients and is responsible for 
more than half of the deaths of these patients. Diabetic CV diseases include angina, 
MI and congestive heart fai lure (diabetic cardiomyopathy) [ 1 32 ] .  Risk factors for 
diabetic CV diseases incl ude uncontro l led hyperglycemia, dysl ipidemia, nephropathy 
and hypertension [9 1 ] . The age-comparative mortal i ty ri sk of coronary artery disease 
( CAD) is 3-fo ld in diabetic  men and 2 to 5-fold in diabetic women compared to non­
diabetic individuals [94 ] .  
A . I .  Angina  
Atherosclerotic CAD is  the major cause of  myocardial ischemia [94 ] .  Angina 
is  usual ly an i ndicati e symptom for myocardial i schemia [268] .  The type of angina 
mainly observed in diabetic patients i s  unstable angina [9 1 ] . Angina is associated 
with pressure. t ightness. constricting or burning pain that is mainly fel t  near the 
sternum. but can also occur in other areas such as the epigastrium. lower j aw, 
shoulders and arms [94] . Other symptoms may also occur such as shortness of breath, 
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fatigue. nau ea and re tle sne [94 ] .  Moreover. orne patients exhibit si lent 
myocardial i chemia v'v hich occurs without angina or an angina symptoms and can 
occur at re t or with minimal phy ical acti i ty [268] .  DM i a risk factor for si lent 
myocardial i chemia and therefore, it is common among diabetic patients [ 1 1 1 ;  268 ] .  
A.2. Myoca rd ia l  I nfarction 
MI takes place due to a rupture of atherosclerotic plaque deposited in  the 
coronar arteries. This can result in coronary arterial occlusion, consequent 
myocardial i chemia and m ocardial cel l necrosis  [278 ] .  The risk of M I  in diabetic 
patients is 3 times that of the general population and is almost equal to that of non­
diabetic individuals with previous MI [9 1 ] . The size of the infarct size is  an indicator 
for the prognosi of the disease [ 1 97 ] .  Diabetic patients ha e a relati ely poor 
progno is and h igher mortal i t  due to ventricular dysfunction and hypertrophy as wel l  
a the abundance of atherosclerotic plaques [ 1 97]  
A.3.  Congestive H eart Fa i l u re ( D iabetic Card iomyopathy)  
Diabetic cardiomyopathy is  a myocardial d isease that occurs as a result of the 
cardiac structural and functional changes induced by DM in the absence of other 
predi sposing factors for CV diseases such hypertension and atherosclerosis [ 75 ] .  
These diabetic changes predispose the patient to  congestive heart fai lure [ 75 ] .  
Congestive heart fai lure is a condition characterized by  structural and funct ional 
impainnent in which the abil ity of the heart to fi l l  with blood and/or ej ect blood is  
impeded [75] .  Congestive heart fai lure can involve diastol ic  dysfunction and/or 
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sy  tol ic dy  function [256 ] .  y tolic dy  function i impaired cardiac contracti l ity_ 
a ociated v.ith 10\\ left ventricular fraction « 45%) [75 ] .  On the other hand, diastol ic 
dy function is impaired cardiac relaxation, which exhibits impaired cardiac abil ity to 
properly relax and fi l l  with blood during diastole [ 75 ] .  Diastol ic  dysfunction cause 
dy pnea upon exertion which pre ents the patient from losing the extra weight 
nece ary for the treatment regimen [9 1 ] . Diabetic patients have several risk factors 
for diabetic cardiomyopath such as persistent hyperglycemia, atherosclerosis. 
chronic hyperten ion and microvascular complications, especial ly autonomic 
neuropathy [ I l l ] . Fortunately. contro l l ing these risk factors by ant i-diabetic, anti ­
hypertensive and cholesterol- lowering medications may prevent the development of 
diabetic cardiomyopath [ 1 1 1 ] . 
B. Cerebrovascu lar  D isease 
DM increases the risk of atherosclerotic plaque fom1ation in  the 
cerebrovascular circulation including intracranial and extracranial ( such as carot id 
arter ) arteries [39] . Rupture of atherosclerotic  plaque fOffi1ed in cerebral arteries 
cau es strokes. Fol lowing ischemic heart disease, strokes are ranked as the second 
most conm10n cause of death [77] . Abnoffi1al it ies that can be associated with DM 
such as hyperglycemia, hypertension, dyslipidemia, retinopathy, nephropathy, heart 
fai lure and atrial fibri l lation predispose patients to strokes [39 ] .  I n  addition, 
hyperinsu l inemia is  also a risk factor for strokes, but the reason behind this is sti l l  not 
c lear [39] . There are two types of stroke : i schemic (arthrothrombic )  and hemolThagic 
[ 77] . Arthrothrombic strokes account for about 85% of acute strokes, whi le 
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hemorrhagic troke account for the remaining 1 5% [78 ] .  Diabetic patients are 2-3 
time more prone to arthrothrombic stroke , and are equal l  prone to hemolThagic 
trokes compared to the non-diabetic population [78 ] .  Unfortunately, ischemic brain 
damage lend to be i lTever ible in  diabetic patients leading to higher disabil ity and 
mortal it . The high rate of troke recurrence also reduces the l ikelihood for long-term 
urvi val [ 78 ] .  
C .  Peripheral A rtery D isease 
Peripheral artery disease involves the blockage of peripheral arteries ( in lower 
extremitie ) as a result of atherosclerosis [9] . Intermittent c laudication is the most 
conU110n symptom, which in olves pain, cramping, or aching in the leg (calves, 
thighs or buttocks) espec ial ly during physical activity which affects the patients' 
quality of l i fe [9; 39] . This pain is usual ly rel ieved by stopping the physical activity .  
However, in  severe cases of peripheral artery disease, the pain is  also felt at  rest and 
can be associated with tissue l oss and gangrene; a condition cal led ' critical l imb 
ischemia' [9] . Peripheral artery disease. together with peripheral neuropathy, can 
lead to a condition !moY'. n as 'd iabetic fool ' ,  which is characterized by foot infections 
and ulcerations and can result in  amputation [ 1 32 ] .  
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1 .2.  H ea rt and Card iova cu Jar  S .  tern 
The CY sy tern is compo ed of a pump (heart ) that pumps a fluid ( blood 
containing c l is and pia rna)  to a network of tubes ( blood vessels) [25 J ] . The CV 
s t m i re pon ible for three types of transportation processes in the bod [25 1 ] . 
These include transporting oxygen, nutrients and water throughout the body, 
tran porting carbon dioxide, metabolic wa tes and heat to lungs. kidneys and skin. 
and tran porting cel lular materials from one cel l  to another [25 1 ] . 
1 .2 . 1 .  Heart Anatomy and  Structure 
The heart the central component of the CV system, is  a hol low fibromuscular 
cone- haped and fist-sized organ [ 1 88 ;  300] . It is located in the middle mediastinum 
in the thorax, \\'here it l ies on the diaphragm facing the sternum anteriorly and the 5th_ 
8th thoracic vertebrae posteriorly [ 83 ;  300] . Two thirds of the heart are located in the 
left side of the midl ine,  whi le the left one third is  located in the right side of the 
midl ine [300] . The heart and origins of the large vessels are surrounded by a 
fibroserous sac cal led ' the pericardium '  [ 83 ;  1 88 ] .  The inferior part of the 
pericardium is firm ly  attached to the diaphragm and tied by a l igament to the sternum 
[83 ] .  The pericardium acts as a protective layer for the heart and the origins of the 
large vessels coming out of the heart [ 1 8 8 ] .  As shown in Figure 1 - 1 3 , the heart i s  
composed of four chambers including the upper right atrium, upper left atri um, lower 
right ventric le and lower left ventric le .  There are also four valves in the heart 
including the tricuspid, mitral ,  pulmonary and aortic valves [ J  88 ] .  The anterior 
surface of the heart is mainly covered by the right ventric le, whereas the majority of  
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the po terior urface i covered b the left atrium and a smal l  portion is co ered by 
the right atrium and the inferior urface ha both ventricle and some of the right 
atrium [ 83 ] .  A fibrous skel ton ha ing the shape of a figure eight provides support to 
the four chamber . which are attached to its central fibrous body. and to the four 
valve (cu p ) .  \-\ hich are attached to its extensions [300] . The right atrium has the 
opening for the superior ena cava on its top and the inferior ena cava at its base, 
wh re it receives the deo. ygenated blood coming from the body [ 83 ) .  It also has 
openings for the coronary inus and the anterior cardiac vein, where it receives the 
deoxygenated b lood coming from the heart [ 83 ] .  Moreover. the atrio-ventricular (A V)  
and the sino-atrial ( SA) nodes are located in  the right atrium [ 1 88 ) .  The left atrium is  
connected to the four alvele s pulmonary veins posteriorly from which it recei es 
the oxygenated blood coming from the lungs [ 1 88 ;  300) . The right ventricle receives 
the deoxygenated blood from the right atrium that passes through an opening guarded 
by the tricu pid valve [300) .  The blood i then pumped by the right ventricle to the 
l ungs through an opening guarded by the pulmonary valve [300] . The left ventric le 
receives the blood from the left atriwl1 through the mitral opening, where the mitral 
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Figure 1 - 1 3 :  Structure of the heart and directions of blood flow 
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B lue arrows i ndicate deoxygenated blood and red arrows indicate oxygenated blood. 
Retrie\'ed from [25 1 ]  
1 .2 . 1 . 1 .  Card iac Blood Supp ly 
The heart receives its share of  the oxygenated blood and nutrients tlu'ough the 
first two branches of the aorta; the right and left coronary arteries [ 1 88 ] .  This occurs 
during cardiac muscle relaxation (d iastole )  [300] .  Above each of the three cusps of 
the aort ic valve, there is a di latation ( sinus) cal led the aortic sinus [ 1 88 ] ,  making a 
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total of thr e inu e : the right coronary aortic sinu ( or anterior inus). left coronary 
aortic inu (or po terior inu ) and non-coronary sinus (or right po terior sinus) 
[300] . The right and left coronary arterie arise from the right and left coronary aortic 
inu e . re pectively [300] . The right coronary artery branches to se eral arteries 
which upply the right atrium. right ventric le and one third of the inter-ventricular 
eptum. I t  also upplies the V node in about 80% of individuals and the SA node in 
about 600 0 of indi iduals. whi le in  the rest of individuals. the A V and SA nodes are 
suppl ied with blood through the c ircumflex artery, a branch of the left coronary artery 
[ 83 ;  1 88 ] .  The left coronary artery branches to other arteries such as the circumflex 
artery and suppl ies the left atrium. left ventricle. i nter-ventricular septum and the SA 
node (::.:: -lmo of indi iduals )  and AV node (::.:: 1 0% of individuals) [ 1 88 ] .  Cardiac 
venous drainage goes from the different coronary veins to the coronary sinus vein 
which transmits the deoxygenated blood to the right atrium [ 1 88 ] .  Trivial amounts (::.:: 
_0-30%) of venous blood can drain into the four cardiac chambers through the 
Thebesian Veins [300] .  
1 .2 . 1 .2 .  Card iac Nerve S upply 
Sympathetic cardiac activity is  suppl ied from nerve fibers corn ing out of the 
cervical and thorac ic sympathetic gangl ia, whereas parasympathetic cardiac activi ty 
originates from the vagus nerve [ 83 ] .  oradrenaline mediates sympathetic activities. 
during exercise for example. resulting in  an increased cardiac contraction force 
( positive i notropism). contraction rate (positive chronotropism ) and conduct ion rate 
of the electrical signal (positive dromotropism) from the A V node to the H is-
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Purkinj ie y tern [ 30 1 ] . ympath tic ner e are al 0 respon ible for cardiac pam 
conduction [ 83 ] .  Vagal nerve effect predominate during rest resulting in decreased 
heart rate ( HR) [30 1 ] . 
1 .2.2.  Heart Phy iology 
1 .2 .2 . 1 .  Card iac Conduction ystem and the Card iac Cvcle 
The heart. being the blood pump of the body, has two main characteristics: 
contra t i l ity and rhythmicity [ 30 1 ] .  The cardiac conduction system is composed of 
special ized tissues that coordinate cardiac contraction resulting in  synchronized 
contraction and relaxation. The ti ssues of the cardiac conduct ion system inc lude the 
node. A V node. A V bundle of H is  right and left branches of the A V bundle of 
H is  and Purkinj ie  fibers [ 1 88 ] .  As sho\\'11 in Figure 1 - 1 4, the cardiac action potential 
CAP) starts in  the right atrium from the SA node. the cardiac pacemaker [ 3 3 ] .  The 
electrical signal of the SA node propagates to both atria causing their contraction 
[30 1 ] .  The signal propagation does not extend to the entric les due to the presence of 
a fibrous t issue that acts as a barrier between the atria and ventricles [33 ] .  Therefore, 
the A V node. at the base of the right atrium, conducts the electrical signal to the 
ventricles v ia the His-Purkinj i e  System [ 3 3 ] .  There is a smal l  time gap between the 
signal conduction in the atria and the bundle of H is owing to the relatively slow 
conduction of the AV node [ 33 ;  30 1 ] .  This gap provides enough time for the atria to 
eject the blood into the ventric les [ 3 3 ] .  In some cases where the SA node fai l s  to 
generate the AP or in atrial fibri l lation where the atria are contracting very fast the 
A V node acts as a back-up pacemaker generating and regulating the electrical signal 
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needed for the ventricular contraction [ 33 ] .  After the signal reaches the bundle of H is, 
in the inter-ventricular septum, from the A V node, it is transmitted to the right and 
left branche of the bundle of His and then to U1e Purkinj ie fibers [ 1 88 ] .  Purkinj ie 
fiber then propagate the signal rapidly  to both ventricle so that the ventricles 
contract imultaneou ly tarting from the posterior side [ 33 �  300] . 
AV node -,-+-----,.o::::. 
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Figu re 1 - 1 4 : Cardiac conduction system and the spread of the electrical impulse 
Adapted from [25 1 ]  
1 )  The sino-atria l  (SA) node depolarizes. 
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2 )  The atria contract and the depolarizing signal travels rapidly to the atrio-
ventricular (A V) node. 
3)  The A V conducts the depolarizing signal s lowly .  
4)  The signal propagates rapidly through the bundle of H is  and its branches. 
5) Purkinj ie fibers spread the signal to both of the ventricles .  
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1 .2 .2 .2 .  Exc i tat ion-Contraction Coupl ing 
everal cel lular event take place during contraction and relaxation. The heart 
a combination of different cel l  type incl uding cardiomyocytes. fibroblasts. 
endocardial and endothel ial cel l s  and immune cel l s  [207] .  Although cardiomyocytes 
account [or approximately 30% of cardiac cel ls .  they compose the vast majority of the 
cardiac ma s and volume [207] . Generation of the contracti le force is the 
re ponsibi l ity of cardiom ocytes pumping more than 7 ,000 l iters of b lood per day 
over a di tance of 1 00.000 mi les of blood essels [248;  304] . There are two types of 
card iomyocytes including pacemaker (cel l s  of SA and A V nodes) and contracti le 
( v,:orking) myocyte ( Fig.  1 - 1 5 ) [223 ] .  Each cardiom ocyte has intercalated disks at 
its blunted ends which connect it with neighboring myocytes ( Fig.  1 - 1 5 ) [248 ] .  The 
membranes of the intercalated disk are connected by three types of junctions: the gap 
j unction. the fasc ia adherens and the desmosome [248 ] .  The gap junctions are 
composed of a group of channels made up of a protein fami ly  cal led the connexins 
[207: 248 ] .  Their function is to a l low the rapid spread of AP between adj acent cel ls 
through ionic movement between the myocytes [207] . The fascia adherens and the 
desmosome connect the plasma membrane of adjacent cel ls  [248 ] .  
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Figu re 1 - 1 5 : tructure of  a contracti le cardiomyocyte 
dapted from [25 1 ]  
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Cardiomyocytes are surrounded by the sacrolemmal membrane which has 
invaginations, cal led transverse tubules ( T-tubules), extending deeply into the cel l  
close to the sarcoplasmic reticulum ( SR) ( Fig. 1 - 1 6) [207; 248 ] .  SR plays a pivotal 
role in  cardiac contraction because it is  the main Ca2+ store inside the cell [207] . Ca2+, 
a ubiquitous second messenger ion, is the main regulator of contracti l i ty in  the heart 
which direct ly activates myofilament contraction [26; 27] . The sarcomere, which is  
the fundamental contracti le unit, is composed of contracti le proteins. cal led 
myofibri ls .  and non-contracti le proteins such as t i t in, myomesin and telethonin [207] . 
Contracti le myofibri l s  consist of thin myofilaments cal led actin, thick myofilaments 
cal led myosin and regulatory proteins such as tropomyosin and troponins C, I and T 
[207] . Contracti le myofibri l s  cause contraction in the presence of Ca2+ [207 ] .  On the 
other hand. the non-contracti le proteins play structural and signaling roles [207] . 
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Excitation-contraction coupl ing ( ECC ) in contracti le cardiomyocyte starts 
'" hen an P arrive cau ing activation and opening of the voltage-gated L-type Ca2+ 
channel , which al low Ca2+ to flow inside the myocyte [26] .  In addition to the entr of 
Ca2+ through the L-type Ca2+ channels. a "-;Ca2+ exchanger (NCX) contributes to 
Ca24 ent!) but to a les er extent [26] . The entered Ca2+ stimulates the release of Ca2+ 
from the intracel lu lar store in the R through the ryanodine receptors ( RyR) 
( r  anodine- ensitive intracel lular Ca2+ channels), particularly type 2 RyR ( RyR2 ) as 
they are the most abundant in cardiomyocytes [304] .  The process of enhancing 
calcium release from the R is termed calcium-induced calcium release (CICR)  
[304 ] .  Entry and release of  Ca2-"- causes Ca2+ accumulation inside the myocyte 
resulting in elevation of the free intracel lular Ca2+ concentrat ion (Ca2+ sparks or 
spontaneous local Ca2+ transient) [27] . A Ca2+ spark indicates the synchronous release 
of Ca2+ from about 6-20 RyRs and Ca2+ sparks reach several thousand sparks during 
ECC in each ce l l  [27 :  44] . Ca2+ then binds to troponin C protein on the actin [207 ] .  
Without Ca2-, troponin C pre ents the interaction betvveen actin and myosin but on 
binding to Ca2+, the myosin projections interact with actin fi laments producing 
contraction [207 ] .  Myofilaments are stretched during the blood fi l l ing the heart, 
resulting in increased myofilament sensit ivity to Ca2+ and stronger contraction [27] . 
Relaxation takes place due to the removal of the cytosol ic Ca2
+ resulting in 
dissociation of Ca2+ from troponin C,  which then temlinates the actin-myosin 
interaction to ini tiate relaxation [207] . Ca2
+ is  removed from the cytosol by four 
processes including sarco-endoplasmic reticulum Ca
2+-ATPase (SERCA) pump, 
which remo es the majority of Ca2 , fol lowed by the NCX, whi le the minority (::::: 1 %) 
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i removed by the arcol mmal Ca2+ -ATPase and mitochondrial uniporter (cal led the 
slow J tem ) [27 :  30 1 ] .  nder ph siological condition , the amount o f  Ca2+ entering 
the myo )1e during contraction equals that lea ing during relaxat ion [27] . A summary 
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Figu re 1 - 1 6 : E xcitation-contraction coupling ( ECC) ( left) and relaxation ( right) in  a 
cardiomyocyte 
Adapted from [25 1 ]  
1 )  Action potential arrives from an adjacent cel l .  
2 )  Ca2- enters into the myocyte mainly through the voltage-gated L-type Ca2+ 
channels and to a smaller extent through a+/Ca2+ exchanger (NCX).  
3)  The smal l  entry of Ca2+ triggers Ca2+ release from the sarcoplasmic ret iculum 
( SR)  through the ryanodine receptors ( RyRs). 
4) SR Cah release causes Ca2+ sparks. 
5)  Ca2- sparks create a Ca2.,. signal .  
6)  Ca2+ ions associate with troponin proteins resulting in  myocyte contraction. 
7) Ca2
-
ions dissociate from troponin proteins resulting in myocyte relaxation. 
8 )  ome ci- i s  taken up again by the SR. 
9) Rest of the Ca2+ flows out of the myocyte by NCX in exchange for Na +. 
1 0) a "'"/K+ ATPase maintains the a + gradient. 
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1 .2 .2.3. Card iac Action Potent ia l  and Ion  M ovement 
Cardiac AP di ffer betv,,-een contracti le and pacemaker m ocytes. Contracti le 
myocyte ha e a relatively long AP with a plateau ( Fig. 1 - 1 7  A), whi le pacemaker 
myoc)1e have a horter P \ ith no plateau ( Fig. 1 - 1 7B )  [223 ] .  In a contracti le 
myoc)ie. the P i de cribed by 5 pha es (0,  1 , 2. 3  and 4) that last for a duration of 
approximat ly 300 ms [223 ] .  Phase 4 repre ents the resting potential which is ;:::: -90 
m [ 1 08 ] .  AP arrival begins a series of ionic movements in and out of the myocyte 
tafting with phase 0 ( rapid depolarization) which involves an i nflux of Na + through 
fast voltage-gated a + chmmels causing generat ion of the AP upstroke by 
depolari zing the membrmle from -90 m V to + 1 0 m V [2 1 ] ;  223 ] .  Phase 1 ( rapid 
repolarization) involves inacti ation of a + influx and activation of K .... effl ux leading 
to partial repolarization [2 1 L 223 ] .  During phase 2 ( plateau) .  Ca2+ enters the 
myoC)ies mainly through voltage-gated L-type Ca2+ (L stands for Long opening) 
channels maintaining depolarization causing a plateau in  the AP [223 ] .  Towards the 
end of pha e 2. Ca2+ influx is reduced and a+ influx stmis through CX (3 Na+ : 1 
Ca::!-) to maintain depolarizat ion [223 ] _  Phase 3 ( rapid repolarization) starts after 
inactivat ion of Ca2+ chaIIDels  in which K+ efflux causes rapid repolarization and the 
membrane potential returns to phase 4 [223 ] .  To summarize. the influx of a+ and 
Ca2+ ( inward currents) results in depolarization. whi le the efflux of K+ (outward 
current )  results in repolarization [2 1 1 ] . In pacemaker myocytes the resting membrane 
potential is ;:::: -50 to -65 m V which is more positive than that of contracti le myocytes 
[ 1 08 ] .  The AP of pacemaker myocytes consi sts of only three phases equivalent to 
phases 0, 3 and 4, in  which i t  starts with phase 4 with slow influx of Ca
2+ through the 
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T-t} p a2+ ( T  tand for Tran ient) channels  and influx of a - through CX and I f  
channel [223 :  25 1 ] . I f  channel a l lo the flow of a current known as pacemaker or 
funny current [ 1 08 :  25 1 ] . They permit the infl ux of a + and efflux of K+. where at 
negative membrane potentia! ,  they open and the a+ influx predominates over the K+ 
efflux and the, gradual ly c lose as the membrane gets more posit ive [25 1 ] . 
Depolarization (phase 0) occurs. after the activation threshold is reached, through the 
L-type Ca2+ chaImel a l lowing influx of Ca2+ aI1d repolarizat ion (phase 3 )  occurs by 
K- efflux [223 ] .  
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Figure 1 - 1 7 : Cardiac action potential and ionic movement in ( A) contracti le and ( B )  
pacemaker myocytes 
Adapted from [25 1 ]  
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1 .3. G luco e Tran porter 
Gluco e i the main fuel that uppl ies al l  eukaryotic cel ls with energy. 
ho\\ e\'er. gluco is  a polar molecule that cannot cross the l ipophi l ic  cel lular 
membrane to enter the cel l  [22 ] .  Therefore. entry and exit of gluco e and other sugars 
into and from the cel l are mediated b special ized glucose transporters. Current 
vid nce suggests that there are three glucose transporter fami l ies expressed in the 
eukaryotic c 1 1  . which are encoded by the solute carrier (SLC)  genes [ S7 ;  24S] .  
These inc lude the SLC2A fami ly encoding for faci l i tative glucose transporters 
(GLUT ). LCSA fami ly encoding for sodium/glucose co-transporters (SGLTs) and 
LCSO fami ly  encoding for sugar efflux transporters (SWEETs) [ S7 ;  24S ] .  
1 .3. 1 .  Faci l i tat ive G lucose Transporters 
The GL T fami ly is a part of the Major Fac i l i tator Superfanu ly  ( MFS)  [277] . 
To date. 1 4  protein members ( i sofol111s) ,  including GLUT l - 1 2. 1 4  and proton ( Hl­
coupled myo-inositol symporter (HMIT also cal led GLUT 1 3 ) ,  and 4 pseudogenes 
have been discovered in the GLUT fami ly  [20S ] .  GLUTs are transmembrane proteins 
predicted to have 1 2  spanning transmembrane domains [277] . They are classified 
according to the simi larity of their amino acid sequence i nto three classes inc luding 
c lass 1 comprising GLUT l -4, 1 4, c lass 2 comprising GLUTS 7.9 and 1 L and c lass 3 
comprising GLUT6,8, 1 0, 1 2  and HMIT [20S ] .  Their main function is  to transfer 
glucose and other substrates, such as fructose, myo-inositol and urate, across the cel l 
membrane either from the blood to the cel l  cytosol or vice versa [204: 277] . The 
GLUT isoforms d iffer in their affinit ies to glucose, substrates (other than glucose) 
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and ti ue distribution (Table 1 -2) .  The wide abundance of different isoform for 
GL T i sugge ted to be due to the importance of glucose as a source of energy for 
the cell which require the exi tence of several types of transporters exhibiting 
different kinetic and regulatory properties, and cel l -type specific distribution [205 ] .  
GLUT Substrate(s) Tissue Distribution 
Isoform 
GLUT l Gluco e, galactose, manno e, Erythrocytes, brain, blood-brain 
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glucosam ine barrier, blood-t issue barrier, many 
fetal t issues 
GLUT2 Gluco e,  fructose, galactose, Li er, is let of L angerhans, 
mannose, g lucosam ine intest ine, k idney, brain 
GLUT3 Gluco e, galactose, mannose, Brain ( neurons). testis 
maltose, xy lose, 
dehydroascorbic acid 
G LUT4 Gluco e, galactose, Adipose t issue (white and 
glucosamaine. brown ) heart, skeletal muscle 
deh droascorbic ac id 
GLUTS Fructo e Smal l intest ine. k idney 
GLUT6 G lucose Brain,  spleen, leucocytes 
GLUT7 Gluco e,  fructose Smal l intest ine, colon, testis, 
prostate 
GLUT8 G l uco e, fructose, galactose Testis, brain, adrenal gland,  l iver, 
spleen. brown adipose t issue, 
lung 
GLUT9 Urate Kidney, l iver, smal l intest ine, 
placenta, l ung, leucocytes 
GLUT I O  G lucose, galactose Heart, l ung, brain.  l iver, skeletal 
mu cle, pancreas, placenta, 
Kidney 
GLUT l l G lucose, fructose Hemi, skeletal muscle 
GLUT l 2  G lucose Heart, prostate, skeletal muscle, 
p lacenta 
HMIT Myo-inositol Brain, adipose t issue 
G L UT 1 4  Testis 
Table 1 -2 :  Substrates and tissue distribution of faci l itative glucose transporters 
Adapted from [205;  323 ]  




1 .3. 1 . 1 .  M echan i  m of Gluco e Tran port by Facil ita tive G luco e Transporter 
Glucose is  transported pas ivel b GLUT by faci l i tative diffusion and no 
energy i required. Thi proce s in olves two steps starting when glucose binds to 
GL T protein on the cel l  membrane forming a GLUT-glucose complex ( Fig.  1 - 1 8 ) 
[ 55 ] .  The econd tep in olve inverting the direction of the GLUT-glucose complex 
\\' ith respect to the membrane al lo\ ing the glucose to be released on the other side of 
the membrane ( Fig. 1 - 1 8 ) [ 55 ] .  The inversion of GLUT protein is  then reversed to 
tart another transport c c1e [ 5 5 ] .  Al l  GLUTs (GLUT l - 1 2. 1 4) are bidirectional 
fac i l i tative gluco e uniporter which transport glucose via an energy- independent 
faci l i tative diffusion along its concentrat ion gradient across the cel l  membrane [205 ] .  
On  the other hand, HMIT i s  a pH-dependent myo-inositol specific symporter wluch 
doe not transport glucose [205 : 323 ] .  
gl ucose 












Figu re 1 - 1 8 :  Mechanism of glucose transport by fac i l itative glucose transporters 
Retrieved from [7 ]  
1 .3.2. odiumlG luco e Co-tran porter 
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To date. 12  memb rs ( i  oforms) of the OLT fami ly ha e been identified 
including OLT I -5 .  MlTL 2 ( odium/myo-inositol co-transporters). MCT L 2 
( odiumJmonocarboxylate co-transporters). MYT ( odium/multivitamin co-
tran porter), IS ( odiumliodide s mporter) and CHT (sodium/chol ine co-
tran porter) [3 1 0J .  The belong to a superfan1i ly known as the Sodium/Substrate 
ymporter Fan1i ly ( S F) [ 1 42 ] .  Table 1 -3 shows al l  the members of this fami ly with 
their d ifferent sub trates and tissue distributions. Since SOLT 1 and SOL T2 are the 
most extensively studied members of this fami ly, they are discussed in more detai l in 
this section. 
SGLT Substrate(s) Tissue Distribution 
Isoform 
GLT l  Gluco e, galacto e Smal l Inte t ine ,  heart, trachea, 
k idney, brain, testes, prostrate 
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GLT2 Gluco e Kidney, brain, l iver, heart ,  thyroid 
gland. sal ivary glands 
MIT l M o-ino itol Brain, heart, kidney, lung, 
pancreas, placenta, skeletal 
musc le  
GLT3 Na+ Smal l  Intestine (cholinergic 
neurons), skeletal muscle, kidney, 
uterus, testis 
I S  1 - Thyroid gland, lactating breast. 
colon, stomach, ovary 
SMVT B iotin.  l ipoate panthothenate. Brain, heart, k idney, lung, 
1 - placenta 
CHT Choline Spinal cord, medul la  
MCT l Short chain fatty acids Smal l  I ntest ine, k idney, brain, 
ret ina, skeletal muscle 
SGLT4 Mannose, fructose, g lucose K idney. smal l  intestine, brain, 
l iver, heart, uterus, l ung 
SGLT5 Mannose. fructose, glucose Kidney cortex 
SMIT2 Myoinositol ,  chiro- inositol Thyroid  gland, brain ,  heart, 
skeletal muscle, spleen, l iver, 
l ung 
SMCT2 Short chain fatty acids Intestine, brain, ret i na, skeletal 
muscle 
Table 1 -3 :  Substrates and tissue distribution of sodium/glucose co-transporters 
Adapted from [25 ;  3 1 0] 
Isoforms are arranged according to the ascending order of the number given to their 
genes (not shown) 
SGL T: sodium/glucose co-transporter; S M I T :  sodium/myo-inositol co-transporter; 
SMCT: sodium/monocarboxylate co-transporter; SMVT: sodium/multivitamin co­
transporter; N I S: sodium/iodide symporter; CHT:  sodium/choline co-transporter 
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1 .3.2. 1 .  od i u m/G luco e Co-t ran porter 1 and 2 
hO\>.1  in Figure 1 - 1 9. after a dietary intake of carboh drates (glucose). 
gluco ab orption in the mal l intestine to the bloodstream i carried out by GL T 1  
[ 270] . Glucose then circulates in the blood and is di stributed to different body t issues 
including the kidneys where the blood is fi l tered and glucose is reabsorbed [270] . 
Reabsorption i mediated by G L T2, which is  located mainly in S 1 segment of the 
pro. imal con oluted tubule ( peT) and reabsorbs the majorit of glucose (:.::::: 90%), 
and GLT l , wluch i located in 21 3 of the peT and reabsorbs the remaining 
glucose [56] . As shov..,1  in  Table 1 -3 .  both GLT I and SGLT2 are expressed in 
different t issues such as the heart. However owing to their essential roles in glucose 
ab orption and reabsorpt ion. GLT I and SGL T2 have their highest expression levels 
i n  the small  intestine and kidneys. respecti el [327] . SGL T 1  is a low-capacity high­
affinity co-transporter, transporting a+ and glucose with a 2 : 1 stoichiometry, 
whereas GLT2 is a h igh-capacity low-affinity co-transporter, transporting Na
+ and 
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K'  Na Glucose 
Figure 1 - 1 9 : The role of sodium/glucose co-transporters 1 and 2 in glucose 
absorption ( left) and reabsorption ( right) 
Retrie ed from [270] 
GLUT:  faci l itative glucose transporter' SG LT: sodium/glucose co-transporter 
1 .3 .2 .2 .  Mechanism of Transporting G lucose 
SGLT -mediated glucose transport across the cel l  membrane against its 
concentration gradient i s  a process that reqmres energy (adenosine triphosphate; 
A TP) [240] . However, SGLTs do not directly consume ATP rather they depend on 
another transporter that directly consumes ATP which is Na+/K+ ATPase [240] .  That 
is why glucose transport by SGLT is cal led secondary active transport [303 ] ,  while 
�9 
a + tran p rt by a � /K+ TPa e i primary active transport. s hown in Figure 1 -_0, 
GL T i located in  the cel l  side facing the lumen of the organ ( intestine or kidne ) 
v. hil . a � /K� TPa e i located on the other side of the cel l  facing the inter titial 
fluid and blood tream. a + /K+ ATPase con tantl expels a + into the blood tream 
which make the intracel lular concentration of a + re lati ely lower than in the lumen. 
On tran porting glucose from the lumen to the cel l ,  Na+ moves along its 
e lectrochemical potential gradient driving gluco e transport with it (against its 
concentration gradient) [240] . Then aT is remo ed from the cel l  to the blood by 
a � IKT A TPa e and glucose accumulation inside the cel l  allows it to passively move 
to the blood through GLUTs [ 5 1 ] . 
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Figu re 1 -20 :  Mechanism of glucose transport by sodium/glucose co-transporters 
Retrieved from [ 1 9 1 ] 
G LUT: fac i l i tative glucose transporter' SG LT: sodium/glucose co-transporter 
1 .3.3. ugar Efflux Tran porter 
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WEET are ugar uniporters which direct glucose out of the cel l  (efflux) 
[ 57 ] .  They were recently di covered in 20 1 0  by Chen and colleagues in  Arabidoposis 
plant gene [ 57] . WEETs ha e been found to be expressed by humans. plants. fungi. 
bacteria and other [ 5 7 :  3 1 1 ;  3 1 2 ] .  Humans express only one SWEET protein 
( WEET1 ) .  \\ hich i h pothe ized to be responsible for glucose efflux in hepatocytes 
and enterocytes in pathophysiological conditions involving impaired function of 
GLUT_ such as Fancoru-Bickel Syndrome [ 5 7; 242; 26 1 ] . In plants. SWEETs have 
es ential function such as phloem loading and nectar secretion [ 58 ;  1 77) . Pathogenic 
bacteria and fungi were found to increase expression of SWE ET genes in  plants. 
which is thought to be the mechanism by which these organisms get nutrients from 
their host cel ls [ 5 7 ] .  
1 .3.4. G lucose Transport in  Card iomyocytes 
To maintain continuous contraction. the heart has to be constantly suppl ied 
with energy and oxygen. About 3 . 5 -5 kg of ATP are produced and consumed by the 
human heart dai l y  [28 ) .  Cardiomyocytes are not only dependent on glucose for their 
energy source, but they can also acquire their fuel from FF A, lactate and ketone 
bodies [20 1 ) . At rest, under physiological conditions. glucose accounts for only about 
25% of cardiac energy whi le  FAA contribute the major share [200) . This is attributed 
to the fact that the process of FF A oxidation leads to inhibiting glucose uptake and 
catabol ism [28 ] .  However, during exercise and under some pathological condit ions 
such as hyperthyroidism, ischemia  hypertrophy and congestive heart fai lure, 
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util ization of gluco e by cardiomyocytes becomes more ignificant [ 1 ] . nder 
phy iological condition . glucose intracel lular concentration is low. which faci l itates 
the transport of glucose from outside into the myocyte along its concentration 
gradient [ 3 1 6] .  The GL T isoforms GLUT I and GLUT4 pIa the major role in 
gluco e ab orption in cardiomyocyte [200] . Fetal and postnatal cardiomyocytes are 
mainly dependent on GLUT 1 whi le, adult cardiomyocytes are mainly dependent on 
GL T -+ [200] . GL T4 ha a higher affinity to glucose and is insul in-sensiti e, on the 
other hand, GL T 1  has a lower affinity to glucose and is insul in-insensitive [200; 
303 ] .  In adult cardiomyocytes, the predominance of GLUT4 function is shifted to 
GL T l  in pathophysiological conditions such as post-ischemic reperfusion, post­
infarction heart fai lure and pressure overload hypertrophy [200] . It has been shown 
previously that cardiac hypeliroph is associated with an increased glucose uptake 
due to the increased expression of GLUT I [ 1 ] . Moreover, it has been found that 
cardiac GLUT -+ knockout mice exhibited about a 3-fold increase in GLUT I 
expression and glucose uptake as wel l  as abol ished insul in-dependent glucose uptake 
which is mediated by GLUT4 [ 1 ] . 
U nder physiological conditions, GLUT4 is  located in  the intracel lu lar 
compartments when no glucose is  being transported into the cel l  [200] . Insulin 
stimulus, which indicates the presence of a relatively high BGL, triggers the 
translocation of GLUT4 from its intracel lular compartments to the surface of the cel l  
membrane to stimulate the uptake of glucose into the myocyte [200] .  I t  should be 
noted that i nsulin presence swaps the energy substrate preference of the 
cardiomyocyte from FF A to glucose [28 ] .  Obesity and accumulation of FF A and their 
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metabol i te in the cardiomyocytes cau e l ipotoxicity a \vel l  as in ulin resi tance 
becau e FF metabol i te inhibit in ul in ignaling [ 1 04 ] .  tudie in  insul in-re i tant 
and T2DM animal models have demonstrated increa ed expression and a ailabil ity 
on the membrane surfac of the FF A transporter protein leading to increa ed FF A 
tran port, which exceeds the cel lular capacity to oxidize,  thus resulting in their 
accumulation [ 1 04 ] .  The consequent abol ished insul in signal ing prevents stimulation 
of GLUT 4 translocation and impaired cel lular glucose uptake [ 1 04 ] .  
1 04 .  Sod iu m/G l ucose Co-tran porter I nh ibi tors 
Ov"ing to the central hmction of GLT I and SGL T2 in glucose homeostasis 
by control l ing glucose ab orption and reabsorption. respectively, studies were carried 
out to target them as a no el way to treat DM. The first SGLT inlUbitor discovered 
was Phlorizin ( PH LOR) which was isolated from apple tree bark by French chemists 
in  1 83 5  [80] .  In the late 1 980s. experiments by Rossetti and col leagues, in partial ly 
pancreatectomized rats, showed nonnal ized insul in ensitivi ty, increased urinary 
exertion and impro ed BGL in PHLOR-treated rats compared to untreated rats [236] . 
SGLT inhibitors can be subc lassified into three subclasses, based on their SGLT 
i soforrn selecti ity. including non-selecti e SGLT I and 2,  selective SGLT I and 
selective SGLT2 inhibitors. To date, the subc lass of non-selective SGLTI and 2 
inhibitors comprises two compounds including PHLOR [80]  and LX42 1 1 [ 3 1 9] .  The 
subc lass of selective SGL T I  inhi bitors includes Quercetin-3 -0-g1ucoside (QUER-3-
G) [2 ;  54] . KGA-2727 [250] and KGA-3235 [ 1 62 ] .  The majority of the known SGLT 
inh ibitors belong to the subclass of selective SGL T2 inh ibitors, such as Dapagliflozin 
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o P ) [ 1 95 J ,  canagl iflozin [2 1 3 ] ,  empagliflozin [ 1 09J ,  ipragliflozin [246J. 
topogliflozin [265] and other . 
1 .... . 1 .  Mechan i  m of Action of Sod iu m/G luco e Co-tran porter I nh ib itors 
The mechanism of GL T inh ibitors is  unique compared to the mechanisms of 
other ant i-diabetic medications ( Fig. 1 -2 1 )  because it targets insulin- independent 
pathways to reduce BGL. 
ince the bru h-border membrane of the small  i ntestine exhibits the highest 
expres ion of SGLT1  protein. it is the main site of action for SGL T 1  inhibitors. 
I nh ibit ing GLTI  protein would result in impairn1ent of intestinal absorpt ion of 
dietary glucose, which was shown to impro e post-prandial hyperglycemia in STZ­
induced diabetic rats after OGTT [250] . Mutations causing dysfunction of SGLT 1 
protein are associated with glucose-galactose malabsorption leading to severe 
diarrhea in neonates which might be fatal [ 309] . Despite the concerns about glucose­
galactose malabsorption result ing from inhibiting SGLT1 protein by non-selective 
and selective SGLT 1 inhibitors, i t  was found that, after gastric bypass surgery and 
after an intake of dietary-resistant starch. increased i ntestinal glucose can improve 
glucose tolerance without gastrointest inal side effects (3 1 9) .  
O n  the other hand. SGLT2 inhibitors obviously target SGLT2 protein i n  the 
renal peT where it is highly expressed . This causes inhibition of glucose reabsorption 
causing glycosuria and decreased BGL.  Mutations of SGLT2 protein result in  fam i l ial 
renal glycosuria which i s  associated with glucose excretion despite the absence of 
DM as indicated by normal plasma glucose and plasma insulin levels (3 1 0) .  
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nl ik other anti-diabetic drugs, GL T inhibitor are unJ ikely to cause 
hypogl cemia for two rea ons; they are in ul in-independent meaning that the do not 
mediate in ul in product ion. and the do not interfere with hypoglycemia-induced 
gluco e production [288) .  
TIssue site Mechanism 
Gastrointestinal tract 
Delay of gastric emptying 
Inhibition of glucagon release 
Inhibition of glucose absorption 
Stimulation of GLP 1 release 
Pancreatic 13 cell 
Acute stimulation of insulin release 
Stimulation of insulin biosynthesis 
Inhibition of 13-cell apoptosis 
Stimulation of 13·cell differentiation 
Liver 
Inhibition of glucose production 
Increase in hepatic insulin sensitivity 
Muscle Increase in muscle insulin sensitivity 
Suppression of NEFA release 
Adipose tissue 
Fat redistribution (visceral to subcutaneous) 






GLPl a nalogues l 
DPP 4 inhibitors 
Metformin 
Thiazolidinediones 
Figu re 1 -2 1 :  Mechanisms of pharmacological treatment of diabetes mel l itus 
according to site of action 
Adapted from [262] 
G L P  1 :  glucagon-l ike peptide 1 ;  DPP 4: dipeptidyl peptidase 4 ;  NEFA:  non­
esterified fatty acid  
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1 04.2. Ph lorizin 
PHLOR (al  0 known as phloretin 2 '-O-glucoside. phlOIidzin. phlorrhizin. 
phlorhizin or phlorizo ide [ 1 7] )  i a competitive non-selective inhibitor of SGLT 1 
and 2 proteins [80] . It i s  a natural phloretin glycoside that belongs to the chalcone 
c Ia [ 1 4 1 ] .  Phloret in  gl  co ides are found in several plants such as apples ( leaves. 
bark. seeds and roots). strawberr fruits and sweet tea [ 1 4 1 ] . Although it was the first 
GL T inhibitor discovered, it was not developed into a medication itsel f, due to its 
low oral bioavai lab i l ity. rather it was used as a parent molecule for developing other 
GLT inhibitors [280] . However. several animal studies showed that oral [272]  and 
subcutaneous ( s.c . ) PHLOR improved hyperglycemia [ 35 ;  1 44 ' 1 56;  235 ;  236] .  
1 04.3. Quercetin-3-0-G lucoside 
QUER-3-G (al 0 known as Quercetin-3-0-�-D-glucopyranoside, I soquercitrin 
[289] and I soquerceti n  [ 1 74]) i s  a rare fla onol glycoside that i s  found in  several 
p lants such as apples, tea. onions, cratagus, pistachio nuts, Saint John ' s wOli in  
addition to many fruits, vegetables and cereals [228 ;  289; 294] . It has anti-diabetic 
abi l ities due to selective i nh ibition of SGLT I and inhibition of alpha-glucosidase [2 :  
1 74 :  2 1 9] .  In addition to  anti-diabetic  activity, i t  also possesses anti-oxidant. ant i ­
hypertensive, anti -cancer, anti -infl uenza, anti -pro l iferati ve, anti- inflammatory, 
cardioprotective, ant i-al lergic and diuretic properties [289; 294] . 
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l AA. Dapagl iflozin 
D P ( trade name:  Farxiga K in the nited tates; Forxigal! m Europe. 
Au a'al ia and Japan) ha been approved by the American Food and Drug 
Administrat ion (FDA) [90] ,  European Medicine Agency (EMA) [85 ] .  the Austral ian 
Therapeutic Good dministration (TG ) [276] and the Japanese Ministry of Health, 
Labor and Welfare ( M H LW) [ 1 3 ] for treatment of T2DM, It i s  the second FDA 
approved GL T2 inhibitor after canagliflozin [282 ) .  A new formulation combining 
DAPA and metformin has also been approved by EMA ( trade name : XIGD O� ) for 
T:!DM patients [ 1 5 ) .  
DAP A is  the first selective SGLT 2 to be developed [ 1 95 ) .  DAPA selectivity 
for GL T2 protein exceed that for SGLT 1 protein by approximately 1 200 times 
[ 88 ] .  It i s  an oral l administered medication that induces dose-proportional plasma 
concentration and dose-proportional glycosuria [ 1 64 ) .  DAP A reaches its peak 
concentration after 2 hours [ 1 5 1 ] . The oral bioavai labil i ty and pharmacokinetic 
properties of DAP A are not affected by fat rich meals [88 ] . DAPA is  extensively 
metabol ized in  the l iver and k idney to its inactive metabol ite dapagliflozin 3 -0 -
glucuronide which is mainly e l iminated by the k idneys [ 1 5 1 ]  
Despite being the first member of its c lass to be developed, it was not the first 
to be approved by the FDA [282) .  C l inical studies revealed some side effects such as 
mi ld  or moderate genitourinary tract infections that were either sel f- l imiting or 
respondent to treatment [ 1 58 ]  and a 2-fold i ncrease in genital infections that were also 
respondent to treatment [ 88 ) .  There were also cases reported of urinary bladder and 
breast cancer [ 1 58 ] .  
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There are sti l l  i x  po  t-marketing tudie required by  the FDA for evaluating 
D P effects on the CV outcomes, ri sk of bladder cancer, and phannacolcinetics. 
e fficac) and safety in pediatric and pregnant pat i nts [90] . The CV safety and 
outcome of DAP are being evaluated b a large cl inical trial called ' DECLARE­
TIMI58 · .  which is  expected to be completed in Apri l 20 1 9  [ 1 4] .  
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Chapter 2: Hypothe i , A im and Objective 
Owing to the progres ive nature of DM which results in the development of 
nou complication , ongoing research is  continuously \,: orking on finding new afe 
ant i-diabetic  therapie that would properly control DM and prevent the development 
of ubsequent compl icat ion . One of the recentl de eloped c lasses of anti-diabetic 
medications i GLT inhibitor . In thi study, the effects of PHLOR, a non-selective 
GLTI  and 2 inhibitor. QUER-3-G, a selective SGLT I inhibitor, and DAPA, a 
elective SGLT2 inhibitor. on contracti l i ty and intracel lular Ca2+ were investigated in  
ventricular myocytes from streptozotocin ( STZ)-induced diabetic rats. 
It is important to study new therapeutic natural compounds that can be 
dewloped later, if pro en to be safe.  PHLOR was studied because it i s  the parent 
from which developing and commercial ly  avai lable SGLT inhibitors, such as DAP A. 
were derived. on-selective SGLT I and 2 inhibitors are also being developed as 
potential anti-diabetic medications. Since there are studies in progress testing 
select ive SGL T I  i nh ibitors including KGA-2727 and KGA-3235 ,  this might pave the 
wa for other natural ly  found elective SGLT I i nhibitors, l ike QUER-3-G, to be 
considered in the future as candidates for DM treatment . DAPA is the second FDA 
approved selective SGLT 2 inhibitor and was recently released onto the market. 
There is not enough data about the effects of DAPA on the CV system. and this 
evaluation is  crucial for its safety profile characterization and benefit-ri sk assessment. 
Thus. this study contributes to the post -market ing evaluation of DAP A. 
69 
2. 1 .  Hypothe i 
Due to the lack of data avai lable on the effects of GLT inhibitors on the 
diabetic heart. we h pothe ized that these ant i-diabetic compounds may, in some 
\Va) . affect the cardiac function. or may have side effects on the heart. Considering 
that GLT proteins uti l ize a+. there is a strong possibi l i ty that SGLTs interact with 
NCX. which in tum interfere with Ca2+ signal ing. Therefore, inhibiting SGLTs may 
directly  or indirect ly alter Ca2+ mobi l ization in cardiac myocytes. 
2.2 .  Aims and Objectives 
General ly this project has two main objectives. One is studying the safety of 
natural anti-diabetic compounds such as PHLOR and QUER-3-G, and the other is 
studying a chemical ly manufactured and commercial ly available anti-diabetic 
medication such as DAP A. Studying three compounds each from a different subclass 
of GLT inhibitors al lows comparison of the common and different effects of the 
three subc lasses. 
The aim of this study was to investigate the fol lowing: 
1 )  The effects of SGLT inhibitors PHLOR, QUER-3-G and DAPA on the amplitude 
and t ime course of ventricular myocyte shortening. 
2) The effects of these SOL T inhibitors on the amplitude and time course of 
ventricular myocyte intracel lu lar Ca2+. 
3)  The effects of these SGLT inh ibi tors on ventricular myocyte myofilament 
sensitivity to Ca2+ . 
4 )  The effect of the e GLT inhibitor on entricular myocyte R Ca2� transport. 
S)  The long-tenn effects of DAPA on the ampl itude and time course of ventricular 
myocyte hortening. 
6) The effect of D PA on ventricular myocyte L-type Ca2+ Current. 
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The experiments in thi stud provide an insight into the effects of SGL T 
inhibitor on cardiac contract i l ity and some of the underlying Ca2
+ -mediated 
mechani ms. 
7 1  
Cha pter 3 :  Methodologica l Principle 
3. 1 .  Diabete Mel l i tu I nduction in  Rat 
Man) a pect of DM would sti l l  be unexplained, i f  it \ a not for e 'perimental 
model . Experimental models provide a convenient tool to understand DM 
path genesi and it compl ications, and to test new therapeutic strategies [ 1 69] . 
Animal model al 0 develop the compl ications of DM faster than humans making 
them easier to study [ 53 :  1 69] . Moreover, experimental models have a narrower range 
of ariation regarding gender, age differences, etlmicity, diet, l ifestyle and drug 
interaction compared to c l inical studies [ 53 ;  1 69] . Mo t research uses rodent models 
as they are easier to handle and maintain, and are cost-effective [ 1 86] . Large animal 
models such as cats and dogs can also be used [ 1 86] . There are several ways to create 
experimental models of DM in animals including surgical pancreatectomy. chemical 
induction, dietary induction. hormone induction. virus induction, genet ic induction 
and crossbreeding [ 1 69 ;  1 86; 259] . The first animal model for DM was the 
pancreatectomized dog in the experiments of Mehring and Minkowski [ 1 86] . 
Chemical induction of DM. sometimes cal led pharmacological induction, i s  another 
method of DM induction [ 1 86] . Intraveneous ( i .v . ), intraperitonial ( i . p . )  (F ig. 3- 1 )  or 
s .c .  injections of diabetogenic agents such as STZ, STZ-nicotinamide mixture. 
al loxan. vacor (vitamin B antagonist), dithizone. dehydro-ascorbic acid, pentamidine 
and 8-hydroxyquinol ine. which destroy the insu l in-producing pancreatic beta-cel ls (�­
cel ls ) ,  are used i n  this method [96;  1 86: 229;  267] . 
S TEP 1 
Intrapentoneal lnjectlOn The animal IS restrained by holding 
the front legs In one hand and stretching the tall out with the 
other 
Figure 3-1 : Intraperitonial injection in rats 
Retrieved from [234]  
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Position the forearm of the hand holding the front legs over 
the tail Use the opposite hand to administer the injection 
Be sure to deliver the injection In the lower nght quadrant of 
the abdomen 
The animal model produced by this method is suitable for screening natural 
products for their anti-diabetic properties ( insu l inomimetic ,  insul inotropic and anti -
hyperglycemic) as  wel l  as  studying the effect/respon e of anti-diabetic medications 
whose mechanism of action is  �-cel l - independent [ 1 59 ;  259] . However, this method 
has a disadvantage as the chemicals used might not be specific to the pancreas [ 1 59] . 
STZ and al loxan are the most commonly used diabetogenic chemicals. STZ 
has some advantages over al loxan. including a longer half- l ife ( 1 5  min) [259] .  Thus, 
i t  takes longer to be metabol ized and produces a more sustained hyperglycemia [259] . 
STZ also produces wel l-defined diabetic complications with a low chance of DKA 
and a low rate of mortal ity [259] .  STZ ( cal led Streptozotocin, Streptozocin, Izostazin 
or Zanosar) i s  i solated from Streptomyces achromogenes and was first discovered to 
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b diabetogenic in  1 963 b Rakieten and his col legues from their experimetns on 
dog and rat [ 5 :  259] . ] t  i al 0 a broad-spectrum antibiotic, ant i-neoplastic agent and 
alk) lating agent with pecific cytotoxic effects on the endocrine act ivity of pancreatic 
B-cel l  [206: 229] . It i used to induce both T 1 DM and T2DM [266] . Its structure is  
compo ed of two different moietie . a deox glucose and nitrosourea moieties ( Fig.  3-
2 ) .  The deoxygluco e moiet in the STZ structure interacts with GLUT2 protein 
which th n al lows TZ molecules to cross the cel l  membrane and enter the pancreat ic 









Destruction of B-ce l l s  by STZ takes place VIa both direct and indirect 
pathways ( Fig.  3 -3) .  The direct pathway is caused by the alkylating nitrosourea 
moiety of TZ which induces fragmentation of the D A strands leading to activation 
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of pol) - . DP-ribose yntha e ( P  R ) \\ hich diminishe nicotinamide adenine 
dinucleotide ( D+) co-enzyme and eventual ly causes a reduction in cellular A TP 
and necro is [259] . The indirect pathwa, in olves the generat ion of nitric oxide 0) 
and RO , and an inhibition of the Krebs Cycle  [266] .  0 and i nhibi tion o f  the Krebs 
Cycle cause a drop in cel lular ATP production and A TP dephosphory lation by 
xanthine oxida e [266 ] .  Xanthine oxidase then catalyzes the production of superoxide 
anion ( 02-) fol lowed by hydrogen peroxide H202) and hydroxyl radical COHO) 
generation [266 ] .  O2- can react v ith 0 to generate peroxynitrate CONOO) which is  a 
highly toxic compound. 0 and ROS cause D A alkylation and cel l  necrosi s [266] . 
ecrosi of �-ce l ls causes reduced i nsul in  production and DM. 
STZ 
/:0 
Krebs  / CYc i e  
.,[J,. O2 consumpt ion _....--1 
.,[J,.ATP product ion 
� itATP dephosphory lat ion 
U by Xanth ine Oxi dase 
� 0 -�2 NO o --+) ON OO DNA alky lat ion 
� PRAS activat ion 
� .,[J,.NAD+ 
� .,[J,. ATP 
Figure 3-3 : Mechanism of diabetes mel l itus induction by streptozotocin 
Adapted from [266] 
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STZ: streptozotocin; DNA: deoxyribonucleic acid: PARS: poly-ADP-ribose 
synthase: N A D+: nicotinamide adenine dinuc le06de; ATP: adenosine triphosphate; 
NO: nitric oxide: ROS: reactive oxygen species; O2-: superoxide anion; H 202 : 
hydrogen peroxide: OH-:  hydroxyl radicals ;  ONOO: peroxynitrate 
STZ can produce DM in rodents by a single injection of a large dose or by 
multiple injections of smal l  doses [229] . After STZ injection, fluctuations in �-ce l l  
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activity are observed cau ing sub equent change in blood insul in and blood gluco e 
[266] . Initial ly .  the in ul in-producing acti i ty of �-cel l s  i s  uppressed two hours after 
injection, which i reflected in low blood insul in and hyperglycemia [266] . Then after 
ix hour . their activit i transiently restored causing high levels of blood insul in and 
hypogly cemia but eventual ly the cel l s  lose their activity leading to a persistent rise in 
the BGL ( Fig. 3 -4)  [266] . The STZ solution needs to be freshly  prepared before 
injection due to its low stabi l i ty ,  and experiments should take place at least 5-7 days 
after DM induction in order to attain stable hyperglycemia [ 1 59] . 
A B 
c ·  
Figure 3-4: E ffect of streptozotocin on rat pancreat ic �-cel ls  
Retrieved from [ 5 ]  
.­
,. 
(A)  Biopsy of healthy pancreatic t issue before streptozotoc in (STZ) inj ection 
( B) Biopsy of pancreatic tissue after STZ injection showing destruction of �-cel ls  
3.2 .  Isolat ion of Ventricu lar  Myocytes 
In 1 846 at the University of Marburg, a student of the German Physiologist 
Carl Ludwig reported the development of experiments for studying isolated heart 
functions [328] .  In 1 866, Carl Ludwig and El ias Cyon publ ished a paper describing 
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the fir t heart i olation exp riment done with a frog' heart [ 1 75 :  328 ] .  Before 1 880, 
e. periment were done on frogs which are cold-blooded spec ies becau e their heart 
are imple having only one ventric le and not ha ing a coronary circulation unl ike 
warm-blooded mammal ian hearts [253 :  328] . The heart \ a mounted, cannulated and 
perfu ed ',,\' ith rabbit erum through the vena cava [253 ;  328 ] .  The perfusate was 
di charged [rom the a0l1a to a glass tube then recirculated back to the vena cava [253 ' 
328 ] .  Different scientists were able to improve the procedure. Kronecker showed the 
importance of upplying the heart with oxygen and Ringer was the first to real ize that 
i olated heart contraction can be maintained by perfusing it with electrolyte solutions 
containing Ca2+, a+ and K+ [ 1 75 ;  253 ] .  He developed ' Ringer' s solut ion ' ,  that was 
later modified to produce other physiological solutions including Tyrode and Krebs­
Henseleit [ 1 75 ;  253 ] .  In 1 880, Henry ewel l  Martin tried to develop experiments to 
i solate manlmal i an hearts using heart- lung preparations from cats or dogs [328] . In  
1 895,  the German physiologist Oscar Langendorff developed the Langendorff 
method. a method which is sti l l  widely used in many laboratories [ 1 75 ;  328 ] .  In  this 
method, the ascending aorta i s  cannulated and perfused in  a ' retrograde manner' 
(opposite to the physiological c irculation d irection ) ( Fig .  3 - 5 )  [ 1 75 ] .  In 1 967. Howard 
Morgan and James Neely adapted the Langendorff retrograde method to develop the 
so-cal led ' working heart ' model [ 1 75 ;  328 ] .  
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A. B. 
Coronary Aortic valve 
Figu re 3-5: Cannulation of the heart through the aorta 
Retrieved from [ 1 83 ]  
(A)  The aorta o f  the heart i s  mounted on the cannula o f  the Langendorff apparatus 
using fme-tipped forceps. A s i lk  thread can be tied around the cannulated aorta to 
secure it in place. 
( B) The Cannula should be i nserted above the aortic valve to close it during perfusion 
al lowing the perfusate to flow to the comary arteries. I f  the cannula is inserted 
deep below the aortic alve, the perfusate flows to the heart chambers instead and 
the isolation process becomes unsuccessful . 
After developing methods to study the intact i solated heart, the next step was 
to develop a method to study cardiac cel ls .  This  was made possible in  1 969 when 
Kono used rat hearts to develop a technique for isolating adult mammalian ventricular 
myocytes [32 ;  86] . General ly in  physiological studies, freshly isolated cel ls  are 
closely related to cel l s  in vivo and more rel iable than inunortal ized cardiac cell l ines 
in tem1S of structure and function [ 1 83 ] .  Adult cardiac cel ls  can be isolated by 
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mounting the heart on a cannula as mentioned previously. The cannula is connected 
to a perfu ion tern upplied with water-jacketed reservoirs and heat exchangers to 
maintain the temperature at 3 7°C throughout the whole perfusion process ( Fig. 3-6) 
[23 ] .  Perfu ing solutions are delivered to the cannula by either gravity using constant 
pre ure perfusion v,here a pre ure transducer is connected above the cannula to 
monitor the coronary perfusion pressure or b using constant flow perfusion where a 
peri taltic pump is connected to a chan1ber to which the cannula is fixed ( Fig. 3 -6) to 
deliver the perfusate at a constant flow rate ( flow rate range is 7-9 ml/min for rats) 
[23 ; 1 83 :  253 ] .  The cannula can be fabricated from glass, plastic or metal and its 
diameter ize d iffers according to the species, and the age and sex of the same 
species ranging from 1 .6 -3 .2 mm for rats and 0.6- l .3 mm for mice according to the 
age and sex [ 1 83 ] .  If it is too large. the cannula may not fit the aorta or may tear i t  and 










Figu re 3-6: Ventricular myocyte isolation using retrograde perfusion 
Retrieved from [ 1 87 J  
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The cannulated heart i s  connected via tubes to  three reservoirs and a peristaltic pump. 
The heart is  perfused at a certain rate with ( 1 )  Ca2+ -containing, ( 2 )  Ca2+-free ethylene 
glycol tetra-acetic acid-containing and (3) collagenase/protease isolation solutions. 
I solation of cardiomyocytes is done in several steps [32] . F irst. the cannulated 
heart is perfused with Ca2+ -containing isolation solution to wash out blood [32 ] . Heart 
contraction is  al lowed to stabi l ize. The heart contraction rate observed is  bradycardiac 
8 1  
compared to that in \'iro (250-320 compared to 350-400 beats/min in rats due to the 
lack of neuro-humoral control and extra-cardiac vascular supply to the A node [23 ] .  
econd, i t  i perfu ed with Ca2+-free isolation solution to  loosen the intracel lular 
connections. Third, the heart is perfu ed ith an enzyme-containing isolation solution 
[ 32 J .  Langendorff retrograde enz matic digest ion is  commonly used to isolate 
ventricular m ocyte [32;  1 83 ] .  In some laboratories, Langendorff retrograde 
enzymatic digestion can be replaced or combined with another enzymatic digestion 
method called the ' immersion method ' which in olves incubation of t iny pieces of 
the tissue in different solutions and gentle agitation [32 ] .  This  method is used to 
isolate ventricular myoc)1es from bovine or canine healis that cannot be perfused. 
and myoc)1es from certain heart t issues such as the SA node. Purkinj ie fibers, and 
human heart biopsies [32) . Choosing the perfusing enzyme is a crucial step. Different 
types of col lagenases. with col lagenase type I I  from Worthington being the most 
common. can be used alone or with other enzymes including proteases or pancreatin  
for adult rats and mice cardiomyocyte isolation [ 1 83 ) .  Hearts of older animals are 
bigger in size and have d ifferent extracel lular matrices so, they usual ly need a higher 
concentration of enzymes, longer perfusion duration or both. After the heart i s  
perfused with the three solutions. i t  becomes soft, swol len and pale [ 1 83 ) .  Fourth, the 
heart tissue is shaken mechanical ly  to release the myocytes from the t issue [32 ) .  
Scattered myocytes are al lowed to  sediment on a myocyte mesh col lector (fi l ter) 
( 200-500 j.tm for adul t  myocytes) by means of gravity or gentle shaking [ 1 83 ) .  
Myocytes pass through the pores o f  the mesh col lector whi l st undigested cardiac 
t issue remains in the mesh [ 1 83 ] .  Finally, the t issue is centrifuged to separate the 
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high-den ity rod-shaped iable m ocyte from the low-density rounded dead 
myocytes [ 32 ;  1 83 ] .  The upematant is discarded and the pel lets of myocytes are re­
suspended in a physiological solut ion. The shaking, fi ltration and centrifugation 
processes are repeated se eral times as needed [ 1 83 ] .  Myocyte viabi l i ty can be 
a e ed b) mea uring the ratio of rod-shaped (al ive)  myocytes to round-shaped 
(dead) my c)1es using a eubauer hemocytometer [34] .  I f  the myocyte isolation 
process was perfom1ed proper! . its final yield mainl consi sts of viable 
cardiomyoc)1es ( Fig.  3 -7) .  
Rod-shaped myocyte Rounded myocyte 
Figure 3-7:  I solated rat ventricular myocytes 
Adapted from [ 326] 
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3.3. Video Edge Detection 
The exp riment pre iousl mentioned developed to isolate heart myocytes 
paved the wa to tudying hortening and contracti le functions within individual 
myocyte . Cardiomyocyte hortening bas been studied by monitoring the movement 
of one or both end of the myocyte [74 ] .  Three popular methods are Llsed i ncluding 
video edge detector , photodiode arrays and laser diffraction teclmiques [260] . Video 
edge detection eVED) i \ idely used especial ly with adult cardiomyocytes [ 1 9] .  
E lectrical ly- timulated cardiom ocytes in vitro change their length along their 
longitudinal axi during contraction and relaxation: they shorten during contraction 
and return to their resting length during relaxation [260] . VED assesses changes in  the 
length of the cardiomyocyte by using a raster- l ine at each of the left and the right 
edges of the myoc)1e to monitor its movement during shortening and relaxation [ 1 9] .  
V E D  can be done either b single-edge detection (SED), where the contraction of 
only one horizontal edge is  monitored. or b double-edge detection ( DED) ( Fig. 3 -8 ). 
where both horizontal edges of the myocyte are monitored [74] . DED is  better 
because it avoids some problems that occur with the SED such as unequal contraction 
ben\'een both edges and inaccurate monitoring of myocytes moving non­
longitudinall [ 74] . 
Figu re 3-8: Double-edge detection video image of an isolated entricular myocyte 
Retrieved from [3 1 5 ]  
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The ventricular myocyte IS anchored between two black raster- l ines with white 
tracking dot to monitor the movement of the myocyte along its longitudinal axis .  
The VED system is  used along with an electrical stimulator. a television 
camera, an analogue-digital converter, a monitor screen, a computer and/or a chart 
recorder. To generate contractions, electrical stimul i  are sent from the stimulator to 
the myocyte chamber ( Fig. 3-9)  ia two platinum or s i lver wire electrodes, placed 
opposite to each other [ 1 63 ] .  This causes a series of consecutive events in the 
chamber that eventual ly lead to myocyte contraction. First, an electric field is created 
around the myocytes which in turn generates a flow of current (charges movement) 
[283 ] .  ubsequently. a gradient i n  potential i s  developed around the cel l  membrane 
leading to change of the outer membrane potential with respect to the inner 
membrane potential ( transmembrane potential ) which triggers voltage-gated ion 
channels of myocytes to produce transmembrane currents and then myocyte 
contraction [283 ] .  
Perfus ion i n l et P latfonn 
Myocyte chamber Perfus ion out let 
S t imulat i ng wire e lectrodes 
Figu re 3-9: Myocyte perfusion chamber with field stimulation 
Retrieved from [297] 
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Cardiomyocytes are characterised by having variable width, and having gap 
j unction and i ntercalated discs around their edges which make their edges irregular 
[ 1 9 : 74] . Those chosen for shortening experiments should be viable rod-shaped with 
intact morphology and defined edges, they should contract consistently during the 
whole electrical stimulation process and they should not exhibit spontaneous 
contraction [ 1 9: 260; 3 1 5 ] .  The two raster- l ines are positioned at each end of the 
myocyte ( Fig 3 -8 )  from which l ight intensity-dependent voltages at myocyte edges 
can be measured [260] . The television camera focuses the image of the electrical ly-
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stimulated myocyte al lov"ing the image to be recorded [260] . The signal then pas es 
from th camera to the YED stem which analyzes the data and measures the 
distance between the two edges on a mi l l  i-second Cms) by ms basis [ 1 9: 260] .  The 
analy zed data i then conveyed via an analogue-digital converter. which digitizes the 
ignaL to the computer and/or chart recorder [260] . The analyzed data is also sent to 
the monitor screen to show the myocyte contraction. A series of contractions are 
recorded in each myocyte and their mean is used to evaluate the extent of shortening 
in  the cel! [260] . A summary of measuring shortening in electrical !  -stimulated 
myocytes is hO\\l1 in Fig 3 - 1 0 . 
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( B) (C) 
F igu re 3- 1 0 : Measuring cardiomyocyte shortening 
The stimulator (A) sends electrical signals to the cell chamber ( B) .  The camera (C )  
records the image of the myocyte .  Movement is analyzed by  the video edge detection 
system ( D )  and can be seen on the monitor ( F) .  The signal passes to the analogue­
digital con erter (E) .  Data are captured, stored and analyzed on the computer ( G )  
and/or chart recorder ( R ) .  
3.4.  Fluorescence Photometry 
Fluorescence photometry is  an optical technique that can be used to measure 
the concentration of intracel lu lar ions and other parameters with fluorescent 
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indicator [45 ] .  I t  i ba d on loading the cel l  with a fluorescent indicator by al lowing 
it to pa pa ively into the cel l  acros the membrane (d iffusion). by injecting it into 
the cel l  via a microelectrode (micro injection) ( used with relativel large cel ls)  or by 
patch clamping in cel l -attached configuration to introduce the indicator intracel lularly 
(u ed with relatively mall cel ls)  [45 ;  65 ] .  There are two fonns of indicators 
avai lable: pota ium salt and acetoxy meth I (AM) ester fOnTIS [65 ] .  Potassium salt 
indicators can be loaded by microinjection. with large cel ls, or patching, with smal l 
cel l s  [45:  65 ] .  On the other hand, AM ester indicators are often loaded by d iffusion 
becau e i t  al lows loading man cel l s  together, but they can also be loaded with 
microinjection and patching [45 ] .  AM ester renders the indicator molecule l ipophi l ic  
o that it i s  able to cross the cel l  membrane passively [65 ] .  The ester l ink i s  then 
degraded by cyto ol ic  esterases releasing the free indicator [65 ] .  The fluorescent 
indicator binds to the intracel lular ion of interest causing a change in the indicator 
electronic configuration and a subsequent change in its fluorescence [45 ] .  Photons are 
then bombarded at fl uorescent indicator-loaded cel ls [45 ] .  Photons react with the ion 
molecules bound to the fluorescent indicator ( fluorescent molecules) i n  the cel l  that 
have absorbance within the photons wavelength range. The fluorescence molecules 
absorb the photons and they reach an excited state [45 ] .  The excited molecules then 
emit the absorbed photon and return to the ground state (Fig. 3 - 1 1 )  [45 ] .  Quantum 
efficiency is the ratio between photons emitted to photons absorbed [45 ] .  Since the 
emitted photons are always less than those absorbed because they get reabsorbed or 
col l ide with other molecules and quench, quantum efficiency is always less than one 
[45 ] .  The photons emitted have relatively low energy and long wavelengths, whi le 
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ab orbed photon have relatively high energy and short wavelengths [45 ] .  The 
emitted fluore cence i mea ured in which the indicator-photon interaction results in 
a change in the indicator fluorescence wavelength [45 J .  
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Figu re 3-1 1 :  Effect of photons on the molecule of the fluorescence indicator 
Retrieved from [45 ] 
When the molecule absorbs the photons, the electron energy is increased and the 
electrons j ump to the higher singlet level S* (excited state) .  Electrons then emit the 
absorbed photon and return from S* direct ly to their ground level ( ground state) 
releasing fluorescence of a certain wavelength. If the indicator is bleached due to 
oxidation and thermal decay the electron does not go directly  to its ground level and 
non-radiative loss occurs where no fluorescence is emitted. 
I t  should be noted when applying this method that some contan1ination errors 
might occur due to cel l  auto-fluorescence which occurs due to spontaneous 
fl uorescence of some cel lu lar components, or the presence of other molecules within 
the range of photons absorbance other than the molecules of interest [45 ; 27 1 ] . 
Energy associated with the photons can be very high, resulting in generation of large 
amounts of heat which might degrade the indicator by b leaching and destroy the cell 
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[45 ] .  In addition. i f  the concentrat ion of the ion measured, or that of the indicator, i 
to smal l to produce a ignaL low ignal to noi e ratio is  obtained [45 ] .  
There are h 0 classes o f  fluorescence indicators : non-ratiometric and 
rat iometric [27 1 ] . on-rat iometric indicators have one excitation and one emission 
wavelength and they do not how any shi ft in any of their wavelengths on ion 
binding. but they inc rea e their emission fluorescence yield [232;  2 7 1 ] .  Ratiometeric 
indicator . on the other hand, either ha e two excitat ion and one emission wavelength 
uch as Fura-_ ,  or one excitation and two emission wavelengths such as Indo- 1 and, 
on ion binding. they shift their excitation or emission wavelengths, re pectively. 
increasing their emission fluorescence yield [232; 2 7 1 ] .  Having a pivotal role in 
contraction regulation, Ca:!+ is  the fir t ion that comes to mind when studying musc le 
contraction in general and cardiac contraction in particular. In  the early 1 980s. Tsien 
and his col leagues developed several fluorescent CaH chelators inc luding Quin-2. 
Fura-2 and Indo- l by adding fluorophores to I .  2-bis-(2-an1i nophenoxy) ethane­
NNN' '-tetra-acetic acid ( BAPTA) [65 ] .  These indicators bind to Ca2+ with a 
stoichiometric ratio of 1 :  1 [65 ] .  In some respects, Fura-2 is  better than Quin-2 
because i t  has a better absorption coefficient. quantum yield ( 30  times brighter), Ca2
+ 
selectivity and b leaching resistance [65 ] .  The high brightness of Fura-2 signals makes 
autofluorescence negligible [65 ] .  These advantages make Fura-2 a popular indicator 
for studying intracel lular Ca2
+ [2 1 8] .  Fura-2 has two excitation wavelengths at 340 
and 380 nm and one emission wavelength that i s  usual ly measured at 5 1 0  nm [65 ] .  
Fura-2 produces a bluish-green glow that can be seen under the standard 
epifluorescence microscope [65 ] .  On binding to Ca2
+, its electronic configuration 
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changes where the inten it of its 340 run excitation fluore cence is  increa ed 3 times 
while the intensity of it 3 80 nm e ci tation fluorescence is decreased 1 0  times ( Fig. 3 -
1 2 ) [65 J .  
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Figu re 3- 1 2 : The shift in Fura-2 excitation fluorescence intensity on binding to Ca2+ 
Retrieved from [65 ;  1 76J  
Left panel :  the sol id l ine represents the wavelength of Fura-2 saturated with Ca2+ and 
the dashed l i ne represents the wavelength of free Fura-2. Right panel :  gradual 
increase in concentration Ca2+ bound to Fura-2 causes gradual increase and decrease 
in the intensity of 340 and 380 nm excitation wavelengths, respectively .  
To measure i ntracel lu lar Ca2+ with Fura-2, a ratio method is  appl ied where the 
ratio of bound to free i ndicator is calculated. This method remo es any variations 
resulting from instrumental fluctuations as wel l  as changes in  the indicator 
concentration l ike leakage or bleaching, as i t  is independent of the indicator 
concentration [65 ;  2 1 8J .  The fol lowing equation can be used to calculate this rat io :  
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Where KJ i the dis ociation constant, Fo is  380 nrn excitation fluore cence intensity 
at zero Ca2+ concentration, Fs i 380 nm e ci tation fluorescence intensity at saturated 
a2+ c ncentration. G �) i the ratio of 380 nm excitation fluore cence intensity at 
zero to aturated Ca2+ concentrations, R is the ratio of fluorescence intensity induced 
b} 340 nrn to that induced by 380 nm, Rmm is the ratio of excitation spectra (340/380)  
at  zero Ca2+ concentrat ion and Rma'\ i s  ratio of excitation spectra (340/3 80) at 
saturated Ca2+ concentration [65;  2 1 8] .  
Despite the advantages of Fura-2 AM, i t  also has some problems. One of its 
major problems is  compartmental leakage where i t  can bind to various cel lular 
organel les including SR and mitochondria [65 ] .  This  problem can be overcome by 
to ring the cel l s  at 4°C before Fura-2 AM loading, by loading the cel l s  at low 
temperatures or by dialyzing Fura-2 in  its salt fom1 into the cell using a pipette [233 ] .  
I n  addition to leaking into cel lular organel les, Fura-2 can also leak outside some types 
of cel ls .  This can be reduced by lowering the temperature of the experiments below 
the physiological temperature to 1 5 -33°C [65;  233 ] .  Some Fura-2 commercial 
preparations are contaminated with esterase resistant elements resulting in  insufficient 
degradation of AM l i nks in  the cytosol [23 3 ] .  This  problem can be avoided by 
replacing AM l inks in  Fura-2 molecules with pentapotassium salt [233 ] .  Fura-2 is 
also susceptible to quenching with heavy metals, which can be avoided by adding 
heavy metal chelators such as , , ' .N'-tetrakis (2-pyridylmethyl )  ethylenediamine 
(TPE ) [23 3 ] .  A summary of measuring intracel lu lar Ca2+ concentration in Fma-2 
loaded myocytes is shown in Fig 3 - 1 3 .  
93 
Light source (A)  Monochromator 
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Figu re 3- 1 3 :  Measuring cardiac intracel lular Ca2� in  Fura-2- loaded myocytes 
Light is projected from the l ight source to the monochromator (A)  which generates 
l ight of required wavelength ( 340/3 80 nm), bandwidth and mi l l i second time 
resol ution. This l ight i s  then projected via a l ight guide through the microscope optics 
to the Fura-2 loaded myocytes (B ) .  Emitted fl uorescence is  passed through a 5 1 0  nm 
fil ter to the photomultiplier tube ( PMT) (C)  and col lected by the camera ( D). The 
PMT (C)  converts l ight to electrical energy (vol ts) ,  amplifies the signal and sends i t  
to the fl uorescence photometry system (E) which analyses the signal .  The signal then 
passes to the analogue-digital converter ( F) .  Digitized signal is then sent to the 
computer ( G )  and/or chart recorder ( R ). During experiments, the myocyte (B )  i s  
electrically stimulated by the stimulator ( 1 ) .  The camera (D)  records the image and 
sends it to the monitor screen (J ) .  
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3.5. Patch Clamp 
Ion channel are transmembrane proteins which serve as  pa sage for ions 
from and to the cell [302] . It is important to tudy their activity as they regulate the 
gen ration of card iac and neural APs. through production of cunents, because of their 
ion electi\ e permeabi l i ty and sub equent ionic mo ement [ 1 08 ;  302 ] .  Electrical 
activity in mu cles \ as fir t discovered b Luigi Galvani in 1 79 1  [324 ] .  Afterwards 
in 1 939.  Hodgkin and Huxley mea ured the intracel lular AP for the first time in giant 
squid axon using gla capi l laries [324 ] .  In 1 946, Graham and hi s col leagues 
developed micropipettes ( less than 5 �m in outer diameter) to study APs in smaller 
structures [324] . In  1 949, the voltage clamp technique was developed by Cole and 
Marmowlt to measure the voltage and current of the cell membrane using a 
micropipette [324 ] .  The patch clamp technique was developed in the late 1 970s by 
eher and Sakman to al low recording of the membrane cunent in smal l  cel ls with 
low noise where they replace the micropipette with a blunt-ended pipette (0 .5 -2.0 �m 
in diameter) [ 1 49; 324 ] .  The teclmique involves positioning a glass pipette against the 
cel l  membrane t i l l  a seal .  with 1 0- 1 00 GO resistance, is fomled [ 1 1 6] .  This  seal is 
cal led a . giga-seal ' and i t  improves the resolution of the cunents recorded by 
reducing the background noise that might arise from the cell membrane, pipette and 
recording electronics [ 1 1 6] .  This glass pipette injects current into the cell to stimulate 
it [ 89] . The depolarization of the cel l causes ion channels  to open [ 1 08 ] .  Ion channels 
general ly  shift between three transitional conformations which are open, inactive and 
c losed ( resting) (Fig .  3 - 1 4) [ 1 66] . When the channel is open, i t  is activated and 
produces a current, whi le no cunent is produced when i t  is c losed or inactivated 
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[ 1 66] .  Gating i the proce s of opening and closing of the channel .  orne channels 
� +  .. 
( a- and a )  become inacti at d after ustained acti ation (depolarization) or after 
clo ure [ 1 08 ] .  Inacti ation is observed as slow degradation of the cunent [ 1 49] . 
Inactiyated channel cannot open directly, but should fir t reco er by c losure to 
become read) to re-open [ 1 49] .  The inactivation proce s prevents premature 
activation and provide a refractory period before the fol lowing activation [ 1 08 ] .  
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Figure 3- 1 4 :  Behavior of voltage-gated channels 
Retrieved from [ 1 49] 
The ion channel goes through three transitional confom1ations; open (0 ), inactive ( 1 )  
and closed ( C ) .  The asterisk indicates a confonnation that passes current. Relative 
probabi l ity of transitions is  indicated by size of anows. Init ial ly, a change in 
membrane voltage (depolarization ) changes the c losed transition to open 
(activat ion) .The opened channel then becomes inactivated ( inactivation). The channel 
eventual ly  transitions from inactivated confonnation to c losed again ( recovery) .  
The patch c lamp technique can be  used for the measurement of  a single 
channel or whole cel l channels e lectrical act ivity, gat ing, ion selectivi ty and ion 
permeabi l ity which makes i t  a useful tool for studying the molecular mechanisms 
underlying the electrical activity in  cardiac cel l s  as wel l  as neurons [59 ' 1 66] . It is 
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al 0 an ideal technique to tudy how ion channels are affected by different 
compound [302 ] .  e\"ertheless, patch clamp is a chal lenging and compl icated 
technique that demand \ el l -control led experimental conditions and a ski l l ful ,  
experienced researcher. I t  al 0 has very low throughput [59 ] .  
Two modes of patch c lamp can be appl ied which are voltage c lamp, that 
inyol\"es holding membrane voltage at a certain value while measuri ng CUlTent 
generated a a re ult of ionic movement across the membrane, and CUHent c lamp that 
in\"olves holding membrane CUHent at a certain value whi le measur ing voltage (action 
potentia l )  [50 �  1 49 �  1 66] . 
There are two types of electrodes used in patch c lamp recording: the reference 
(ground) and recording electrodes [50 ] .  These electrodes are usual ly made of 
platinum or si lver (Ag/AgCl )  but Ag/AgCI is commonly  used due to the high cost of 
platinum [324 ] .  These metals ha e low j unction potentials which minimizes the 
generation of a potential at the sol id- l iquid junction between the electrode and the 
solution in the chamber [324 ] .  The AgCl layer at the surface of Ag electrodes is worn 
over t ime as it undergoes a re ersible redox reaction, therefore, it needs to be 
replenished by either electrophoresis in a chloride solution or immersing it in sodium 
hypoch lorite bleach [ 324] . The reference electrode is  imm ersed in the bath solution 
for comparison with the recording electrode [50 ;  324 ] .  A glass pipette is placed 
around the recording electrode with which the cel l  is approached [324 ] .  The recording 
electrode translates the ionic CUlTent produced by the cel l  to an electrical current 
[324] .  The glass pipette should have low resistance and capacitance transients in the 
range that can be compensated by the amplifier [324] . Glass pipettes are very 
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convenient a they can be fi l led with olution . dyes or any compounds to be dialyzed 
into the cel l  during th experiment [ 50] . Before a glass pipette can be fi l led. it i 
fabricated by either pull ing it once or more than once. in a horizontal or ertical pul ler 
[ 1 66: 1 1 5 ] .  metal fi lament or a laser is  used to heat the glass pipette fol lowed by 
dra\\ ing out the pipette using gra i ty or a mechanical s stem [36] . Figure 3- 1 5  shows 
a pipette produced by double pul l s. One of the techniques that can be used to estimate 
the diameter of the pipette tip is by measuring the pressure taken by the pipette to 
expel air bubbles from its t ip in c lean ethanol [2 1 5 ] .  The tips of the pul led glass 
pipettes should be smooth and blunt to prevent damage to the cel l  membrane and to 
make better seals [324] . To a oid contamination of the pipettes and their tips with 
airborne particulates. pipettes are usual ly pul led short ly before use and kept in  a 
sealed case [ 1 66] . After pul l ing. the pipette is fire pol ished using a heated platinum 
wire to smoothen and flatten the surface of its t ip [2 1 5 : 324 ] .  Borosi l icate glass 
( Pyrex) is the most commonly used glass because i t  softens at low temperatures 
fac i l i tating its pul l ing. it seals easi ly  with cel l  membranes during high resi stant- and 
giga-seal formation and it has relatively low electrical noise during recordings [ 1 66 ;  
2 1 5] .  I t  has been reported that fl int glass is  better than borosi l icate because i t  has a 
lower melting point and forms membrane seals with higher stabi l i ty [ 1 1 6] .  
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Figu re 3 - 1 5 :  Heat double-pu l l ing of  patch pipette 




The patch c lamp set-up is composed of several components as shown in 
F igure 3- 1 6 . Cel l s  are put in  a bath chamber with volume usual ly ranging from 500 fll 
- 1  ml .  its bottom is made of glass to al low attachment of the cel ls when they settle 
[ 1 66] .  The chamber is  placed on an inverted microscope which is used to select 
suitable cel ls  and adj ust the patch pipette orientation as it approaches and makes 
contact with the cel l  [ 1 66] .  There two main reasons for using an inverted microscope . 
The presence of the objective lens below the chamber faci l itates the movement of the 
electrodes in the chamber, and it serves as a sol id support and a large stage for the 
manipulator [50] . The location and movement of the patch pipette is  control led by a 
mechanicaL electrical or hydraul ic  micromanipulator which al lows three-dimensional 
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movement of the pipette in X, Y and Z axes [50:  1 66] . A headstage is mounted on the 
micromanipulator and is connected to the recording electrode (via an electrode 
holder), reference electrode, and a suction tube which i used to achieve a giga-seal 
[ 50: 1 66] . The headstage connects the cell chamber with an anlplifier [ 1 66 ] .  The main 
function f the anlplifier i to ampl ify the signal ( l  00- 1 000 x ), coming from the two 
electrode of the headstage, and compare them [50 ;  1 66] . In addition, the amplifier 
can be u ed to switch between oltage and cunent modes, compensate capaci tance 
and a i t in data acquisition [ 1 49: 1 66] . An analogue-digital converter converts the 
acquired analogue data, coming from the head stage, to digital and sends it to the 
computer to be analyzed and recorded [ 1 66 ] .  The analogue-digital converter also 
convert the digital output data. coming from the computer, to analogue and sends it 
to the headstage [ 1 66] . Data is eventual ly  acquired and analyzed using computer 
software [ 1 66] . An osc i l loscope can either be used as the main source of data output 
where it displa s the signal of the membrane oltage coming from the amplifier 
throughout the experiment. or instead, a computer with virtual osc i l loscope software 
programs can perf 01111 this function [50 ] .  The inverted microscope, micromanipulator 
and headstage are a l l  placed on an anti -vibration table to provide a steady platf01111 
that e l iminates vibrations during giga-seal f01111ation and patch c lamp experiments 
[ 1 66] . A Faraday cage, which is  fonned of a mesh made of a conductive material 
( usual ly copper), usual ly sunounds the entire patch c lamp system and is  connected to 
a ground source to insulate it from any ambient electromagnetic fields that may cause 
noise during recordings [50 ;  1 66 ] .  
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Figu re 3- 1 6 :  Main components of patch c lamp set-up 
Retrieved from [ 1 66]  
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The internal recording electrode ( A ), in  the patch pipette, and the reference electrode 
( B) are connected to the head stage (C)  which is mounted on the micromanipulator 
( D) .  The inverted l ight microscope ( E )  is used to visual ize the isolated cel l s  to select a 
suitable ce l l .  The headstage (C). the micromanipulator ( D )  and the inverted l ight 
microscope ( E) are all placed on the anti-vibration table ( F) to protect them from 
vibrations during giga-seal formation. The entire system is  surrounded by Faraday 
cage ( G )  to insulate the system from ambient electrical noise .  The head stage (C)  
sends the acquired analogue signal to  the analog-digital converter ( H) .  The digitized 
signal i s  then sent to the computer ( 1 )  which is used to generate experimental 
protocols, and acquire and analyze the data. The experiment is monitored and data is  
displayed on the oscil loscope (J ) .  
The configurations that can be obtained with patch pipettes include ce l l -
attached, whole-cel l ,  inside-out. outside-out and perforated c lan1p configurations ( Fig.  
3 - 1 7 ) .  Cel l -attached configuration i s  the non-invasive starting point for obtaining a l l  
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th other four configuration [324] . It invoh'es approaching the cel l  with the glass 
pipette and then applying orne negative pres ure (suction) to the pipette. using the 
uction tube attached to the headstage. unt i l  a high re istance seal i obtained [ 1 66] . 
The tight attachment of the patch pipette with the patched cel l  membrane traps the 
ion in the patched area, which cau es the ions to flow to the patch pipette reflecting 
the activit of ion channe ls  in the patched area [50; 1 66] . Whole-cel l  configuration 
i l1\'o )ves reaching cel l -attached (giga-seal ) configuration and applying more suction 
to di rupt the patched area of the membrane providing continuity of pipette with the 
cel l  membrane and continuit of the pipette solution with the intracel lular fluid [324] . 
The electrical activity of the whole cel l membrane can then be recorded [50] . Inside­
out configuration can be obtained after cel l -attached (giga-seal )  configuration 
fol lowed by withdrawing the pipette taking a patch of the membrane with it and thus, 
subjecting the intracel l ular en ironn1ent to the chamber solution [324] .  I t  i s  used to 
measure the electrical activity of single ion channels while changing the solution to 
which the intracel lu lar envirolID1ent is exposed [50 ;  324] . Outside-out configuration 
can be obtained by retracting the pipette after whole-cell configuration causing the 
removed membrane patch to invert its position with respect to the orientation of the 
cel l  membrane [50] .  Thus, the exterior surface of the membrane comes in  contact 
with the chamber solution [50] . It is used to study the effects of extracel lular chemical 
signals on ion channel act ivity [50 ] .  Both Inside-out and Outside-out configurations 
are cal led cel l -excised configurations [ 324 ] .  Perforated patch configurat ion is 
sometimes used instead of whole-cell configuration. It al lows measuring the 
membrane activity without the risk of leakage of the intracel lular contents that occurs 
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w ith whole-cell patching [ 50; 1 66 ) .  It invol es appl ing a chemical in  the glass 
pipene uch a amphoth ric in-B. nystatin or gramicidin, instead of suction. after c l l ­
attached configuration w hich form membrane perforations [50 ;  1 66 ] .  
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Figu re 3- 1 7 : The four configurations of patch clamp teclmique 
Retrjeved from [50]  
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Chapter .. k Materia ls and Method 
4. 1 .  M aterial 
4. 1 . 1 .  Animal  M odel 
Seventy male adult Wistar rats were used for these experiments and were bred 
in the animal hou e faci l i t  at  the Col lege of Medic ine and Health Sciences, United 
Arab Emirate Uni ersity. Rats (::::: 200-250 g) were divided into n-\'o subgroups. At 
the age of 2 months, DM was induced in one subgroup by a single i .p .  inj ection of 
TZ ( 60mg/kg body weight) dissolved in a citrate buffer solution (0 . 1 molll c itric 
acid and 0. 1 molll sodium citrate, pH 4 .5 ) .  The other subgroup received an equivalent 
volume of citrate buffer to form the Controls .  To confim1 DM, non-fasting BGL was 
mea ured in blood obtained from the rat tail vein, 3-5  days fol lowing the induction of 
DM. Each ubgroup was caged separately .  but both groups were kept under the same 
l ight and temperature conditions, and were suppl ied with standard rat chow diet and 
water ad libitum. Experiments were started 2 months ( 8- 1 2  weeks) after DM 
induction. Prior to each experiment. rat body weight, heart weight and non-fasting 
blood glucose were measured. A l l  the procedures implemented in  this  project were 
approved by the Animal Ethics Committee, Col lege of Medic ine and Health Sciences, 
U nited Arab Emirates U niversity. 
4.2. M ethods 
4.2. 1 .  I solat ion of Ventricu lar  Myocytes 
Fresh ventricular myocytes were isolated on a daily basis .  Rats were 
euthanized using a guil lotine and their hearts were rapidly removed. The heart was 
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mounted in Langendorff mode on the cel l i olation apparatus. Hearts were perfused in 
a retrograde manner at a con tant flo\ rate of 8 mllg heart .min (Fig .  4- 1 ) . lnit ial l  . 
the heart wa pernl ed with cel l  isolation solution containing in mmolll : 1 30.0 aCt 
SA KCL 1 .4 MgCb. 0 .75 CaCb. 0.4 NaI-hPO,J. 5 .0  4-(2-hydroxyethyl)- 1 -piperazine 
ethane ulfonic acid ( HE PE ). 1 0 .0 glucose. 20.0 taurine and 1 0 .0 creatine ( pH 7 .3 ). 
When contraction had tabi l ized. perfusion was switched to Ca} -free cel l  i solat ion 
olution containing 0. 1 mmolll ethylene glycol tetra-acetic ac id ( EGT A) for 4 minutes 
and then to cel l i olation olution containing 0.05 mmolll Ca2+, 0 .60 mg/ml type 1 
col lagenase ( Worthington Biochemical Corp, Lakewood. J, USA) and 0.075 mg/ml 
type XIV protease ( Sigma, Taufkirchen, Germany)  for 6 minutes. The heart was then 
removed and ventric le t i ssue was excised and minced with scissors. The tissue was 
then shaken gently  in col lagenase and protease containing isolation solut ion 
supplemented with 1 %  bovine serum albumin ( BSA).  Ventricular myocytes were 
fil tered from this solution at 4 minute intervals. using a nylon mesh (pore size ::::; 300 
11m) .  The fi ltered myocytes were then centrifuged for 1 minute and the supernatant 
was discarded whi le the myocyte pel lets were re-suspended in cel l  i solation solution 
containing 0 . 75 mmolll Ca}+. The shaking, fi ltration and centri fugation steps were 
repeated 4-5 t imes. Ventricular myocyte viabil ity. indicated by the myocyte rod­
shape. was checked after each shake under an upright compound microscope (Zeiss, 
Goningen, Germany) .  F inal ly, isolated ventricular myocytes were stored in the 
refrigerator (4°C) in isolation solution containing 0 .75 mmol/l Ca}
+. or in Kraft-Bruhe 
( KB )  solution for patch c lanlp experiments containing in mmolll : 0 .5  EGTA, 1 0 .0 
glucose. 1 0.0 HEPES, 40.0 KCI, 50.0 K glutamate, 20.0 KJ'hPO,J and 20.0 KOH (PH 
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7 .4) .  It was report d that storing m ocytes in KB olution increases the number of 
Ca2+ tolerant myocyte [ 1 3 5 :  325 ] .  Myocytes were u ed up to 8 hours after isolation. 
( l )  Ca2+ -conta in ing isolation solut ion 
( 2 )  Ca2+- free EGTA isolation solution 
(3 ) Col lagena e/protease i so lat ion solution 
Langendorff apparatus 
pump 
Cannu lated mounted heart 
Figure 4- 1 :  Ventricular myocyte isolation apparatus 
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4.2.2 .  Electrophy iological Mea u rement 
4.2.2 . 1 .  Preparation of od i um/G luco e Co-tran porter I n hibitor and Normal  
Tyrode Working olu tion 
Working olutions \'-.'ere freshly prepared prior to each experiment. In the 
experiment , two working solutions ere u ed, one containing normal Tyrode (NT) 
(comp sed of in  rnmol/l : 1 40.0 NaCL 5 .0 KCl .  1 .0 MgCh, 1 0 .0 glucose, 5 .0  HEPES, 
1 . 8 CaCh and pH 7.4) + 0.005% dimethyl sulfoxide ( DM 0 )  (0 .005 ml DMSO in 
each 1 00 ml T) and the other containing 1 0.6 M of any sodium glucose co-
transporter ( GLT) i nhibitor tested + T + 0.005% DMSO. 
DM 0 was used as an organic solvent for a l l  SGLT inhibitors : PHLOR 
(CD 000 1 04 .  S igma-Aldrich, Saint Louis. Missouri .  USA). QUER-3-G ( 1 7793, 
Igma. Taufkirchen. Gem1any) .  and DAPA ( S I 548, e l leck Chemicals. Houston. 
Texas. SA).  at a final concentration of 0.005%. At 0 .0 1 %  concentration. DMSO has 
been reported to have no significant  effects on contracti le  parameters and Ca2+ cunent 
[ 1 05 ;  263 ] and �0. 1  % DMSO showed no significant effects on myocyte morphology 
and contracti le function [ 1 82]  in rat myocytes. In this study. equivalent concentration 
of DMSO (0.005%) was di ssolved in  both T and SGLT inhibitor working solutions 
to make sure that myocytes were exposed to the same concentration of DMSO in a l l  
experiments. 
The electrophysiological set-up shown in Figure 4-2 was used to measure 
ventricular myocyte shortening. intracel lular Ca2
+ transient, myofilament sensitivity 
to Ca2+ and SR Ca2+ release. 
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Figu re 4-2 : Electrophysiological set-up 
( 1 )  Micropumps power supply. ( 2 )  Micropumps control ,  (3)  Rapid solution switching 
device control ,  (4)  Rapid solution switching device (5)  I nverted microscope, (6 )  
Faraday cage. (7 )  Anti-vibration table, (8 )  Camera control (9)  Video edge detection 
system. ( 1 0) Fluorescence photometry system. ( 1 1 )  Temperature control system ( 1 2 ) 
TV monitor, ( 1 3 )  Computer. ( 1 4)  Chart recorder and ( 1 5) Stimulator. 
4.2.2 .2 .  Mea u rernent  of Vent ricu lar  Myocyte horten ing 
1 09 
Ventricular myocyt shortening was recorded using a VED system ( Fig. 4-
3 ) .  nloaded myocyte (Fig.  4-3 B )  were a l l  0\, ed to sett le on the glass bottom of a 
Per pex chamber mounted on the stage of an in erted microscope ( Axiovert 35 ,  
Zei . Gottingen. Germany). Myocytes were continuously superfused with T at a 
rate '" -5 mllmin.  hortening parameters inc luding resting cel l length ( RCL),  time to 
peak ( TPK) hortening. time to  half ( THALF) relaxation and the amplitude (AMP) of 
shortening (expressed as a percentage of shortening in Control and STZ myocytes 
perfused with T and expressed as a percentage of RCL)  were measured in 
electrical ly  t imulated ( 1  Hz) unloaded myocytes maintained at 35-36°C ( Fig. 4-3B) .  
Data were acquired and analyzed with Signal Averager software v 6 .37  (Cambridge 
Electronic De ign, Cambridge. UK)  ( Fig. 4-3C).  statistical ly  analyzed with SPSS 
statist ics " 20.0 ( I BM Software. Inc) and figures were plotted with Fig.P v 2 .98 ( Fig.P 
Software Corp . ,  ON, Canada). 
A 
B c 
Figure 4-3 : Measurement of ventricular myocyte shortening 
(A) V ideo edge detection system 
( B )  nloaded ventricular myocyte on the monitor 
(C)  Typical record of shortening 
1 1 0 
I I I  
4.2.2.3. Mea u rement of Ventricu lar  Myocyte I n tracel l u lar  Ca2+ Tran ient 
Fluore cent ind icator Fura-2 M ester (F -] 22 1 .  Molecular Probes, Eugene, 
OR. ) wa u ed to a sess intracell ular Ca2+ in ventricular myocytes. Fura-2 AM 
was dis olv d in  DM 0 to make a ] .0 mmolll stock solution. Myocytes were loaded 
with Fura-2 M by adding 6.25 III of Fura-2 AM stock solution to 2 .5  ml of isolated 
myoc)1e to give a final Fura-2 concentration of 2 . 5  Ilmoll l .  Myocytes were then 
shaken gently (300 rpm) for 1 0  minutes at room temperature (24 °C). After loading 
with Fura-2 AM. the myocytes were centrifuged, washed with T to remove 
extracel lular Fura-2 and then left for 30 minutes to ensure complete hydrolysis of the 
intracel l ul ar ester. I ntracel lular Ca2+ concentrat ion was measured in Fura-2 AM 
loaded myoC)1es with a fluorescence photometry system ( Fig.  4-4; Cairn Research. 
Faversham. UK) .  The loaded myocytes were i l luminated alternately  by 340 run and 
380 run l ights using a monochromator which changed the excitation l ight every 2 ms. 
The resulting fluorescence emitted at 5 1 0  run was recorded by a photomultipl ier tube 
( PMT) and the ratio of the fl uorescence emitted at the two excitation wavelengths 
( 340/380 ratio) was calculated to provide an index of intracel lular Ca2+ concentration 
( Fig .  4-4E). Rest ing Fura-2 ratio, t ime from st imulation to peak ( TPK) Ca2+ transient. 
time from peak Ca2
+ transient to half-decay (THALF) of the Ca2
+ transient and the 
ampli tude (AMP) of the Ca2+ transient (expressed as a percentage of Ca2
+ transient in  
Control and STZ myocytes superfused with NT) were measured in electrical ly  
stimulated ( 1  Hz)  myocytes maintained a t  3 5 -36°C ( Fig.  4-4D).  Data were acquired 
and analyzed with Signal Averager software v 6 .37  (Cambridge Electronic Design. 
1 1 2 
ambridge. K). tatisticall analyzed with P statistics 20.0 ( IBM oftware. 
Inc) and figure \\ere plotted with Fig.P 2 .98 (Fig.P oftware Corp. ,  0 , Canada). 
A Light source Monochromator B 
D E 
Figure 4-4:  Measurement of ventricular myocyte intracel lular Ca2+ 
(A) Light source and monochromator 
( B )  Photomultipl ier tube assembly 
( C) Fluorescence photometry system 
( D) Fura-2 AM loaded ventricular myocyte surrounded by iris diaphragm 
(E )  Typical record of a Ca2+ transient 
�.2.2A. A e ment of Ventricu lar Myocyte Myofi lament Sen it ivity to Ca2+ 
1 1 3 
M) ofi lament ensiti ity to Ca2+ was assessed by recording shortening and 
Fura-2 ratio imultan ously ( Fig. 4-5 ), and analyzing phase-plane diagrams of Fura-
2 rat io ver u cel l  length by measuring the gradient of the Fura-2-ce l l  length 
trajectory during late relaxation of the twitch contract ion [ 1 26] ( Fig. 4-5B) .  Previous 
studie have demonstrated that the position of the trajectory reflects the relati e 
1+ myofilament respon e to Ca- and thus. can be used as a measure of myofilament 
sensitivi ty to Ca2+ [ 1 24; 257) . Data were acquired and analyzed with Signal Averager 
software v 6 .37  (Cambridge E lectronic Design, Cambridge, UK), stat istical ly 
analyzed with SP statistics v 20 .0 ( IBM Software, Inc) and figures were plotted 
'-'vith Fig.P \' 2.98 ( Fig .P Software Corp. ,  0 , Canada) .  
A B 
10 11m 
Figu re 4-5: Assessment of myofilament sensitivity to Ca2+ 
0 . 1  R U  
(A)  Typical record of shortening and Ca2+ transient recorded simultaneously 
( B )  Typical phase plane diagram of Fura-2 ratio unit ( RU)  vs. cel l length. The arrow 
indicates the region where the gradient was measured 
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4.2.2 .5. Mea u rement of Ventricu lar Myocyte Sarcopla mic Reticu lum Ca2+ 
Transport 
R Ca:!+ relea e was as es ed using previou I de cribed techniques [ 1 25 ] .  
Myocyte maintained at 35 -36°C and loaded with Fura-2 were electrical ly st imulated 
( 1  Hz) unt i l  Ca:!+ tran ients reached a teady state. Electrical stimulation was then 
pau ed for 5 econd and caffeine ( 20 mmol ) was rapidly  appl ied using a solution 
witching device [ 1 73 ]  (Fig .  4-6A,B) .  After 1 0  seconds of caffeine appl ication, 
e lectrical t imulation was resumed and the Ca
:!+ transients were aUO\ ed to recover to 
a tead state ( Fig.  4-6C) .  R releasable Ca2+ was assessed b measuring the AMP of 
the caffeine- timulated Ca2+ transient. B comparing the AMP of the electrical l y-
stimulated steady state Ca2+ transients with that of the caffeine-stimulated Ca2+ 
tran ient. fract ional release of SR Ca:!+ was measured . Recovery of intracel lular Ca2+ 
was as essed by measuring the gradient of reco ery of electrical ly-stimulated Ca2+ 
transients after the appl ication of caffeine. Data were acquired and analyzed with 
Signal v 1 . 82 (Cambridge Electronic Design, Cambridge, UK), statistical l  analyzed 
with SPSS tatistics v 20.0 ( IBM Software. I nc )  and figures were plotted with Fig.P 
2 .98 (Fig.P Software Corp. , ON, Canada). 
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Figu re 4-6: Measurement of ventricular myocyte sarcoplasmic ret iculum Ca2+ 
transport 
( A )  Rapid solution switching device 
( B) Rapid solution switching device control 
(C) Typical record of the electrical ly-stimulated and caffeine-stimulated Ca2+ 
transient in  a ventricular myocyte 
1 1 6 
4.2 .2 .6. Mea u rement of Ventricu lar  Myocyte L-Type Ca2+ Cu rrent 
fter ventricular m oc le i olation. m ocytes \ ere stored in KB solution. 
oltage-dependent L-type Ca2+ current was measured in ventricular myocytes with a 
\\ hole-cel l patch clamp y tem ( Fig. 4-7) .  The current was recorded with an Axopatch 
200B amplifier (Molecular Devices, unn ale, CA, U A). The analog signal was 
filtered using an eight-pole Be sel fi lter with a bandwidth of 5 kHz and digitized at a 
sampl ing rate of 1 0 kHz under control of pCLAMP v 8 .2 software ( Molecular 
Device . Sunn_ ale. CA. USA) ( Fig. 4-7 A.B) .  Patch pipettes were fabricated from 
filamented BF  1 50-86- 1 0  borosi l icate glass ( utter Instrument. CA, U A) .  
Experiments were perfonned at  34-36°C and myocytes in the chamber were 
uperfu ed with Ca2+-free extracel lu lar solution containi ng in mmoI/I : 1 50 .0 aCl .  
2 .0  MgCb. 1 0.0 HEPES and 1 0 .0  glucose (PH 7 . 35 )  to  faci l it iate patching procedure. 
Once whole-cell mode had been achieved. the solution was switched to Ca2+_ 
containing extracel lular solution containing in mmolll : 1 45 .0  NaCl,  2 .0  CaCb, 2 .0  
MgCb. 1 0.0 HEPE and 1 0 .0 glucose (PH 7 .35 ) .  Recordings of L-type Ca2+ current 
were made after 5 minutes of superfusion with the Ca2+-containing extracel lular 
solution and after 5 minutes of superfusion with the tested SGLT inhibitor. The patch 
pipette was pul led (Sutter Instrument. CA, USA) and fi l led with intracel lular solution 
containing in mmolll : 1 40 .0 CsCL 2.0 MgCb, 1 0 .0 N.N,N,  -tetramethylarnn10nium 
(TEA C l ). 1 0 .0  EGTA. 1 0 .0 HEPES, 1 .0 MgATP and 4 .0 CaCh (PH 7 .25) .  The 
pipette sol ution contained Cs + and TEA + to supress K+ currents [ 1 34;  1 55 ;  255 ]  and 
fast Na+ current was inactivated by holding myocytes at -40 mV [ 1 06] or -50 mV 
1 1 7 
[ 3 1 8 1 .  E lectrode re i tanc ranged from 3 to 5 MQ, and eal resistances were 1 -5 
GQ. erie resistance were compensated to > 75% of the uncompensated val ue. 
The current-voltage relationship was used to measure the acti ation of Ca2+ 
current which wa obtained by applying 300 ms test pulses in the range -60 m V to 
+ 70 m in 1 0 m V steps from a holding potential of -50 m V.  The steady-state 
inact ivation of Ca2+ current was measured by stepping the membrane from various 
1 000 ms pre-pulse between -60 and +30 m V to a test pulse of 0 m V. Ca2+ current 
was measured as the relationship between the AMP of peak currents produced at each 
of the pre-pulses to those measured at the test pulse 0 m V. Time course of recovery 
from i nactivation \�'as measured using a two-pulse protocol .  Two 1 00 ms membrane 
depolarizing pulses. from a holding potential of -40 m V to + 1 0 m V, were separated 
by inter-pulse interval s with ariable duration, which was increased gradual ly.  Peak 
Ca2� current AMP measured by the second pulse wa normalized to that measured by 
the first pulse and their ratio was plotted against the durations of inter-pulse interval . 
Data were acquired and analyzed with pCLAMP v 8 .2 ( Molecular Devices. 






del ivery and 
heater 
assembly 
Cel l  
Figu re 4-7: Patch c lamp system 







( 1 )  Monitor. ( 2 )  Temperature control system, (3)  Patch c lamp ampli fier. (4) 
Analogue-digital converter, (5)  Micromanipulator control ,  (6) Rapid solution 
switching device, ( 7 )  Inverted microscope, (8) Anti-vibration table and (9) Faraday 
cage. 
4.2.3. tati tical Analy i 
1 1 9 
Re ult are expr sed a the mean ± standard error of the mean ( EM)  of ' 17 '  
observations. ' n "  refers to the number of animals or ventricular myocytes. Data were 
analyzed by either Paired amples T -Test, Independent amples T -Test. or one-way 
A 0 A ,  ith Bonferroni po t hoc for multiple comparisons as appropriate using 
P stati tics v 20.0 ( I BM oftware. Inc ) .  Statistical ignificance was set at P < 
0.05.  
1 20 
Chapter 5: Re u lts 
5. 1 .  An imal  General Characteri t ic 
Experiment were performed 2 months after STZ injection. DM was 
confiml d b measuring the non-fasting BGL in a blood sample taken from the tai l 
vein. 3-5  days after TZ injection. Table 5 - 1  shows the general characteristics of 
STZ-induced diabet ic and Control rats inc luding BGL. body weight, heart weight and 
heart v, eight to bod weight ratio. Non-fasting BGL was significantly (P < 0.05)  
elevated in  TZ rats compared to Controls .  The body weight and heart weight of STZ 
rats were significantly  (P < 0.05)  lower compared to Controls .  There was a significant 
(P < 0.05) increase in heart weight to bod weight ratio in STZ rats compared to 
Controls .  
B lood glucose level 
( mg/d l )  
Body weight (g)  
Heart weight (g)  
Heart weight : Body 
weight (mglg) 
Control  STZ 
1 00 . 77 ± 2 .07 ( 3 5 )  452 .09 ± 1 7 . 1 6  ( 3 5 )* 
3 5 1 .60 ± 6. 1 1  ( 3 5 )  262.46 ± 5 .96 ( 3 5 ) *  
1 . 1 9  ± 0 .0 1 ( 3 5 )  1 .05 ± 0 .02 ( 3 5 )* 
3 .40 ± 0 .04 ( 3 5 )  4 .07 ± 0.08 ( 3 5 )* 
Table 5- 1 :  General characteristics of STZ-induced diabetic rats and age-matched 
Controls 
Results were analyzed using I ndependent Samples T -Test. Data are mean ± SEM. 
umbers of animals are shown in parentheses, * P < 0.05 .  
1 2 1  
5.2. t reptozotocin- I nd uced D ia bete Re u l t  
5.2. 1 .  Effect of treptozotocin - I nd uced Dia bete on Ventricu lar  M) ocyte 
Shorten ing 
The effect of TZ-induced diabete on shortening were investigated in TZ-
induced diabet ic and ontrol ventricular myocytes, st imulated electrical ly  ( l  Hz) and 
superfused \\'ith T at 35 -36 °C. 
RCL TPK shortening. THALF relaxation and AMP of shortening (expressed 
a a percentage of RCL )  are shown in Figures 5 - 1 A-D. RCL was significantly 
( Independent Sample T-Test; P < 0.05)  reduced in  STZ ( 1 23 . 30  ± l . 7 1 ,  n = 1 36 )  
myocytes compared to  Controls ( 1 29.24 ± 1 . 88.  1 7  = 1 40) (Fig .  5 - 1 A ).TPK shortening 
was significant ly ( Independent Samples T-Test P < 0.05) prolonged in STZ ( 1 26 .74 
± l . 74 . 17 = 1 36) myocytes compared to Controls ( 1 1 4 .55 ± l .63 ,  n = 1 40)  ( Fig.  5- 1 8) .  
There was no significant ( Independent Samples T -Test; P < 0.05 ) d ifference in 
THALF relaxation in  TZ myocytes compared to Controls ( Fig. 5- 1  C) .  The AMP of 
shortening was significantly ( Independent Samples T-Test; P < 0.05) reduced in STZ 
(6 .60 ± 0 . 1 6. n = 1 36)  myocytes compared to Controls ( 7 . 35  ± 0.20, n = 1 40)  ( Fig. 5-
I D ). 
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Figu re 5- 1 :  Effects of streptozotocin ( STZ)-induced diabetes on the ampl itude and 
time course of ventricular myocyte shortening 
Graphs showing the mean : 
( A) Resting cel l  length ( RCL)  
( B) Time to  peak CTPK)  shortening 
(C) Time to half (THALF) rel axation of shortening 
( D) Amplitude (AMP) of shortening 
Results were analyzed using I ndependent Samples T-Test . Data are mean + S .E .M . ,  n 
= 1 36- 1 40 myocytes from 27-3 1 hearts. Asterisks above the bars represent significant 
differences at the level of P < 0.05 .  
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5.2.2.  Effect of tre£tozotocin - Ind uced Dia bete on Ventricu lar Myocyte 
I n trace l lu lar  Ca + Tran ient 
Th effect of TZ-indu ed diabete on intracel lular Ca2+ transient were 
investigated in Fura-2 M-Ioaded TZ-induced diabetic and Control ventricular 
myocyte . timulated electrical ly ( 1  Hz) and superfused with NT at 35-36 dc. 
The resting Fura-2 ratio, TPK Ca2+ transient. THALF decay of the Ca2+ 
transient and MP of the Ca2+ transient (expressed as a percentage of resting Fura-2 
rat io) are shown in Figures 5 -2A-D. The resting Fura-2 ratio was not significantly 
( Independent Sample T-Test; P < 0.05)  altered in STZ myocytes compared to 
Controls ( Fig. 5-2A).  There was a significant ( Independent Samples T-Test ; P < 0.05)  
prolongation in  TPK Ca2+ transient in STZ (63 .87 ± 2 . 1 2 , n = 5 1 )  myocytes compared 
to Control s  ( 56 .75 ± 1 .24. n = 83 )  ( Fig .  5-2B) .  THALF decay of the Ca2+ transient 
(Fig .  5-2C)  and AMP of the Ca2+ transient ( Fig. 5-2D) were not significantly 
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Figure 5-2 : E ffects of streptozotocin ( STZ)-induced diabetes on the ampl itude and 
time course of ventricular myocyte Ca2+ transient 
Graphs showing the mean : 
(A)  Rest ing Fura-2 ratio 
(B)  Time to peak (TPK) Ca2+ transient 
(C) Time to half (THALF)  decay of the Ca2+ transient 
( D) Ampli tude (AMP) of the Ca2+ transient 
Results were analyzed using I ndependent Samples T-Test. Data are mean + S .E .M. ,  n 
= 5 1 -83 myocytes from 1 6-24 hearts. Asterisks above the bars represent significant 
differences at the level of P < 0.05 .  
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5.2.3. Effect of treptozotocin - Induced Diabete on Ventricu lar Myocyte 
Myofi lament en itivity to Ca2+ 
The effects of TZ-induced diabetes on myofi lament response and sensiti i ty 
to a2+, in TZ-induced diabetic and Control entricular myocytes, were tested by 
recording myocyte hortening and intracel lular Ca2+ transient simultaneously during 
uperfusion \\ ith T. 
By measuring the gradient of the Fura-2-ceU length trajectory. the relative 
m ofilament response and sensitivity to Ca2+ were estimated during late relaxation of 
the tv.·itch contraction during the period 500-800 ms. There was no significant 
( Independent Samples T-Test ; P < 0.05)  difference in the gradient of the trajectory in 
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Figu re 5-3 : Effects of  streptozotocin ( STZ)-induced diabetes on  ventricular myocyte 
myofilament sensit ivity to Ca2+ 
Graph showing mean gradient of the Fura-2-ce l l  l ength trajectory during late 
relaxation of the twitch contraction during the period 500-800 ms. Results were 
analyzed using Independent Samples T-Test. Data are mean + S .E .M. ,  n = 5 1 -83 
myocytes from 1 0- 1 4  hearts. 
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S.2A. Effect of treptozotocin- I nduced Diabete on Ventricu lar Myocyte 
a rcopla mic Reticu lum Ca2+ Tran port 
The effects of TZ-induced diabete on R Ca2+ transport \ ere in est igated 
in Fura-2 - loaded TZ-induced diabetic and Control entricular myocytes after 
caffeine ( ... 0 mmol ) appl ication at 3 5 -36 dc . 
The protocol u ed in these experiments involved several steps stru1ing with 
electrical t imulation of myocytes at 1 Hz. When the Ca2+ transients had stabi l ized, 
electrical t imulation was paused for 5 seconds. Caffeine was then appl ied using a 
rapid olution s\vitching device for 1 0  seconds. E lectrical stimulation was then 
resumed. 
The R Ca2+ was asses ed b measuring the AMP of the caffeine-stimulated 
Ca2+ transient fractional release of Ca2+ (measured as the relationship between the 
electrical ly-stimulated and caffeine-stimulated Ca2+ transients), and the gradient of 
myocyte recovery after caffeine application and fol lowing resumption of electrical 
stimulation (Fig .  5 -4A-C ). The AMP of caffeine-st imulated Ca2+ transient was 
significantly  ( Independent Samples T-Test: P < 0.05)  reduced in STZ myocytes 
(0.489 :J: 0.022, n = 48)  compared to Controls (0 . 562 ± 0.024, n = 62) ( Fig. 5-4A). 
Fractional release of Ca2+ did not show any significant ( Independent Samples T -Test ; 
P < 0.05 ) change in  STZ myocytes compared to Controls (Fig .  5-4B) .  The gradient of 
myocyte recovery wa also not significantly ( Independent Samples T -Test P < 0.05 ) 
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Figu re 5-4: Effects of streptozotocin ( STZ)- induced diabetes on ventricular myocyte 
I 
. . 
I C 2+ sarcop asmlC ret lcu urn a 
Graphs showing mean : 
(A) Amplitude of caffeine-st imulated Ca2+ transient 
( B) Fractional release of Ca2+ ( Electrical stimulationlCaffeine stimulation ) 
(C)  Reco ery of the Ca2+ transients fol lowing rapid appl ication of caffeine 
Results were analyzed using Independent Samples T-Test. Data are mean + S .E .M. ,  n 
= 48-62 myocytes from 1 0- 1 3  hearts. Asterisks above the bars represent significant 
differences at the level of P < 0.05 .  
ES: electrical stimulation; CS:  caffeine stimulation 
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5.3. Concent rat ion-Re pon e Experiment 
In rder to select a suitable concentration of the compound tested in the 
xperim nt , d ifferent concentrations of DAP A were tested on the AMP of shortening 
(expre ed as a percentag of shortening in TZ and Control myocytes superfused 
with T olution) in TZ-induced diabetic and Control ventricular m ocytes during 
electrical stimulation ( 1  Hz) at 35 -36°C ( Fig. 5 -5 ) .  Three concentrations ( 1 0-7 M, 1 0-6 
L and 1 0-5 M)  of DAPA were tested . There were three stages in the protocol ;  
myocytes were irut ial ly superfused with T, then they were superfused with DAP A 
di olved in  T for 5 minute fol lowed by T washout for 5 minutes to assess 
re\,ersibi l ity. and the AMP of shortening was measured after each stage of the 
experiment. 
General ly, the AMP of shortening was significantly ( ANOYA; P < 0.05) 
reduced, to imi lar extents in TZ and Control  myocytes. at concentrations 1 0-5 M 
and 1 0-6 M .  0 significant (ANOYA; P < 0.05)  alteration was seen with 1 0-7 M 
DAPA in TZ and Control myocytes. As shown in Figure 5-5 .  there was a sigruficant 
( AN OYA: P < 0.05)  reduction in  the AMP of shortening with 1 0-5 M DAPA in  
STZ/DAPA ( 78 .59 ± 2 . 1 2%. 11 = 26 )  and ControllDAPA ( 73 .42 ± 2 .6 1 %, n = 25 )  
myocytes compared to  STZ and Control ( 1 00%, 11 = 87-95 ) myocytes. S imi larly, 1 0-6 
DAPA reduced the AMP of shorterung significantly  (ANOYA; P < 0.05) in  
STZIDAPA ( 76 .58 ± 1 . 89%, 11 = 42) and ControllDAPA (76.68 ± 2.28%. 1 1  = 37)  
myocytes compared to STZ and Control  ( 1 00%, 1 1  = 25-95) myocytes, respectively 
( Fig.  5 -5 ) .  However. there was no significant (ANOYA; P < 0.05) al teration in the 
AMP of shortening seen with 1 0-7 M DAPA in both STZ and Control myocytes ( Fig. 
1 29 
S -S ) .  It h uld be not d that although both OAP concentrat ions 1 0-5 and 1 0-6 M 
howed ignificant ( OVA; P < O .O� )  response, there \ as no  significant (AN OVA; 
P < O .OS)  d ifference betv·;een both concentrations in their effects ( Fig. S -S ) .  
Therefore, 1 0-6 1 \Va u ed in al l ubsequent experiments. 
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Figure 5-5: Effects of Dapagl iflozin ( DAP A)  d ifferent concentrations on entricular 
myocyte ampl itude of shortening 
Graph showing the mean ampli tudes (AMP) of shortening, expressed as a percentage 
of shortening in STZ and Control  m ocytes superfused with normal Tyrode (NT) and 
in the presence of different concentrations of DAP A.  
Results were analyzed using ANOV A and post hoc Bonferoni test. Data are means + 
S .E .M . ,  n = 1 82 myocytes from 30 hearts. Horizontal l i nes above the bars represent 
sign ificant differences at the level of P < O .OS .  
SA. Ph lorizin Re u lt 
504. 1 .  Effect of Ph lorizin on Ventricu lar Myocyte horten ing 
1 30 
The effect of 1 0-6 M PHLOR on hortening \ ere investigated In  STZ­
induced diabetic and Control venh'icular myocytes during electrical stimulation ( 1  
Hz) at 3 5-36 0c . 
Figure 5 -6 show typical records of hortening in a Control myocyte. 
1yocyte were uperfu ed with T, then with 1 0-6 M PHLOR dissolved in T for 5 
minute fol lO\\"ed by T washout for 5 minutes to assess reversibi l i ty. The effects of 
PHLOR, on RCL TPK shortening, THALF relaxation and AMP of shortening 
(expres ed as a percentage of shortening in  STZ and Control myocytes superfused 
with T)  are shovm in Figures 5-6B-E. There was no significant ( ANOYA; P < 0.05)  
d ifference in  RCL ( Fig. 5-6B).  TPK shortening ( Fig. 5-6C) and THALF relaxation 
( Fig.  5-6D) by PH LOR in STZ and Control myocytes. Howevec PHLOR resulted in 
a significant ( AN OYA; P < 0.05)  reduction in the AMP of shortening in  
TZIP HLOR (8.+ .76 ± 2 .9 1 %, n = 20) and ControllPHLOR (83 . 72 ± 2 .65%, n = 23 ) 
myocytes compared to TZ and Control  ( 1 00%, n = 2 1 -23 )  myocytes. respectively 
( Fig .  5-6E) .  
The AMP of shortening part ia l ly recovered in a few STZ myocytes from 
72 .58 ± 1 0 . 76% (n = 2) with PHLOR to 88 .99 ± 2 l . 72% (n = 2) after washout and in 
some Control myocytes from 80.77 ± 4. 1 7% (n = 1 0) with PHLOR to 87 .32  ± 3 . 73% 
(n = 1 0) after washout. Col lectively, recovery was approximately 1 6% in STZ 
myocytes and 6% in Controls after washout. While it cont inued to decrease (no 
1 3 1  
reco\ ery) in orne TZ myocyte from 88 .8  J ± 1 . 8 1  % (n = 9) with PHLOR to 82.85 
± 2 .42% ( /1 = 8 )  after \ ashout and in orne Control myocytes from 84.34 ± 4.33% (n 
= 5) \\i th PHLOR to 80. J 0 ± 3 .66% (n  = 5) after washout. 
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NT 10-6 M P H LO R  N T  washout 
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200 m s  
Figu re 5-6 : Effects o f  Phl orizin ( PHLOR) on the ampl itude and time course of 
ventricular m ocyte shortening 
(A) Typical records of shortening in a Control  myocyte superfused with normal 
Tyrode T) ( left panel ) .  1 0-6 M PHLOR + T (middle panel )  and during 
washout with T ( right pane l )  
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Figure 5-6 (cont inued ) :  Effects of Phlorizin (PHLOR) on the ampl itude and time 
course of ventricuJar myocyte shOliening 
Graphs sho\"iing the mean: 
( B) Resting cel l  length 
(C) Time to peak ( TPK) shortening 
( D) Time to half (THALF) relaxation of shortening 
( E) Amplitude (AMP) of shortening 
Results were analyzed using ANOV A and post hoc Bonferoni test. Data are mean + 
.E .M . .  n = 23-20 myocytes from 7 hearts. Horizontal J i nes above the bars represent 
significant differences at the level of P < 0 .05 .  
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504.2. Effect of Ph lorizin on Ventricu lar  Myocyte I n trace l lu lar  Ca2+ Tran ient 
The effects of 1 0-6 M PHLOR on intracel lular Ca2+ tran ient were investigated 
111 Fura-2 AM-loaded TZ-induced diabetic and Control ventricular myocytes, 
st imulated electrical ly ( 1  Hz) at 35 -36 0c . 
T} pi cal records of the Ca2+ transient in a Control myocyte, superfused with 
T and then 1 0-6 M PHLOR dissolved in T for 5 minutes, are shown in Figure 5-
7 . 
The resting Fura-2 ratio, TPK Ca2+ transient. THALF decay of the 
Ca2� transient and AMP of the Ca2+ transient (expressed as a percentage of Ca2+ 
transient in  TZ and Control myocytes superfused with T) are shown in Figures 5-
7B-E.  There was no significant ( A  OVA; P < 0.05)  change i n  the rest ing Fura-2 ratio 
( Fig.  5-7B) ,  TPK Ca2+ transient ( Fig. 5-7C) and THALF decay of the Ca2+ transient 
( Fig. 5-7D) in both TZ and Control myocytes after exposure to PHLOR. The AMP 
of the Ca2� transient was ignificantly (A OVA; P < 0.05) reduced in  STZIPHLOR 
( 82 . 37  ± 3 . 1 6%, 11 = 1 6 ) and ControllPHLOR ( 73 .94 ± 5 .22%, 1 1  = 2 1 ) m ocytes 
compared to STZ and Control ( 1 00%, n = 1 6-23 )  myocytes, respectively ( Fig. 5-7E) .  
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Figu re 5-7: Effects of  Phlorizin ( PHLOR) on  the amplitude and time course of  
yentricular myocyte Ca2� transient 
(A)  Typical records of Ca2+transient in a Control  myocyte superfused with nonnal 
Tyrode ( T) ( left panel ) and 1 0-6 M PHLOR + T ( right pane l )  
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Figure 5-7 ( cont inued ) :  Effects of Phlorizin ( PH LOR) on the ampl itude and time 
course of ventricular myocyte Ca1+ transient 
Graphs showing the mean : 
( B) Resting Fura-2 ratio 
(C)  Time to peak (TPK) Ca2+ transient 
( D) Time to half (THALF) decay of the Ca2+ transient 
( E) Amplitude (AMP) of the Ca2- transient 
Results were analyzed using ANOV A and post hoc Bonferoni test. Data are mean + 
S .E .M. ,  n = 1 6-23 myocytes from 3 -4 hearts. Horizontal l ines above the bars 
represent significant d ifferences at the level of P < 0 .05 .  
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SA.3. Effect of Ph lorizin on Ventricu lar  Myoc te Myofi lament Sensit iv ity to 
Ca2+ 
The ffe ts of ] 0-6 M PH LOR were investigated on myofilament response and 
sen itivity to Ca2+ in TZ-induced diabetic and Control entricular myocytes. 
In these experiment . myocyte shortening and intracel lular Ca2+ transient were 
recorded imultaneously after superfusion with NT and after 5 minutes of superfusion 
with 1 0-6 1 PHLOR dissolved in T. Figure 5-8A shows a typical record of myocyte 
shortening and Ca2+ transient. and Figure 5 -8B shows a typical phase-plane diagran1 
of Fura-2 ratio versus cel l  length recorded in a Control myocyte superfused with T. 
The relative myofilament response and sensiti ity to Ca2+ were assessed by 
measuring the gradient of the Fura-2-cel l length trajectory during late relaxation of 
the twitch contraction. The gradient of the trajectory was measured during the period 
500-800 ms. As shown in Figure 5-8C, there were no significant (ANOVA; P < 0.05) 
differences in  myofilament sensit ivity in STZ and Control myocytes with PH LOR. 
Therefore. myofilament sensit ivity to Ca2+ is  unl ikely to underl ie the effects of 













I/') - 1 5  c: 
/I) 

















1 3 7 
B 
10 J.lm v ) 





Figu re 5-8: Effects of Phlorizin ( PHLOR) on ventricular myocyte myofilament 
sensit ivi ty to Ca2� 
( A) Typical record of shortening and Ca2+ transient recorded simultaneously in an 
electrical ly stimulated myocyte from a Control heari 
( B) Typical phase plane diagram of Fura-2 ratio unit ( RU )  versus cel l  length in a 
myocyte from a Control heart. The an-ow indicates the region where the gradient 
was measured 
(C)  Graph showing mean gradient of the Fura-2-cel l  length trajectory during late 
relaxation of the twitch contraction during the period 500-800 ms 
Results were analyzed using ANOVA and post hoc Bonferoni test. Data are mean + 
S .E .M . . n = 1 0- 1 2  myocytes from 3-4 hearts . 
1 38 
5.404. Effect of Ph lorizin on Ventricu lar  Myocyte arcopla m ic Reticu lum 
�+ 
Ca- Tran  port 
The effect of  1 0.6 M PHLOR 11 R ci+ transport were investigated in Fura-
2 M-loaded TZ-induced diabet ic and Control ventricular m ocytes, when exposed 
to 20 mmol of caffeine at 35-36 °c . 
A typical record of the protocol used in the e experiments is shown in a 
Control myocyte superfused with T in Figure 5-9A. Init ial ly, myocytes were 
electrical ly stimulated at 1 Hz. When the CaH transients had stabi l ized, electrical 
stimulation was paused for 5 seconds. Caffeine was then applied using a rapid 
solution switching de ice for 1 0  seconds. E lectrical st imulation was then resumed . 
This protocol \vas repeated after the cel l was superfused with NT and again after 5 
minute superfusion of 1 0.6 M PHLOR dissolved in  NT. 
The A MP of the caffeine-stimulated Ca2+ transient was not significantly 
( AN OV A: P < 0.05) altered by PHLOR in TZ and Control myocytes ( Fig. 5-9B) .  
Fract ional release of Ca2+. measured as the relationship between the electrical ly-
stimulated and caffeine-stimulated Ca2• transients. d id not show any significant 
( ANOV A; P < 0.05) change in STZ and Control myocytes with PHLOR ( Fig.  5 -9C). 
The gradient of m ocyte recovery ,  after caffeine application and fol lowing 
resumption of electrical stimulation, was also not significantly ( ANOVA; P < 0.05)  
altered by PHLOR in STZ and Control myocytes (Fig .  5-9D) .  
A 
0 . 1  RU I 
E lectr ica l  
stimu lat ion 
10 sec 
Caffe ine 
sti m u lation 
E lectr ica l 
sti m u lation 
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Figure 5-9: Effects of Phlorizin ( PH LOR) on ventricular myocyte sarcoplasmic 
. 
I C 1+ reticu um a-
(A)  Typical record showing the protocol employed in a Control myocyte during SR 
Ca2- experiments. Init ia l ly .  myocytes were electrical ly stimulated at  1 Hz .  When 
the Ca2- transients had stabi l ized. electrical stimulation was paused for 5 seconds 
( sec ). Caffeine was rapidly appl ied for 1 0  sec . Electrical st imulation was then 
resumed. 
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Figu re 5-9 (cont inued) :  Effects of Phlorizin ( PH LOR) on ventricular myocyte 
sarcoplasmic reticulum Ca2+ 
Graphs showing mean : 
( B) Amplitude of caffeine-stimulated Ca2+ transient 
(C)  Fract ional release of Cah (E lectrical st imulation/Caffeine stimulation) 
( D) Recovery of the Ca2+ transients fol lowing rapid appl ication of caffeine 
Results were analyzed using A OV A and post hoc Bonferoni test. Data are mean + 
S .E .M . ,  n = 1 3- 1 6  myocytes from 3 -4 hearts. 
ES:  electrical stimulation; CS: caffeine stimulation 
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5.5. Quercet in-3-0-G luco ide Result 
5.5. 1 .  Effect of Quercetin-3-0-Gluco ide on Ventricu lar Myocyte Shortening 
The effl cts of 1 0-6 M Q ER-3-G on shortening, in electrical ly stimulated ( 1  
Hz) TZ-induced diabetic and Control ventricular myocytes at 35 -36°C, were 
i nye tigated. 
Typical records of shortening, in a Control  myocyte superfused with T 
fol lov,ed by T + 1 0-6 M QUER-3-G for 5 minutes and then T washout for 5 
minutes to as ess reco ery, are shown in Figure 5 - 1 0A. The effects of QUER-3-G on 
RCL, TPK shortening. THALF relaxation and AMP of shortening (expressed as a 
percentage of shortening in  Control and STZ myocytes superfused with NT) are 
ho\'.11 in  Figures 5 - 1 0B-E.  RCL was not significantly ( ANOVA; P < 0.05) altered by 
QUER-3-G in STZ and Control myocytes ( Fig. 5 - 1 0B) .  TPK shortening was 
significant l  ( A  OVA; P < 0.05 ) reduced on exposure to QUER-3-G from 1 29.65 ± 
3 . 9 1  ms (n  = 20) in  STZ m ocytes to 1 09.80 ± 3 . 34 (n  = 20) in  STZ/QUER-3-G 
myocytes, and from 1 1 4 . 37  ± 3 .34 ms (n  = 30)  in Controls to 98 .40 ± 3 . 1 8  (n  = 30) in  
Contro llQ ER-3-G myocytes ( Fig.  5 - 1 0C) .  THALF relaxation d id not show any 
significant ( A  OVA: P < 0.05)  change i n  STZ and Control myocytes with QUER-3-
G ( Fig.  5- 1 0D) .  The AMP of shortening was significantly  ( ANOV A; P < 0.05)  
decreased i n  STZ/QUER-3-G ( 79. 1 2  ± 2 .28%, n = 20) and ControllQUER-3-G ( 76.69 
± 1 .92%, n = 30)  myocytes compared to STZ and Control ( 1 00%, n = 20-30) 
myocytes, respectively ( Fig.  5 - 1 0E ) .  
1 -+2 
The M P  of hortening partial l recovered in some TZ m ocytes from 76.78 
± 3 . 1 1 % (n  = 7)  \vith Q ER-3-G to 9 1 .82 ± 9.49% ( n  = 7)  after wa hout and in some 
Control m ocyte from 75 .04 ± 4 .47% ( n  = 5 )  with QUER-3-G to 94.87  ± 6 .87% (n = 
5 )  after \Va hout. Col lect ively, recovery was approximately 1 5% in STZ myocytes 
and 1 0% in ontrol after wa hout. While it cont inued to decrease (no recovery ) in 
orne TZ myocy1es from 79.56 ± 3 .86% (n = 1 0 ) with QUER-3-G to 73 .32  ± 3 .35% 
( 1 7  = 9)  after \� ashout and in some Control myocytes from 76 ± 3 . 1 2% ( / 1  = 1 4) with 
Q ER-3-G to 67 .86 ± 4 .38% (11 = 1 2 ) after washout. 
A 
NT 10-6 M QU E R-3-G 
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NT washout 
Figure 5- 1 0 : Effects of Quercetin-3 -0-glucoside (QU ER-3-G) on the amplitu de and 
time course of ventricular myocyte shortening 
(A) Typical records of shortening in a Control myocyte superfused with normal 
Tyrode (NT) ( left pane l ), 1 0-6 M QUER-3-G + NT (middle panel )  and during 
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Figu re 5- 1 0  (cont in ued) :  Effects of Quercetin-3 -0-glucoside (QUER-3 -G) on the 
ampl i tude and time course of ventricular myocyte shortening 
Graphs showing the mean : 
( B) Resting cel l length 
(C)  Time to peak (TPK) shortening 
( D )  Time to half (THALF) relaxation of shortening 
(E )  Amplitude (AMP) of shortening 
Results were analyzed using A OVA and post hoc Bonferoni test. Data are mean + 
S .E .M. ,  11 = 20-30 myocytes from 6-9 hearts .  Horizontal l i nes above the bars 
represent significant d ifferences at the level of P < 0.05 .  
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5.5.2. Effect of Quercet in-3-0-G luco ide on Ventricu la r  Myocyte I n tracel lu lar  
Ca2+ Tran ient 
The effect of 1 0-6 M QUER-3-G on intracellular Ca2+ transient were studied 
in electrical ly t imulated ( 1 Hz )  and Fura-2 AM-loaded TZ-induced diabetic and 
Control ventricular myocytes at 35 -36 dc . 
Typical record of the Ca2+ transient, in a Control myocyte exposed to NT and 
to 1 0-6 M QUER-3-G + T for 5 minutes, are shown in Figure 5 - 1 1 A. 
The effects of QUER-3-G on the resting Fura-2 rat io, TPK Ca2+ transient, 
THALF decay of the Ca2+ transient and AMP of the Ca2+ transient (expressed as a 
percentage of Ca2+ transient i n  STZ and Control myocytes superfused with NT) are 
shown in Figure 5- 1 1 B-E.  There was a signi ficant ( A  OVA: P < 0.05)  i ncrease i n  the 
resting Fura-..... ratio of ControliQUER-3-G (0 .757  ± 0.025, n = 4 1 ) myocytes 
compared to Controls  ( 0 .66 1 ± 0.0 1 8 . n = 4 1 ). whi le there was no significant 
( ANOVA: P < 0.05)  d ifference between STZ/QUER-3-G and STZ myocytes ( Fig. 5-
l I B ) .  TPK Ca2 ... transient was not significantly ( A  OVA; P < 0.05)  altered in  STZ 
and Control myocytes after QUER-3-G (Fig .  5- 1 1 C) .  THALF decay of the Ca2
+ 
transient showed significant ( ANOVA; P < 0.05 ) reduction in  STZ/QUER-3-G 
( 1 30.94 ± 1 0 . 72 ms. n = 1 8 ) myocytes compared to STZ ( 1 82 .06 ± 9 .74 ms, n = 1 8 ) 
myocytes. and i n  ControliQUER-3-G ( l 1 7 . 8 1 ±5 . 52 ms. n = 4 1 ) myocytes compared 
to Controls ( 1 55 .83±6.02 ms, n = 4 1 ) ( Fig. 5 - 1 1 D) .  The AMP of the Ca2+ transient 
was also decreased significantly (A OVA; P < 0.05)  in STZ/QUER-3-G (73 .62 ± 
5 . 83%. n = 1 8) and Control/QUER-3-G ( 78 . 32  ± 3 . 54%, n = 4 1 ) myocytes compared 
to STZ and Control ( 1 00%. n = 4 1 - 1 8) myocytes respectively ( Fig. 5- 1 1 E) .  
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Figu re 5- 1 1 :  Effects o f  Quercetin-3 -0-glucoside (QUER-3-G) on the ampli tude and 
t ime cour e of ventricular myocyte Ca2+ transient 
(A )  Typical records of Ca2�transient in a Control myocyte superfused with nonnal 
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Figu re 5-1 1 ( cont inued) :  Effects of Quercetin-3 -0-glucoside (QUER-3 -G)  on the 
ampli tude and time course of ventricular myocyte Ca2+ transient 
Graphs shov,;ing the mean : 
( B) Resting Fura-2 ratio 
(C)  Time to peak CTPK)  Ca2+ transient 
( D) Time to half (THALF) decay of the Ca2+ transient 
( E) Amplitude (AMP) of the Ca2+ transient 
Results were analyzed using ANOV A and post hoc Bonferoni test. Data are mean + 
S .E .M. ,  n = 1 8-4 1 myocytes from 3 -6 hearts. Horizontal l ines above the bars 
represent significant differences at the level of P < 0.05 .  
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5.5.3. Effect of Quercetin-3-0-G luco ide on Ventricu lar  Myocyte Myofi lament 
en it iv ity to Ca2+ 
The effects of 1 0-6 M Q ER-3-G on m ofilament response and sensiti ity to 
TZ-induced diabetic and Control ventricular myocytes, were tested by 
recording myoc)1e hortening and intracel l ular Ca2+ transient simultaneously during 
uperfu ion with T and with 1 0-6 M QUER-3-G + NT. 
Figure 5 - 1 2A ho\\'s a typical record of 111 ocyte shortening and Ca2+ 
transient and F igure 5- 1 2B shows a typical phase-plane diagram of Fura-2 ratio 
versu cel l  length recorded i n  a Control myocyte superfused with T. 
By measuring the gradient of the Fura-2-cell length trajectory. the relat ive 
myofilanlent response and sensiti ity to Ca2+ were estimated during late relaxation of 
the twitch contraction during the period 500-S00 ms. The gradient of the trajectory 
was modestly decreased in STZ/QUER-3-G (2 .23  ± 2 .05 ms. n = 1 2) rnyocytes 
compared to STZ ( 1 2 . S 1 ± 5 . 30  ms, n = 1 2 ) rnyocytes, and it was significantly 
( ANOV A; P < 0.05)  decreased in ControllQUER-3-G (4 . 1 9  ± 1 .24 ms. n = 29) 
rnyocytes compared to Controls  ( 1 2 .69 ± 2 . 57  ms, n = 29) ( Fig. 5 - 1 2C).  
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Figu re 5- 1 2 :  Effects of Quercetin-3-0-g1ucoside (QUER-3-G) on ventricular 
myocyte myofilament sensitivity to Ca2+ 
(A)  Typical record of shortening and Ca2+ transient recorded simultaneously in  an 
electrical ly stimulated myocyte from a Control heart 
( B) Typical phase plane d iagram of Fura-2 ratio unit ( RU )  versus cel l  length in a 
myocyte from a Control heart . The arrow indicates the region where the gradient 
was measured 
(C)  Graph showing mean gradient of the Fura-2-cel l  length trajectory during late 
relaxation of the twitch contraction during the period 500-800 ms 
Results were analyzed using ANOVA and post hoc Bonferoni test . Data are mean + 
S .E .M. ,  n = 1 2-29 myocytes from 3 -6 hearts. Horizontal l ines above the bars 
represent significant d ifferences at the level of P < 0.05 .  
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5.504. Effect of Quercet in-3-0-G luco ide on Ventricu lar Myoc te arcopla mic 
Reticu l um Ca2+ Tran  port 
Th effects of 1 0-6 M Q ER-3-G on R Ca1+ transport were in estigated in 
Fura-2 M-loaded TZ-induced diabetic and Control ventricular myocytes after 
caffeine (_0 mmol )  appl ication at 35 -36 dc . 
typical record of the protocol used in  these experiments is shown in  a 
Control myocyte superfu ed with NT in Figure 5 - 1 3A.  Init ial ly_ myocytes were 
electrical ly t imulated at 1 Hz. When the Ca2-'- transients had stabi l ized. electrical 
st imulation was paused for 5 seconds. Caffeine was then applied using a rapid 
sol ution switching device for 1 0  seconds. Electrical stimulation was then resumed. 
This protocol was repeated after the cel l was superfused with T and again after 5 
minute superfusion of 1 0-6 M QUER-3-G dissolved in T.  
The AMP of the caffeine-stimulated Ca2+ transient was not significantly 
( ANOV A: P < 0 .05)  altered by QUER-3 -G in STZ and Controls  myocytes (Fig .  5-
1 3B ) .  Fractional release of Ca2-'-. measured as the relationship bem-een the 
electrical ly-stimulated and caffeine-stimulated Ca2-'- transients. did not show any 
significant ( ANOVA; P < 0 .05 ) change in STZ and Control myocytes with QUER-3-
G ( Fig .  5- 1 3C) .  The gradient of myocyte recovery, after caffeine appl ication and 
fol lowing resumption of electrical stimulation, was also not significantly (ANOV A; P 
< 0 .05)  changed by QUER-3-G in  STZ and Control myocytes ( Fig. 5- 1 3D) .  
A 
E lectrica l 
stimu la tion 
0. 1 RU I 
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st imu lation 
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1 50 
Figu re 5- 1 3 :  Effects of Quercetin-3 -0-glucoside (QUER-3-G) on ventricular 
myocyte sarcoplasmic reticulum Ca2� 
(A)  Typical record showing the protocol employed in  a Control myocyte during SR 
Ca:!+ experiments. Initial ly,  myocytes were electrical ly stimulated at 1 Hz. When 
the Ca2+ transients had stabi l ized. electrical stimulation was paused for 5 seconds 
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Figu re 5- 1 3  (cont inued ) :  Effects of Quercetin-3 -0-glucoside (QUER-3-G) on 
entricular myocyte sarcoplasmic reticulum Ca
2+ 
Graphs showing mean : 
( B) Amplitude of caffeine-st imulated Ca
2+ transient 
(C)  Fractional release of Ca
2+ (E lectrical stimulation/Caffeine stimulation) 
( D) Recovery of the Ca
2+ transients fol lowing rapid appl ication of caffeine 
Results were analyzed using ANOV A and post hoc Bonferoni test. Data are mean + 
S .E .M ., n = 1 3 -3 1 myocytes from 3 -6 hearts. 
ES:  electrical stimulation; CS: caffeine stimulation 
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5.6. Dapagl iflozin Re u lt 
5.6. 1 .  Effect of Short-Term Expo u re to Dapagliflozin on Ventricu lar M ocyte 
horten ing 
The effect of 1 0-6 M DAP A on sholtening, in electrical ly stimulated ( J  Hz) 
TZ-induced diabetic and Control ventricular myocytes at 35 -36°C were 
inve tigated_ 
Figure 5 - 1 4A shows typical records of shortening in a Control myocyte 
uperfu ed \vith T. 1 0-6 M DAPA + NT ( 5  min) and NT washout (5 min) to assess 
reversibi l it) . The effects of DAP A on RCL, TPK shortening. THALF relaxation and 
MP of hOltening (expressed as a percentage of shortening in STZ and Control 
myocytes superfused with NT) are shown in Figure 5 - 1 4B-E.  There were no 
ignificant (ANOVA; P < 0.05 ) changes observed in RCL (Fig .  5 - 1 4B) ,  TPK 
shortening ( Fig. 5 - 1 4C)  and THALF relaxation (Fig .  5 - 1 4D) in  STZ and Control 
myoc)1es with DAPA. DAPA significantly (ANOVA; P < 0.05 ) reduced the AMP of 
shortening in  STZ/DAPA ( 76 .58  ± l . 89%, 11 = 42) and ControllDAPA ( 76.68 ± 
2 .28%. 11 = 3 7) myocytes compared to STZ and Control ( 1 00%, 11 = 3 7-42) myocytes_ 
respectively ( Fig.  5 - 1 4E) .  
The AMP of shortening partial ly recovered in  some STZ myocytes from 80.82 
± 5 . 39% ( 11 = 9)  with DAPA to 89.80 ± 5 .45% (1 1  = 9) after washout and in some 
Control myocytes from 79.28 ± 5 . 1 8% (n = 9) with DAPA to 89.34 ± 5 .24% (n = 9 )  
after washout. Col lectively, recovery was approximately 1 0% in both STZ and 
Control myocytes after washout. While it continued to decrease (no recovery) in  
some TZ myocytes from 75 .72 ± 2 .28% (n = 2 5 )  with DAPA to 68.22 ± 2 .84% (n = 
1 53 
23 ) after wa hout and in orne Control myocytes from 76.83 ± 3 .00% (n  = 1 7 ) with 
D PA to 63 .85 ::l: 3 .69% (n  = 1 6  after washout. 
A 
NT DAPA 10-6 M 
200 m s  
NT washout 
Figu re 5- 1 4 : Effects of short-tern1 exposure to Dapagl iflozin ( DAP A) on the 
ampl itude and t ime course of ventricular myocyte shortening 
( A) Typical records of shortening in a Control myocyte superfused with nonnal 
Tyrode T) ( left pane l ), 1 0-6 M DAPA + NT ( middle pane l )  and during washout 
with T (right panel ) 
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Figu re 5- 1 .t  (cont in ued) :  Effects of short-term exposure to Dapagl iflozin ( DAPA) on 
the ampl itude and t ime course of ventricular m ocyte shortening 
Graphs showing the mean : 
( B) Rest ing cel l  l ength 
(C)  Time to peak (TPK) shortening 
( D) Time to half (THALF) rel axation of shortening 
( E )  Ampli tude (AMP) of shortening 
Results were analyzed using ANOV A and post hoc Bonferoni test . Data are mean + 
S .E .M. ,  17 = 3 7-42 myocytes from 1 8  hearts. Horizontal l ines above the bars represent 
significant d ifferences at the Ie el of P < 0.05 .  
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5.6.2. Com paring bort-Term ersu Long-Term Effect of Dapagl iflozin on 
Ventricu lar  Myocyte Shorten ing 
The effect of 1 0.6 M DAP on myocyte shortening were tested by exposing 
myoC)1eS to D PA for a longer time to compare if this would exacerbate its effects. 
TZ-induced diabet ic and Control ventricular myocytes were split into 2 
ubgroups ach. One ubgroup of myocyte was incubated with T and the other 
ubgroup wa incubated with 1 0.6 M DAPA + NT and both were shaken in an 
0, ygenated haker ( 1 50 osci l lations per minute ) at 37° C for 1 -3 hours. After the 
incubation period, RCL TPK shortening, THALF relaxation and AMP of shortening 
(expressed as a percentage of shortening of RCL )  were measured ( Fig .  5 - 1 5B .D.F,H ). 
On Comparing myocyte shortening after short- and long-term exposure. the 
fol lowing was observed : 
RCL was not significantly ( A  OYA: P < 0 .05)  altered in  STZ and Control 
myocytes after short and long-term exposure to DAPA ( Fig. 5 - 1 5AB ). Significant 
( ANOYA: P < 0.05)  prolongation of TPK shortening was observed after long-term 
exposure to T in STZ ( 1 1 8 . 88  ± 2 .73 ms, n = 32 )  myocytes compared to Controls  
( 88 .47 ± 2 .58  ms, n = 30) (Fig .  5 - 1 5C.D) .  THALF relaxation was not signi ficantly 
( A  OY A :  P < 0.05)  altered i n  STZ and Control myocytes after short- and long-term 
exposure to DAPA ( Fig .  5 - 1 5E ,F) .  Short-term exposure of 1 0.6 DAPA significantly 
( ANOY A; P < 0.05)  reduced the AMP of shortening (expressed as a percentage of 
RCL )  in  STZIDAPA ( 5 . 1 5  ± 0 . 3 1 %, n = 42) compared to STZ (6 .63 ± 0.33%, n = 42) 
myocytes and i n  ControllDAPA (6 .02 ± 0.4 1 %, n = 3 7 )  compared to Control ( 7 . 86 ± 
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0 .47°'0. 11 = 3 7 )  myocytes ( Fig.  5 - 1 5G) .  However, 10ng-tenTI exposure to 1 0-6 DAPA 
did not cau e any sign i ficant (A  OVA; P < 0 .05)  change in STZ/DAPA and 
ontro llDAP myocyte compared to TZ and Control myocytes, respectivel . A 
significant ( OV A:  P < 0.05)  increase in  the AMP of shortening was observed 
when comparing TZ (8 . 5 3  ± 0 .57%, n = 32)  myocytes to Controls (6 .84 ± 0 .35%, n 
= 30)  (Fig. 5 - 1 5 H ). 
Short-term exposure 
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Figu re 5- 1 5 : Short-term versus long-term effects of Dapagl iflozin (DAPA) on 
ventricular myocyte shortening.  
Graphs showing the mean : RCL after (A) short-tem1 and (B) 10ng-tem1 exposure 
TPK shortening after (C)  short-term and ( D )  long-term exposure 
THALF rel axation after ( E )  shOli-term and (F )  long-term exposure 
AMP of shortening after (G)  short-term and ( H )  long-term exposure 
Results were analyzed using ANOV A and post hoc Bonferoni test. Data are mean + 
S .E .M. ,  n = 24-42 myocytes. Horizontal l ines above the bars represent significant 
differences at the level of P < 0.05 .  
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5.6.3. Effect of Da pagliflozin on Ventricu lar  Myocyte I n trace l lu lar Ca2+ 
Transient 
The effect of 1 0.6 M DAP A on intracel lular Ca1+ tran ient were investigated 
111 Fura-2 M-Joaded TZ-induced diabetic and Control ventricular myocytes, 
stimulated electrical ly ( 1  Hz) at 35 -36 °C 
Typical records of the Ca1+ transient, in a Control myocyte exposed to T 
and 1 0.6 M OAPA + T for - minutes, are shown in Figure 5- 1 6A .  The resting Fura-
2 ratio, TPK Ca2-'- transient THALF decay of the Ca2+ transient and AMP of the Ca2-
transient (expressed as a percentage of Ca1+ transient in STZ and Control myocytes 
uperfused with NT) were measured ( Fig. 5 - 1 6B-E) .  The resting Fura-2 ratio was not 
signi ficantly (ANOYA; P < 0.05)  altered in STZ and Control myocytes with OAPA 
( Fig.  5- 1 6B) .  TPK Ca2-'- transient was significantly (A  OYA; P < 0 .05 )  prolonged in  
STZIDAPA (82 .38 ± 7 .85  ms ,  n = 1 6 ) myocytes compared to STZ myocytes (60 .56 ± 
2 . 7 1  ms, n = 1 7) ,  and modestl prolonged in ControllDAPA (67.62 ± 3 .68 ms, 1 1  = 
1 7) myoc,tes compared to Controls (60.55  ± 2 .79 ms, n = 1 9) (Fig.  5- 1 6C) .  There 
was no significant (ANOY A; P < 0.05 ) change in THALF decay of the Ca2+ transient 
by OAP A in STZ and Control myocytes (Fig .  5 - 1 6D).  The AMP of the Ca2- transient 
was significantly  ( ANOYA; P < 0.05 ) reduced in  STZ/DAPA ( 7 1 .45 ± 5 . 3 5%. n = 
1 6) myocytes compared to STZ ( 1 00%, n = 1 7) and was modestly reduced in  
ControllDAPA (92 . 0 1  ± 2 .72%. n = 1 7) myocytes compared to Controls ( 1 00%. n = 
1 9) ( Fig. 5 - 1 6E ) .  
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A 
NT DAPA 10-6 M 
0. 1 RU I 
200 ms 
Figure 5- 1 6 :  Effect of Dapagl iflozin ( DAPA) on the ampl itude and t ime course of 
ventricular myocyte Ca2+ transient 
(A) Typical records of the Ca2+ transient in a Control myocyte superfused with nOnTIal 
Tyrode T) ( left pane l )  and ] 0-6 M OAP A + NT (right panel )  
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Figure 5- 1 6  ( cont inued) :  Effects of Dapagl iflozin (DAPA) on the ampl i tude and 
time course of ventricular myocyte Ca2+ transient 
Graphs showing the mean : 
( B )  Resting Fura-2 ratio 
(C) Time to peak (TPK) Ca2+ transient 
( D) Time to half (THALF) decay of the Ca2+ transient 
(E )  Ampli tude (AMP) of the Ca2+ transient 
Results were analyzed using A OVA and post hoc Bonferoni test. Data are mean + 
S .E .M. ,  n = 1 6- 1 9  myocytes from 4 hearts .  Horizontal l ines above the bars represent 
significant d ifferences at the level of P < 0.05 .  
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5.5"'. Effect o f  Dapagl iflozin on Ventricu lar  Myocyte Myofi lament Sen itivity to 
Ca2+ 
The effects of 1 0-6 M DAPA on m ofilament response and sensit ivity to Ca2+ 
were tested _ 
Myocyte shortening and intracel l ular Ca2+ transient were recorded 
imuJtaneou ly after superfusion with NT and after 5 minutes of superfusion with 1 0-6 
1 D P A + Y- Figure 5- 1 7  A shows a typical record of myocyte shortening and Ca2+ 
tran ient, and Figure 5 - 1 7B shows a typical phase-plane  d iagram of Fura-2 ratio 
Yer u cel l  length recorded in a Control myocyte superfused with NY-
The relative myofilament response and sensiti ity to Ca2+ were assessed by 
mea uring the gradient of the Fura-2-cel l  length trajectory during late rel axation of 
the tv,,-itch contraction_ During the period 500-800 ms, there was no significant 
CANOY A: P < 0_05)  change in the gradient of the trajectory by DAPA in STZ and 
Control  myocytes ( Fig _  5 - 1 7C)_  
Therefore, myofilament sensit ivity to Ca2+ i s  unl ikely to be the cause for the 
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Figu re 5- 1 7 : Effects of Dapagl iflozin ( DAPA) on entricular myocyte myofilament 
en it ivity to Ca2-r 
( A) Typical record of shortening and Ca2+ transient recorded simultaneously in  an 
electrical ly stimulated myocyte from a Control heart 
( B) Typical phase plane d iagram of Fura-2 ratio unit ( RU)  versus cel l length in a 
myocyte from a Control heart .  The arrow indicates the region where the gradient 
was measured 
(C)  Graph showing mean gradient of the Fura-2-cell length trajectory during late 
relaxation of the twitch contraction during the period 500-800 ms 
Results were analyzed using A OVA and post hoc Bonferoni test. Data are mean + 
S .E .M . . 11 = 1 6- 1 9  myocytes from 4 hearts. 
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5.5.5. Effect of Dapagl iflozin on Ventricu lar Myocyte Sarcopla mic Reticu lum 
Ca2+- Transport 
The effect of 1 0-6 M D PA on R Ca2-r- transport, in Fura-2 AM-loaded TZ-
induced diabet ic and Control ventricular myocytes, were invest igated. 
A typical record of the protocol used in these experiments is  shown in Control 
myocyte superfused with T in Figure 5 - 1 8A. Init ial ly, myocytes were electrical ly 
stimulated at 1 Hz.  When the Ca2;- transients had stabi l ized, electrical stimulation was 
paused for 5 econds. Caffeine was then appl ied using a rapid solution switching 
device for 1 0  seconds. E lectrical st imulation was then resumed . This protocol was 
repeated after the cel l  was superfused with T and again after 5 minute superfusion 
of 1 0-6 M DAPA di solved in T. 
The AJv[p of the caffeine-stimulated Ca2;- transient was not significant ly 
( ANOY A; P < 0.05) altered in  STZ and Control  myocytes with DAP A ( Fig. 5 - 1 8B) .  
Fract ional release of Ca2+ (measured as  the relationship between the electrical ly-
stimulated and caffeine-stimulated Ca2;- transients) did not show any significant 
( ANOY A; P < 0 .05)  change by DAPA in STZ and Control myocytes ( Fig.  5 - 1 8C) .  
The gradient of myocyte recovery after caffeine appl icat ion was also not significantly 
( ANOY A: P < 0.05)  altered in STZ and Control myocytes with DAP A ( Fig.  5- 1 8D) .  
0. 1 RU I 
A 
E lectr ica l 
st imu lat ion 
10 sec 
Caffeine 
sti m u lation 
E lectrica l 
sti m ulation 
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Figu re 5- 1 8 : Effects of Dapagl iflozin ( DAPA) on ventricular myocyte sarcoplasmic 
reticulum Ca2+ 
( A )  Typical record showing the protocol employed in  a Control myocyte during SR 
Ca2 experiments. In i tial ly, myocytes were electrical ly stimulated at 1 Hz .  When 
the Ca2� transients had stabi l ized. e lectrical st imulation was paused for 5 seconds 
( sec) .  Caffeine was rapidly applied for 1 0  sec . E lectrical stimulation was then 
resumed. 
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Figu re 5- 1 8 :  Effect of Dapagli flozin ( DAP ) on \ entricular myocyte sarcoplasmic 
reticulum Ca2-.-
(A)  Typical record ho\'\:ing the protocol employed in  a Control myocyte during R 
Ca2� experiments. In it ial l • .  myocytes were electrical ly st imulated at 1 Hz. When 
the Ca2 tran ient had tabi l ized. electrical t imulation was paused for 5 econds 
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Figu re 5- 1 8  (cont in ued ) :  Effects of Dapagl iflozin ( DAPA) on ventricular myocyte 
arcoplasmjc ret iculum Ca2-
Graphs showing mean :  
( B )  Amplitude o f  caffeine-st imulated Ca2+ transient 
(C)  Fractional release of Ca2+ ( Electrical st imulation/Caffeine stimulation) 
( D) Recovery of the Ca2 transients fol lowing rapid application of caffeine 
Results were analyzed using A OVA and post hoc Bonferoni test. Data are mean + 
S .E .M. ,  n = 1 3 - 1 8  myocytes from 3 -4 hearts .  Horizontal l ines above the bars 
represent significant d ifferences at the l evel of P < 0.05 .  
ES:  electrical stimulation; CS: caffeine stimulation 
5.5.6. Effect of Da pagliflozin on Ventricu lar  Myocyte L-Type Ca24- Current  
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ince the effects of 1 0.6 M DAP observed could neither be attributed to 
myofilament en it i  i t)' to Ca2-t- nor to R Ca2+ relea e. it effect on L-type Ca2+ 
current \\ere in\'e tigated . 
L-type Ca2+ current was recorded at 34-36°C in entricular myocytes 
uperfu ed with Ca:!+-containing (2 .0  nunol/l ) extracel lular solution for 5 minutes 
fol lowed by superfu ion with 1 0.6 M DAPA + Ca2+ -containing extracel lu lar solution 
for 5 minute . Whole-cell configuration was employed and L-type Ca2-'- current 
act ivation. teady tate inactivation and restitution were recorded. 
Figure 5 - 1 9  shows the activation protocol ( upper panel ) and t pical records 
of L-type Ca:!+ current (pico-ampere/pico-farad� pA/pF) from a holding potential of -
50  mV to d ifferent potentials. from -60mV to + 70 mY. in  1 0  mV steps each of 200 
ms duration ( lower pane l ) .  In general L-type Ca:!+ current, over the test potential 
range -40 to +40 m V. was largest in myocytes from Control ,  fol lowed by 
ControVDAPA. fol lowed by STZ and smal lest in STZIDAPA ( Fig .  5- 1 9B) .  The 
results at each voltage from ControL Control/DAP A, STZ and STZIDAP A myocytes 
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Figu re 5- 1 9 : Effects of Dapagl iflozin on activation of L -type Ca2+ current in 
ventricul ar myocytes from STZ and Control rats 
(A)  Voltage protocol ( upper panel )  and typical records of L -type Ca2+ current ( lower 
panel )  in a ventricular myocyte from a Control heart. 
( B) Graph showing the amplitude of membrane currents evoked at different test 
potentials in the range -60 to + 70 ill V in ventricular myocytes from STZ- induced 
diabet ic and Control rats superfused with normal Tyrode (NT) or NT + 1 0-6 
DAPA. 
1 68 
Voltage Control ControUDAPA STZ STZID APA 
( mV)  ( pAJp F) (pAJpF) ( pAJpF) (pAJp F) 
-60 -0. 26 ± 0. 1 64 -0.599 ± 0 . 1 09d -0.4 1 4  ± 0. 1 59 -0.202 ± 0 .076 
-50 -0.0 7 ± 0.0 1 7  -0.0 0 ± 0.0 1 6  -0.068 ± 0.0 1 9  -0 .058 ± 0.0 1 
-40 0.02 ± 0.08 0.096 ± 0.052 -0.230 ± 0 .0563 b -0.095 ± 0 .024c 
-30 -4. 57 ± 2 . 1 24 - 1 .459 ± 0 .878 - 1 .632 ± 0.677 -0 . 578 ± 0. 1 66 
-20 -6 .  32 ± 2 . 362 -2 .598 ± 0 .90 1 d -5 .392 ± 0 . 840 -2 . 1 84 ± 0 .735c 
- 1 0  - 1 0 .573 ± 1 . 9 1 8  -6 .370 ± 1 . 522d -7 .2 1 4  ± 0 .758 -3 .920 ± 0.949c 
0 - 1 1 .269 ± 1 . 5 70 -7 .856 ± \ . 558d -7 . 362 ± 0.88 1 b  -4 .334 ± 0 . 729c 
+ 1 0  -9 .977 ± 1 .402 -7 .294 ± 1 . 396d -4 . 585  ± 0 .93 1 a.b -3 .39 1 ± 0 .687c 
�20 -8 .287 ± 1 . 246 -6. 1 67 ± 1 . 1 87d -3 . 597 ± 0 . 933a b -2 .607 ± 0.650c 
+30 -6 .395 ± 1 .083 -4 . 739 ± 0.974 -2 .094 ± 0 .4 1 0a.b - 1 . 666 ± 0 .327 
+40 -4.509 ± 0 .928 -3 . 329 ± O.  04 - 1 . 369 ± 0 .3 83a.b - 1 . 0 1 8  ± 0 . 302 
..l..50 -2 .652 ± 0 .745 -2 .007 ± 0 .644 -0.835  ± 0 .397b -0. 705 ± 0.289 
+60 - 1 .089 ± 0 .62 1 -0 . 868 ± 0 .506 -0. 543 ± 0 .457 -0 .459 ± 0.263 
,70 0. 1 1 7 ± 0.630 -0.063 ± 0 .4 1 7  -0.276 ± 0 .495 -0 .282 ± 0.240 
Table 5-2 : Effects of Dapagliflozin on activation of L-type Ca2+ current in  ventricular 
myocytes from STZ and Control rats 
Table howing the mean membrane current ( pA/pF) at each test voltage in the range 
from -60 mV to +70 mY. Results were analyzed using ANOYA and post hoc 
Bonferoni  test and Independent Samples T-Test. Data are mean ± S .E .M. ,  n = 1 0- 1 4  
myoC)1es from -+-7 hearts. Differences between groups, a (ANOVA; P < 0.05 ) versus 
Control m 'ocytes. b ( Independent Samples T -Test; P < 0.05) versus Control 
myocytes, C ( Paired Samples T-Test; P < 0 .05)  versus STZ myocytes. d (Paired 
Samples T-Test P < 0.05)  versus Control myocytes 
The protoco l  studying steady-state inactivation involved stepping the 
membrane from various 1 000 ms pre-pul ses between -60 and +30 m V to a test pulse 
of 0 m V. as i l lustrated in Figure 5-20A ( upper panel ) .  Ca2+ current was measured as 
the relationship between the AMP of peak currents produced at each of the pre-pulses 
to those measured at the test pulse 0 m V. Typical records of steady-state inactivation 
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�+ 
a- current are hown in Figure 5-20 ( lower panel ) .  Figure 5 -20B show 
normal ized peak current mea ured after the pre-pulses at 0 m V plotted again t the 
re pective pre-pul e voltage/potentia l .  teady-state inact ivation was not significantly 
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Figu re 5-20: Effect of Dapagl iflozin on steady state inact ivation of L-type Ca2+ 
current i n  ventricular myocytes from STZ and Control rats 
( A) Voltage protocol ( upper panel )  and typical records of inact ivation currents ( lower 
pane l )  in  a ventricular myocyte from a Control heart 
( B) A graph showing membrane currents fol lowing different pre-pulse potentials in  
the range -60 to +30 m V 
Results were analyzed using A OV A and po t hoc Bonferoni test. Data are mean + 
S .E .M . . n = 1 0- 1 4  myocytes from 4-7 hearts. 
I mu:  amplitude of peak current at each pre-pulse; I :  ampl i tude of peak current at the 
test pul se 0 m V 
A two-pulse protocol was used to investigate the t ime course of recovery from 
inactivation ( Fig .  5 -2 1 A, upper panel ) .  These pul ses were consecutively separated by 
i nter-pulse intervals and each pulse was 1 00 ms in duration causing depolarization of 
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the membrane potential to + 1 0 m . The inter-pul e interval were variable and 
increa ed gradual l y  ver time the protocol wa appl ied. T pica! records of Ca2-
curr nt recover after different inter-pul e interval are hoWD in Figure 5 -2 1 A  ( lower 
panel ) .  Mea urem nt of the time cour e of reco er fro111 inactivation was done by 
normal izing the P of peak Ca2+ current of the second pulse to that of the first 
pulse and th ir ratio was plotted against the durat ion of the inter-pulse interval ( Fig. 
5-2 1 B ). 0 ign i ficant alterat ions were obtained with the time course of recovery 
from inactivation in  TZ compared to  Control m ocytes or  by  DAP A .  
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Figure 5-2 1 :  Effects of DAP A on restitution of L-type Ca2+ current in ventricular 
myoc)1es from STZ and Control rats 
( A )  Voltage protocol ( upper panel )  and typical records of membrane current during 
recovery from inacti ation ( lower panel )  in a ventricular myocyte from a Control 
heart 
( B) A graph showing recovery from inactivation at various inter-pulse intervals with 
variable duration 
Results were analyzed using A OVA and po I hoc Bonferoni test . Data are mean + 
S .E .M . . n = 1 0- 1 4  myocytes from 4-7 hearts .  
Pn:  ampl itude of peak current of the second pulse; PI : ampl itude of peak current of 
the first pul se 
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Cha pter 6 :  Di cu ion 
Thi tudy inve tigated th effects of the non- elective GL T1 and 2 inhibitor 
PHLOR. elective GL T 1  inhibitor QUER-3-G and electi e GLT2 inhibitor DAP A 
on hortening and intracel lular Ca2
+ 
in ventricular m ocytes from TZ-induced 
diabetic and ontrol rats. The major findings of the tudy were as fol lows: 
1 ) PH LOR. Q ER-3-G and DAPA signi ficant ly reduced the AMP of shortening 
in  TZ and Control myocytes. 
2 )  PH LOR and QUER-3-G significant ly reduced the AMP o f  the intrace l lular 
Ca2+ tran ient in STZ and Control myocytes. 
3)  DAPA signi ficantl reduced the AMP of  the intracel lu lar Ca2-'- transient in  
TZ myocytes. 
4 )  PHLOR and DAP A d id  not significantly alter myofilament sensitivity to Ca2+ 
in  TZ and Control myocytes. 
5)  QUER-3 -G significantly decreased myofilan1ent sensitivity to Ca2+ in  Control 
myocytes and mode tly in STZ myocytes. 
6 )  PHLOR, QUER-3-G and DAPA d id  not s ign ificantly alter fractional release 
of SR Ca2-+ in STZ or Control myocytes, and 
7)  The AMP of L-type Ca2T current was reduced in  STZ compared to Control 
myocytes and was further reduced by DAP A .  
6. 1 .  Dia bete Mel l i tu I nd uction i n  An ima l  
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Choo ing an animal model for any study rel ies on the nature of the study and 
the variable to be inve tigated. Being a tud that focuses on investigating the 
diabet ic heart after a pharmacological intervent ion. the appropriate animal model 
hould exhibit features of the diabetic heart. Rodents are a preferred option In 
research studie a they are ea i ly handled and maintained at low cost and In 
relative ly mal l paces [ 1 86] .  Among the d ifferent experimental methods used to 
obtain d iabet ic animal models  inc luding surgical l  - induced, diet-induced and 
genet ically-derived. the chemically-induced STZ model has several advantages 
inc luding cost-effectiveness and the ease of inducing DM regardless of the genetic 
background or the age of the animal [38; 72] . STZ-induced DM i s  a widely used 
animal model for human d iseases. ranking second after the spontaneously 
hyperten ive rat [298 ] .  The STZ rat model resembles DM in  humans in various ways. 
It exhibits diabetic sign such as hyperglycemia. reduced body weight, polyphagia 
and polydipsia [298 ] .  as wel l  as diabetic symptoms/compl ications such as reti nopathy 
and cataract [ 1 2 ; 1 36 ;  l 70 :  298] ,  cardiom opathy [287] ,  neuropathy [42; 1 99; 298] 
and nephropathy [49; 1 39;  1 6 1 ;  299] ( for a detailed review see [279] ) .  
Different cardiac dysfunctions have been reported in  STZ rats at  the whole 
animal ( in vivo) and i solated heart/cardiac tissue ( in vitro) level s .  Some effects at the 
whole animal Ie el include reduced resting H R  [30;  3 1 ;  46; 64; 244] , decreased 
cardiac contracti l i ty and relaxation, increased stroke volume, increased cardiac output 
[46] .  decreased myocardial blood flow reserve [66] , reduced mean arterial pressure 
[ 3 1 ;  244J and reduced left ventricular function [64; 66; 67J .  Effects at the isolated 
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heart/cardiac ti ue level include tructural and functional effect . tructural effects 
rna] involve reduced heart weight. reduc d atrial .  right and left ventricular eights 
[252] ,  increased l ipid deposi tion, 10 s of contracti le proteins. myocytolysis [ 1 3 7] .  
decrea ed  diam ter and urface area of capi l laries in the myocardium [66] ,  increase in 
the nWl1ber of sarcolemmal a2+ channels  [ 1 07] .  decreased thickness and increased 
internal diameter of the left ventricle [298] and increased col lagen content in left 
ventricular t i  sue [30] . Functional effects rna involve depressed cardiac 
performance [ 1 3 7; 287 ] ,  reduced H R  [64; 1 2 1 ;  298 ] ,  prolonged AP duration in the SA 
node. right atrium and right ventricle [ 1 2 1 ;  298] .  diastol ic  sti ffness [298] .  impaired 
r laxation (dia tole) and contraction ( systole)  [64] .  reduced depolarizat ion of the 
resting membrane potential [298] ,  decreased ATPase acti ity of cardiac contracti le  
proteins [ 1 89] .  increased ventricular sensitivity to Ca2+. depressed atrial activity. 
enhanced right ventricular activity [227] ,  elevated Fe2+ levels in the right ventricle, 
e levated a + level s in the atria and right ventric le lower Ca2+ levels  in the atria, right 
and left ventric les. increased Cu2+ level s  in the atria and decreased Cu2+ levels  in the 
left ventric le [252 ] .  
To  induce DM,  STZ (60 mglkg body weight) d i s  sol ed  in  citrate buffer was 
injected i .p .  i n  male adult Wi star rats. It would have been preferable to i nject STZ via 
the i .v .  route because the i .p .  route involves the additional step of absorption of STZ 
into the bloodstream before its effects can take place. This decreases its 
bioavai labil ity compared to that injected by the i .v. route [ 1 60 ] .  The commonly used 
doses of STZ to induce DM in rats include 40 mglkg [258] ,  45 mg/kg [66; 67;  249], 
50 mg/kg [3 1 ;  1 40; 3 1 3 ] ,  60 mglkg [60; 252;  264: 287] ,  65 mglkg [30;  46; 1 3 7 ;  1 48 ;  
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226: 292: 3 1 7 ] .  I 0, some tudies u e TZ do e a high as 90 mg/kg [29: 1 22]  and 
1 00 mg/kg [2 1 4 ] .  TZ at do e 50-65 mg/kg induces hyperglycemia without DKA. 
Ho'W e\'er, DKA or even death can occur at higher doses of TZ (?.75 mg/kg) [ 1 96; 
298] and can b prevented b the administration of insul in [298] .  Since OKA is a 
characteri tic of T I OM [ 1 0] ,  orne tudies general ly describe models induced b 
dose that do not induce OKA as T2DM models [ 1 40 ] .  
OM induced by  a single injection of  60 mg/kg TZ can be characterized as 
T 1 DM [60; 2 1 7] .  T2D 1 [ 1 1 3 ; 220] or unspecified [3 ;  1 2 1 ] . Like T 1 DM. after a 
ingle TZ injection, the insul in-producing pancreatic p-cel l s  are destroyed and 
hypoinsul inemia rapidly develops [ 1 0: 70; 84] . HO\ ever, unl ike T l  OM. a single dose 
of TZ destroys the cel ls due to toxicity (as a chemical insult )  rather than an 
autoimmune respon e [ 5 :  206 ] .  An autoimm une response can be induced by multiple 
injections [ 1 94 :  237] . On the other hand, several studies reported that damaged 
pancreatic p-cel l s  can spontaneousl regenerate with time after STZ injection in rats 
[203 : 295 : 296] and mice [3 1 4] .  In addition. considering that STZ rat models  
produced by this  dose (60 mg/kg) do not exhibit DKA [ 1 43 ;  1 96; 298] and show 
significant glycemic i mprovement with anti-diabetic medications, other than insulin. 
such as metformin [6 1 ] . tolbutamide [ 1 7 1 ] , gl ibenclamide [4; 1 56 ] ,  vanadyl sulphate 
[224] , piogl i tazone [98] ,  rosiglitazone [82 ;  1 84] and empagl iflzoin [ 1 85 ] ,  it also 
resembles T2DM. Col lectively, it can be concluded that the rat model produced by 60 
mglkg STZ cannot be strictly described as neither T I DM nor T2DM, but rather an 
unspecified model of hyperglycemia. 
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DM characterist ics take some t ime to develop in  TZ-induced diabet ic rats. 
Bod) weight become igni ficantly lower, compared to controls, only after 2 weeks 
fol io\.\ ing TZ injection. Diabetic CY complications begin 5-7 days after STZ 
injection and continue to v,'or en with time. The earl ie t complication is reduced HR 
occurring after 5-7  day . fol lO\ved b reduced mean arterial pressw-e after 1 4  days and 
eventual ly reduced variabi l ity of HR and mean arterial pr ssure after 30-45 da s 
[_44 ] .  In  order to al low these compl ications to develop, the experiments started 2 
month after TZ injection. ince it i s  wel l  known that the key element of DM i s  
hyperglycemia. DM was conflfmed in the rats by measuring their BOL using a 
glucometer. in  blood taken from the tai l vein 3 -5 days after STZ injection. To ensure 
that the injected rats were sti l l  d iabetic and regeneration of �-cel l s  had not occurred. 
measuring the BOL of the tested rat prior to the experiment was essent ia l .  Rats that 
exhibited recovery from DM, indicated by normoglycemia, were excluded from the 
study. Only rats with a BOL of ::::: 200 mg/dl and above were included in the diabetic 
group. Control rats were injected with an equivalent volume of ci trate buffer only and 
their BOL ranged from ::::: 75- 1 30 mg/d l .  Differences in STZ rats compared to 
Controls ,  aside from the hyperglycemia, included reduced body weight reduced heart 
weight and i ncreased heart weight to body weight ratio.  These results have been 
ShO\\l1 repeatedl in previous studies using this model [34;  1 2 1 ;  1 23 ;  1 25 ;  1 48 ] .  Three 
batches of rats were used and each batch was used for a period of approximately 1 2  
weeks after DM i nduction. No cases of death were reported whether in  STZ-induced 
diabetic or Control rats in any of the batches . 
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6.2 .  The Rea on for Choo ing to Study the Effect of Sod iumJG luco e Co­
tran porter I n h ibitor on the H eart 
GLT inhibitor have been recei ing more attention recent ly as a novel ant i -
diabet ic therapy . Before it wa knO\ n that PH LOR mechanism of action involves 
inhibit ing GL T protein , its glyco uric effect had been first observed in 1 886 [80] .  
tudie in  the late 1 980s and early 1 990 showed that s .c .  i njections of PHLOR 
igni ficant ly  improved both fast ing and fed BGL in partial ly pancreatectomized rats 
[ 1 44 :  235 :  236] ,  nom1al ized their t issue insul in sensiti i ty and increased glycosuria 
compared to the untreated d iabetic rats [236] . Tlus was also confirmed by later 
tudie on STZ-induced diabetic rats willch showed that PHLOR significantly 
improved fasting BGL and restored diabetic i nsul in sensit ivity [ 1 57 ] .  Glycemic 
improvement with glycosuria was also observed after s .c .  inject ion of PHLOR in 
cattle [ 35 ] .  Despite its observed anti-diabetic effects via the s .c .  route. no studies have 
been done. or at l east published. on the effects of s .c .  PHLOR in humans. Previous 
tudie showed that PHLOR can be safely admin istered i .v .  in human subjects [80; 
1 72 ] .  
PHLOR was reported to  ha  e a low oral bioavai labi l ity because it i s  
metabol ized in  the i ntestine by  � -glucosidase ( �-glucuronidase) and/or sulfatase that 
splits it  i nto phloret in and glucose [69: 280] . However, oral administration of PH LOR 
in mice reduced their BGL in a dose-dependent manner [272] and intragastric 
admini stration also reduced BGL in diabetic mice [40] . Phloretin,  the metabolite of 
PHLOR. is an inh lbitor of the G LUT transporters which are widely expressed 
throughout the body [280] . GLUTs are responsible for bidirectional passive transport 
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of gluco e betv" een the blood and the cel l cytoplasm [204] and thus, chronic 
inhibition by phloret in can cau e damage espec ial l  i n  gluco e-dependent organs. l ike 
the brain. due to a lack of cellular glucos [280] .  
i nce the oral rout is the best method of admini stration in the c l inical setting. 
PHLOR wa u ed as the parent molecule to produce other oral bioavai lable SGLT 
inhibitors [280] . SGLT inh ibitors that are being developed include non-selective 
GLT ! and 2 inhibitor uch as LX42 1 ] [ 3 1 9] .  selective SGL T l  inhibitors such as 
KG -2727 [250] and KGA-3235  [ 1 62 ] .  and the majori ty are selective SGLT2 
i nhibjtors uch a DAPA [ 1 95 ] ,  canagli flozin [ 2 1 3 ] ,  empagl iflozin [ 1 09] ,  ipragl i flozin 
[246]. topogl iflozin [265 ] .  remogl iflozin etabonate [97] and lesugl iflozin [ 1 46] .  
everal tudie on STZ rat showed improved g l  cemic control  after treatment with 
GLT i nhibitors such as PHLOR [60] , DAPA [ 1 95 ] ,  empagl iflozin [ 1 85 ] ,  
ipragl iflozin [269] and topogl iflozin [265] .  
I n  this study. three compounds from the three subclasses o f  SGLT i nhibitors 
were tested. Thi al lows evaluation of the d ifferences and s imi larities between 
representatives from each subclass. By having the parent compound of SGLT 
i nhibi tors PHLOR. i t  i s  also more l ikely that the other SGLT inhibitors derived from 
P H LOR would act in a s imi lar man er. QUER-3-G was shown to have anti -diabetic 
effects [2 1 9] due to its selective SGL T l  inhibit ing [2 ;  54] and a-glucosidase 
i nhibit ing properties [ 1 74 ] .  DAPA I S now a commercial ly avai lable anti-diabetic 
medication in various countries [282 ] .  I t  i s  the fIrst selective SGLT2 inhibitor 
developed in its c lass and it is the second SGLT2 inhibitor approved by the FDA [90; 
282] . 
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10 e PH LOR. Q ER-3-G and DAPA all have anti-diabetic propertie . their 
effect should be te ted on diabetic organ . especial ly tho e suscept ible to diabet ic 
complication . There appeared to be no data avai lable about the effects of PHLOR, 
Q ER-3-G and DAPA on ventricular myocytes from diabetic heart . 
6.3. Effects of Sod i um/G luco e Co-transporter I n h i bitors on the Card iova cu lar 
y tern 
Previou studies done with PHLOR. QUER-3-G and DAPA showed that they 
can affect the CV ystem . 
PHLOR treatment was shown to ha e protective effects against the 
development of diabet ic cardiomyopathy 10 db/db mice by downregulating the 
expresslOn of cardiac damaging proteins and upregulating the cardiac proteins 
responsible for cardiac l ipid metabol ism. causlOg a reduction in  cardiac l ipid 
accumulation [40] . I soproterenol- induced m ocardial necrosi s  was partial ly prevented 
in mice by PHLOR [ 1 1 4) .  PHLOR suppressed the production of ROS in rat 
cardiomyoc)ies by inhibit ing SGLTI  [ 1 8) .  Hypotension. elevated baroreflex 
sensitivity and i ncreased expression of cardiac M2-muscurinic receptors were 
reversed by PHLOR treatment in STZ-diabet ic rats [ 1 80 ] .  Restoration of glucose 
ut i l ization in heart muscle to the normal level was seen after PH LOR treatment in  
STZ-diabetic rats [ 1 78 ) .  
QUER-3-G was reported to  have several anti -hypertensive mechanisms 
including diuresi s  and potassium-sparing activity [ 1 00; 1 0 1 ] , reduction of angiotensin 
converting enzyme activity and reduction of plasma aldosterone in  spontaneously 
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hypert n i \ e rat [ 1 0 1 ] . Q ER-3-G was al o hown to have a protective effect 
again t RO -induced inj ury in cultured human endothelial cel l s  in a dose-dependent 
mann r. which provide an additional benefit to diabetic patient [29 1 ] . In addition, 
tudies showed that QUER-3-G-containing plant exhibited arious beneficial effects 
again t the development of athero clerosis in rats by lowering total cholesterol ,  
triglycerides and LDL-C. increa ing the beneficial high-density l ipoprotein­
cholesterol (HDL-C) 1 els and decreasing inflan1matory responses [32 1 ] . 
L ittle is 1<110\\<11 about the effects of DAP A on the CV system.  A large c l inical 
trial ' DECL RE-TI 1 1 5 8 ' .  to b e  completed in  Apri l 20 1 9, i s  progressing to evaluate 
DAPA afet), and effects on CV outcomes [ 1 4] .  Several studies showed that DAPA 
mono therapy reduce the systol ic blood pressure [ 1 6; 1 47 ;  1 79] . Smal l and 
incon istent decrea es of H R  [ 1 79] and less pronounced reductions of diastol ic blood 
pres ure have been reported in DAPA-treated diabet ic subjects [ 1 47; 1 79] .  A sl ight 
increa e of HDL-C was seen in diabetic subjects treated with DAPA [ 1 6; 87 ] .  DAPA 
add-on therapy to metformin.  sUlphon lureas or thiazol idinediones produced a 
significant reduction in  various CV outcomes including M I  incidence, stroke 
incidence, coronary heart d isease death, stroke death and al l -cause death compared to 
metformin.  sulphonylureas and thiazol idinediones monotherapies [79] .  
Supratherapeutic doses of DAPA ( 1 50 mg compared to 5 - 1 0  mg as the therapeutic 
dose) did not significantly prolong QT interval in healthy individuals [47] . 
6.4. Concen trat ion of od iurn/G luco e Co-tran porter and their Solvent  
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In th prel iminary experiments, the effects of DAPA on hortening were 
tested at three concentration ( l 0-5 M, 1 0-6 M and 1 0-7) .  DAPA was only significantly 
effective at 1 0-5 M and 1 0-6 M to simi lar extents. Therefore, 1 0-6 M DAP A was used 
in al l xperiment . PHLOR and QUER-3-G were also used at the same concentration 
( l 0-6 M )  to fa i l itate com pari on of re ults . 
Celiainly it is preferable to use mi l l i-Q water to dissolve any compounds 
te ted becau e it ha a neutral effect on whichever parameter is being in estigated, 
\\- hich ensure that any effect obser ed are from the compound tested rather than the 
olvent. HoweveL according to the information suppl ied by the manufacturer, DAP A 
i most oluble in DMSO ( 82 mg/m l )  for in vitro use [_47] .  DMSO is  a widely used 
soh ent and vehicle in research and is soluble in aqueous and organic media because 
of it amphiphi l l ic structure. which is composed of one highly polar (hydrophi l ic )  and 
two apolar ( lipophi l ic )  groups [243 ] .  The solubi l ities of PHLOR and QUER-3-G were 
also tested in DM 0 and they ere found to be soluble in this organic solvent. Using 
one sol ent for all the tested compounds el iminated the chance for any variabi l ity that 
could have occurred if d ifferent solvents were used for each compound. A l l  the 
working solutions in the experiments contained 0 .005% DMSO which does not have 
any detectable effects on any of the parameters measured in this research. Previous 
studies in  rat myocytes have shown that 0 .0 1  % DMSO does not have significant 
effects on contracti le parameters and Ca2+ current [ 1 05 ;  263 ] .  Also, :::;0 . 1 %  DMSO 
does not significantly alter myocyte morphology and contracti le function [ 1 82] . 
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In " ilro uperfu ion f PHLOR, Q ER-3-G and DAPA was employed . In 
,';11'0 treatment al lows more straightforward eval uation of the GLT inhibitors effects 
a it ensure that the effects seen are from the compounds themselves and not from 
their metabol ite , \\'h i le il1 vivo treatment i s  subjected to arious pharmacokinetic 
influences. 
6.5. Ph lorizin ,  Quercetin-3-0-G luco ide and  Dapagliflozin Reduce the 
Am pl i tude of Shorten ing in  Ventricu lar  M yocyte from Streptozotocin­
I n duced Diabetic and  Control Rat  
entricular myocyte were freshly i solated on each experimental day_ Freshly 
i olated cell are general ly preferable to cell l i nes in physiological studies as they 
closely resemble the in vivo cel l  in both structure and function [ 1 8 3 ] .  In addition, cel l 
l i nes do not exhibit the features required for ECC experiments. inc luding rod-shaped 
morphology and complement of protei ns [24 1 ] . 
A VED system was used to measure myocyte shortening. This technique 
oyercomes some di sadvantages of in vim experiments, including the interference of 
autonomic nerve endings, gap junctions and neurotransmitter uptake systems, and in 
vitro s. stems such as Langendorff-perfused heart preparation, including the 
interference of coronary perfusion status [6 ] .  VED al so measures shortening in  a 
single-cel l  rather than in  the whole heart [6] . 
The effects of PHLOR, QUER-3-G and DAPA on shortening were evaluated 
after exposing the myocytes to the tested SGLT inhibitor for 5 minutes, whi le  being 
electrically-st inlUlated at 1 Hz.  Although, the HR of adult Wistar rat under normal 
conditions ranges from about 300-400 beats/min  ( 3 1 4 . 1  ± 4 . 7  beat/min  in l ight to 
3 80 .8  ± 4.6 beaUmin in dark) [320] ,  vv hich i s  approximately equivalent to 5-7 Hz, the 
m 'ocyt \\ ere timulated at a lower frequency because high frequencies ( 5 -9 Hz) 
were hOV,l1 to have a reducing effect on rat myocyte shortening in virro [2 1 0] .  In  
addition. man) tudies u e thi frequency ( 1  Hz) for entricular myocyte electrical 
t imulation [48;  _22� 23 ] ; 322] .  This  enables comparisons between studies. Al l  
experiment were performed at  phy iological temperature ( 34-36 °C) to mimic the 
ph)' iological conditions of the ventricular myocytes as much as pos ible. 
R L TPK shortening. THALF relaxation and AMP of shortening (expressed 
as a percentage of hortening of RCL and as a percentage of shortening in STZ and 
Control myocytes superfused with T) were measured . There was a significant 
decrea e in RCL in STZ myocytes compared to Controls indicating reduced myocyte 
ize in STZ rats, which is consistent with the significantly reduced heart weights in 
TZ rats. Reduced RCL rna also suggest elevated resting intracel lular Ca2+ levels 
which could be attributed to impaired uptake of Ca2+ by the SR or impai red exit of 
.,� 
Ca- · by CX. Consistent with previous studies, TPK shortening was significantly 
prolonged in STZ myocytes compared to Controls  [ 1 68 ;  252] ,  which may suggest 
slow Ca2"1- entry form the L-type ci+ channels, slow CICR or reduced myofi lament 
sensitivit . THALF relaxation was not sign ificantly altered between STZ and Control 
myocytes as sho\\l1  i n  previous studies [ 1 8 1 · 252) .  The AMP of shortening 
(expressed as a percentage of shortening of RCL )  was significantly reduced in STZ 
myocytes compared to Controls .  Figure 6- 1 shows the effects of PH LOR, QUER-3-G 
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Figu re 6- 1 : Effects of Phlorizin (PHLO R). Quercetin-3 -0-glucoside (QUER-3-G) 
and Dapagl i flozin (DAP A)  on the amplitude and time course of ventricular myocyte 
shortening 
Graphs showing the mean : 
• Rest ing cell length with PHLOR (A) ,  QUER-3-G ( B )  and DAPA (C )  
• Time to peak (TPK) shortening with PHLOR ( D) ,  QUER-3-G ( E )  and DAPA ( F) 
• Time to half (THALF) with PHLOR ( G ), QUER-3-G ( H )  and DAPA ( I )  
• Ampl itude (AMP) of sh0l1ening with PHLOR (J ) ,  QUER-3-G ( K) and DAPA (L )  
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PHLOR. Q ER-3-G and DAP had no ignificant effects on RCL in TZ 
and ontrol m ocyte (Fig. 6- 1 A-C).  These results may indicate that GLT inh ibitors 
do not affect the re t ing intracel lular Ca2+ level . PHLOR and DAPA did not 
sign i ficant l )  affect TPK hortening in TZ and Control myocytes ( Fig .  6- 1 A,C ), 
v" hereas Q ER-3-G ignificantl reduced TPK shortening in TZ and Control  
myocyte (Fig .  6- 1 B) .  PHLOR. QUER-3 -G and D PA did not have significant 
effect on TH LF relaxation (F ig .  6- 1 G- 1 ) .  This indicates that PHLOR and DAPA. in 
particular. have no ignificant effects on the durations of myocyte contraction 
( indicated by TPK hortening) and relaxation ( indicated by THALF relaxation), while 
QUER-3-G has a reduc ing effect on the durat ion of myocyte contraction and no 
significant effect on the duration of relaxation. There were significant and consistent 
reductions of the AMP of shortening (expressed as a percentage of shortening in STZ 
and Control myocytes superfused with T) to simi lar extents in both STZ and 
Control myocytes with P HLOR, QUER-3-G and DAPA ( Fig .  6- l J -L)  i nd icat ing that 
they exert negat ive inotropic effects. It was then speculated that these SGLT 
inhibitors might have effects on the intrace l lul ar Ca2+ transient. 
It was unexpected to observe that long-tem1 exposure ( 1 -3 ills) to DAPA did 
not show an significant d ifference in the AMP of shortening in both Control and 
STZ myocytes.  It seems that DAPA effects were only pronounced after short-telID 
exposure, which might suggest the development of a tolerance towards DAPA effects 
after long-term exposure . 
6.6. Ph loriz in, Quercet in-3-0-Gluco ide 
Am pl i tude of I n tracel lu lar  Ca2+ Tran 
treptozotocin - I nduced Diabetic Rat 
1 8 �  
and Dapagl iflozin Red uce the 
ient in Ventricu lar  Myocyte from 
The econd et of experiments inve tigated whether PHLOR. QUER-3-G and 
OAP A have any effect on myocyte i ntracel lular Ca2+ transient. Ventricular myocytes 
were loaded \\' ith the fluorescent Ca2+ -binding indicator Fura-2 AM. Fura-2AM is  
widely used to image intracel lular Ca2+ owing to its better absorption coefficient. 
quantum yield. Ca2+ electivit , bleaching resi stance and the high brightness of its 
ignal compared to other indicators [65 : 2 1 8] .  
Fura-2 loaded myocytes, maintained at 35-36°C, were electrical ly stimulated 
( 1  Hz) and exposed to the tested SGLT inhibitor for 5 minutes. Rest ing Fura-2 ratio. 
TPK Ca2
� 
transient. THALF decay of the Ca2+ transient and AMP of the Ca2 
tran ient (expressed a a percentage of resting Fura-2 rat io and as a percentage of 
Ca2+ transient i n  Control and STZ m ocytes superfused with T) were measured. As 
in previous studies, STZ myocytes did not show any significant al teration in  resting 
Fura-2 ratio compared to Controls [ 1 23 :  252] . This indicates that the reduction in 
RCL in STZ myocytes is not attributed to increased resting intracel lular Ca2+ levels .  
TPK Ca2� transient was significantly prolonged i n  STZ myocytes compared to 
Controls  which explains the prolonged TPK shorten ing i n  STZ myocytes. THALF 
decay of the Ca2+ transient was not significantly changed in  STZ myocytes compared 
to Controls .  As shown i n  previous studies. the AMP of the Ca2+ transient (expressed 
as a percentage of resting Fura-2 rat io) was not significantly altered in STZ myocytes 
compared to Controls [34;  1 23 ;  1 8 1 :  252] . F igure 6-2 shows the effects of PHLOR, 
QUER-3-G and DAPA on ventricular myocyte intracel lular Ca2+ transient . 
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Figu re 6-2 : Effects of Phlorizin ( PHLOR), Quercetin-3 -0-glucoside (QUER-3-G) 
and Dapagl iflozin (DAP A)  on the ampl itude and t ime course of ventricular myocyte 
intracel lular Ca2+ transient 
Graphs showing the mean : 
• Resti ng Fura-2 ratio with PHLOR (A) ,  QUER-3-G ( B) and DAPA (C)  
• Time to peak (TPK) ci+ transient with PHLOR ( D), QUER-3-G ( E )  and DAPA 
( F) 
• Time to half (THALF)  decay of the Ca2+ transient with PHLOR (G) ,  QUER-3-G 
( H )  and D AP A ( 1 )  
• Amplitude (AMP) of the Ca2+ transient with PHLOR (J ) .  QUER-3-G ( K) and 
DAPA ( L) 
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PHLOR ( Fig. 6-2 ) and D PA ( Fig. 6-2C ) had no significant effects on 
re ling Fura-2 ratio in TZ or Control myocytes (Fig. 6-2A-C) which i consi stent 
with their effects on R L. However. QUER-3-G ignificantly increased rest ing Fura-
2 ratio in ontrol myocyte which might suggest that QUER-3-G affects one of the 
element respon ible for the removal of intracell ular Ca2+ during relaxation, such a 
CX or ERC . PHLOR ( Fig.  6-2D)  and QUER-3-G ( Fig. 6-2E )  did not 
ign i ficant l)  alter TPK Ca2+ tran ient in both TZ and Control myocytes. This was 
exp cted for PHLOR but not for QUER-3-G owing to its effects on TPK shortening. 
Thi may suggest that the observed effects of QUER-3-G on TPK shortening were 
mediated by a factor other than Ca2+ . On the other hand, DAP A ( Fig. 6-2F )  
ignificantly prolonged TPK Ca2+ transient in STZ myocytes without significantly 
affecting TPK shortening. TZ myocytes appeared to be more susceptible than 
Controls to the effects of DAP A on the Ca2+ transient . PHLOR (F ig. 6-2G) and 
DAP A ( Fig.  6-2 1 )  did not significantly affect THALF decay of the Ca2.,. transient in 
either STZ or Control myocytes. On the other hand, QUER-3-G ( Fig. 6-2 H )  
ignificantly  reduced THALF decay o f  the Ca2
'" 
transient i n  both STZ and Control 
myocytes. PHLOR. QUER-3-G significant ly reduced the AMP of the Ca2+ transient 
(expressed as a percentage of shortening in Control and STZ myocytes superfused 
with T) in  both STZ and Control myocytes. and DAPA significantly reduced i t  in 
TZ myocytes which again might suggest a higher susceptibi l ity of STZ myocytes to 
the effects of DAP A. Olson and colleagues have previously reported that PHLOR 
modest ly decreases the AMP of the Ca2+ transient in healthy rat ventricular myocytes 
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[ 2 1 6] .  Lack of ignificance in their re ult might be attributed to the smaller ample 
ize used in their tud ( n  = 6) compared to thi study ( n  = 2 1 -23) .  
6.7 .  Ph lorizin, Quercet in-3-0-Gl uco ide and Da pagliflozin Do Not Alter 
Myofi lament Sen it ivity to Ca2+ in  Ventricu lar  Myoc tes from 
treptozotocin - Induced Dia betic and Contro l  Rats 
hortening and Fura-2 ratio were recorded simultaneously to assess 
'1+ my filan1ent sen itivity to Ca- . Measuring the gradient of the Fura-2-cel l  length 
trajectory during late relaxation of the twitch contraction indicates myofilament 
respon e to Ca2 a reported by previous studie [ 1 24;  257 ] .  
Con i tent with prevlOU studies, there was no significant difference in 
myofilan1ent sensitivity between STZ and Control myocytes [23 1 ] . Figure 6-3 shows 
the effect of PHLOR, QUER-3-G and DAPA on ventricular myocyte myofilament 
sen it ivity to Ca2+. 
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Figu re 6-3 : Effects of Phlorizin (PHLOR) Quercet in-3 -0-g1ucoside (QUER-3-G) 
and Dapagl iflozin ( DAPA) on ventricular myocyte myofilament sensitivity to Ca2+ 
Graph shO\ ing mean gradient of the Fura-2-cel l  length trajectory during late 
relaxation of the tv."itch contraction during the period 500-800 rns with PHLOR (A) ,  
QUER-3-G ( B) and DAPA (C) .  
Although PHLOR effects were not significant, i t  showed a modest decreasing 
effect on myofilament sensit ivit in Control myocytes and an increasing effect in  STZ 
myocytes (F ig. 6-3A) .  Unl ike PHLOR, both QUER-3-G ( Fig .  6-3B )  and DAPA (Fig. 
6-3C)  showed the same pattern of effects in  both STZ and Control myocytes. QUE R-
3-G tended to reduce myofilament sensit ivity in  STZ and Control myocytes, however, 
its effects were only significant in Control myocytes. DAP A also tended to reduce 
myofilament sensitivity i n  STZ and Control myocytes, but none of the effects were 
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ign i ficant. Col lectiv 1y. the e r suit may ugge t that the negati e inotropic effects 
of PH LOR. Q ER-3G and DAP were not mediated by alteration in myofilament 
en it iv ity to Ca2T. Increa ing the sample ize might reduce the variabil ity of the data 
and bring orne of the change reported to significance. 
6.8. Ph lorizin, Quercet i n -3-0-G lucoside and Dapagliflozin Do Not Alter 
a rcoplasm ic Reticu l um Ca2+ Transport in  Ventricu lar  Myocytes from 
Streptozotocin- I nd uced Dia betic and Contro l  Rats 
R Ca2+ transport was mea ured in  ventricular myocytes maintained at 35 -
36°C. The experiment protocol involved electrical ly st imulating the m ocytes at 1 
Hz, then pausing it for 5 seconds. applying caffeine ( 20 mmol )  for 1 0  seconds and 
then re uming the electrical stimulation. Caffeine is a RyR agonist that has been 
widely u ed to trigger CICR from the SR by lowering the threshold of RyR for Ca2+ 
act ivation [ 1 65 ] .  During thi s protocol, the AMP of the caffeine-stimulated Ca2+ 
transient. fractional release of Ca2+ (electrical stimulation/caffeine stimulation). and 
the gradient of myocyte recovery after caffeine application and fol lowing resumption 
of electrical stimulation, were measured once during T superfusion and repeated 
during the superfusion of the tested SGLT inhibitor. 
The AMP of the caffeine-stimulated Ca2+ transient was significant ly reduced 
in STZ myocytes compared to Controls indicating an impaired release of Ca2+ form 
the S R. Fractional release was not significantly altered in STZ myocytes compared to 
Controls .  Recovery of the Ca2+ transients was also not significantly altered in STZ 
myocytes compared to Contro ls  ind icating that STZ-induced diabetes does not 
interfere with the recovery of intracel lular Ca2+ transient and the refi l l  of SR with 
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a2- during rela at ion. Figure 6-4 hows the effects of PHLOR, QUER-3-G and 
D P 
o .  
� ... 
c o 
� 0 . 
� 
E 0..) . 
� 0 1  
0 6  






n ventricular myocyte sarcoplasmic reticulum Ca2+ . 
D NT 









. 1  
0 7  :;-; 0 I 
o 
:;; 0 5  
:; 
! o . 
e 
" OJ c 
"i � 0 2  
U 
0 1  
0 8  
(i) 0.1 
u U; 0 6  w 
i 0 $  
e o . 
'ii 0.3 
c 
2 0.2 II .. 
� 0 ,  
0.022 
0.020 
0 01 8  
0.016 
0.0" 
















0 6  
� o . 
c o 




� c:;; 0 6  w 5 0.6 
� 0 ... 
ii 0.3 c o 
I! 0 .2 
... 0 1  
0 0 1 1 
0 .0 1 2  
0..010  
� 0 008 




H D DAPA 1 0
�M 





Figu re 6-4 : Effects of Phlorizin (PHLOR) ,  Quercetin-3 -0-glucoside (QUER-3-G)  
and Dapagl i flozin ( DAP A)  on  ventricular myocyte sarcoplasmic ret iculum Ca2+ 
Graphs showing mean: 
• Ampl i tude of the caffeine-stimulated Ca2+ transient with PHLOR (A) ,  QUER-3-G 
( B) and DAPA (C)  
• Fractional release of Ca2..- (Electrical stimulation/Caffeine stimulation) with 
PHLOR ( D), QUER-3-G (E )  and DAPA (F )  
• Recovery of the Ca2+ transients fol lowing rapid appl ication of caffeine with 
PH LOR ( G ) ,  QUER-3-G ( H )  and DAPA ( I )  
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o ign i ficant effect for PHLOR. Q ER-3-G and DAPA were ob erved on 
the MP of the caffeine- timulated Ca2+ transient (Fig.6-4B,E,H ), fractional release 
of a2+ ( Fig.6-4c'FJ)  and the recover of the Ca
2T tran ient ( Fig.6-4D,G,J) in TZ 
and ontrol myocyte . PH LOR \ as previousl reported to ha e no effect on the 
caffeine- timulated R Ca2+ load in healthy rat ventricular myocytes [2 1 6] .  These 
findings col lectively ind icate that the negati e inotropic effect produced by PH LOR. 
Q ER-3-G and DAP i i ndependent of SR Ca2+ content and transport. 
6.9. Dapagl iflozin Red uces the  Ampl i tude of L-type Ca2+ Current in Ventricu lar  
Myocyte from Streptozotocin - Ind uced Diabetic and  Contro l  Rats 
As a voltage-gated channel, the Ca2+ channel passes through three transit ions 
includ ing closed. activated (open ) and inacti ated [ 1 49;  1 66] depending on the 
electrical membrane potential of the myocyte [24 ] .  Using the patch c lamp technique, 
the effects of DAP A on each of the three transit ions were studied. The patch pipette 
was made from borosi l icate glass which is widely used and has several advantages 
such as the ease of pul l i ng at low temperature, ease of seal ing with the cel l and lower 
electrical noise during recordings [ 1 66 ;  2 1 5 ] .  I nterference of other cardiac ion 
channel currents was prevented by blocking K+ current with TEA + to suppress A TP-
sensitive K+ currents and residual delayed rectifier K+ currents [ 1 5 5 ;  255 ]  and by 
using Cs+. i n  the intracel lular patch p ipette solution, i nstead of K+ to suppress 
out'.;vard K+ currents [ 1 34 ;  255 ] .  Na + current was b locked by holding myocytes at -40 
mV [ 1 06] or at -50 mV [3 1 8 ] .  
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reported in previous studie , L-type Ca::!- cur ent was smaller in myocytes 
[r m TZ-induced diabetic rats compared to Controls [34;  292] . DAPA further 
ignificantly decreased the AMP of L-type Ca::!+ cur ent in TZIDAPA myocytes 
compared to TZ m) ocytes at -40 mY and from -20 mY to +20 mY, and in 
ntrol/DAP myocytes compared to Control at -60 mY and from -20 mV to +20 
mY. Both TZ/D P and Control/DAPA myocytes howed significant reductions of 
)+ 
L-type Ca- current bern: en -20 mY to +20 mV compared to STZ myocytes and 
Control , respectively. ince the L-t pe Ca2- channel is  the main pathway for entry of 
extracel lu lar Ca2" during contraction, decreasing Ca2+ channel activation by DAP A 
reduce the level s  of Ca2+ entering the myocyte. This in  turn reduces myocyte 
contracti l ity suggesting that the effects of DAP A on L-type Ca2+ current may partly 
underlie the negat ive i notropic effects of DAP A. 
DAP A did not significantly alter the inacti ation and recovery of L-type Ca2+ 
current v.:hich indicates that DAPA only affects the channel when activated/open. 
Voltage-gated ion channels can act as al losteric receptors a l lowing a drug to bind to 
them during a certain transition. B switching to another transition, this alters the 
confom1ation of the drug binding site and thus. the drug would not recognize its 
binding s ite unless the channel goes back to the previous transition [24 ] .  Thi s 
phenomenon i s  cal led ' use-dependence' [24] and can be applied to interpret the 
behavior of DAPA on the L-type Ca2+ channel .  During activation, DAPA may have 
bound to an al losteric s ite of the L-type Ca2+ channel and resulted in the reduction of 
Ca2- current . However, when the channel switched from the activated state to the 
inactivated or closed state, the conformation of the al losteric site. to which DAP A 
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bind . changed preventing 0 P from recognizing and binding to it during closed 
and inactivated tate . The binding of DAPA to the opened channel pre ented the 
in flux of a2- through the channel and decreased myocyte shortening as a result of 
the reduced level of intracel l ular Ca2+. Calcium channel blockers inhibit Ca2+ entry 
through the channel into the cel l [ 1 53 ] .  They are mo t effective during the inactivated 
transition [20: 1 1 9: 1 20] . This ugge t that DAPA is an L -type Ca2+ channel blocker 
that. unl ike the traditional Ca2+ channel blockers. is selective for channels during the 
a tivated transition. 
6. 1 0. Cl in ical  Sign ificance of Sod ium/G lucose Co-transporter I n h ibi to rs on 
Shorten ing and I n trace l lu lar  Ca2+ 
During heart contraction. Ca2+. which is  the main regulator of this process. 
enters the cardiomyocyte mainly through the L-type Ca2+ channels. which then 
triggers Ca2+ release from the SR [26] . The concentration of Ca2+ rises transiently and 
init iates the process of m ocyte contraction [52] . 
PHLOR and QUER-3-G decreased the level of intracel lular Ca2+ levels by one 
or more mechanism( ) which need fUliher investigation. This resulted in a reduction 
of ventricular myocyte shortening. DAPA blocked the activated L-type ci+ chaImel 
at voltages ranging from -20 mv to +20 m V in both STZ aIld Control myocytes, 
\vhich lead to a reduction of intracel lu lar Ca2+ levels aIld consequent reduction of 
myocyte shortening. 
The negative inotropic effects of al l  the tested SGLT inhibitors were produced 
in diabetic ( STZ) myocytes. Since these negative inotropic effects are suggested to be 
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m diated by blocking the activity of the L-type Ca2+ channel (a  in  ca e of DAP A) .  i t  
is  nece ar)' to know the outcome of these effects on the diabetic heart. L-t pe Cah 
channel blockers are widely used to treat V di sorders such as hypertension. angina 
and arrh thmia [ 1 1 0] .  They also have anti- inflammatory [ 7 1 ]  and 
immuno uppres ive [ 1 1 2] effects. Considering that DM patients are usuall 
h) perten i\e. it was reported pre iously in c l inical tria ls  that calc ium channel 
blockers have been beneficial in hypertension treatment in diabet ic pat ients [285;  
286:  293 ] .  The activity of the L-type Ca2+ channel i s  also modulated by several 
factors such as voltage. enzymes and the act ivity of receptors [ 1 93 ] .  The negative 
inotropic effects of GL T inhibitors in this study can be indirectly mediated by one or 
more of these factors. Therefore, the direct mechanism underlying the observed effect 
requires further studies. 
Thi s  study is a lso considered as a toxicological study owing to the relatively 
high concentration of DAPA used compared to that in the c l inical sett ing. A cl in ical 
pharmacokinetic study has shown that oral administration of 1 0  mg DAP A produces 
maxi mum plasma concentration (Cmax) that reaches � 0 .333  x 1 0.6 M, which is less 
than DAPA concentration ( 1 0.6 M) in this study by approximately 3 times [ 1 52 ] .  
6. 1 1 . Lim itations of Study 
There were some technical and t ime l imitations in  th is  study including the 
fol lowing: 
1 )  Induction of DM in rats using STZ employed the i . p .  route that, unl ike the i .v .  
route, requires absorption of STZ to the bloodstream before init iating i ts  action. 
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2 )  Eval uation of myofilament en it ivit to Ca2+ , wruch invoh'es measuring myoC)1e 
shortening and a2 tran ient simultaneously. was performed in the presence of 
the Ca2" chelator and indicator Fura-2 AM which s l ightly hinders shortening. 
Thus. Fura-2 AM does not al low accurate asse sment for the actual myocyte 
shortening. however, it  is essential for Ca2.,. transient measurements. That is why 
eparate experiment were perfonned for measuring shortening in the absence of 
Fura-2 M.  
3)  Experiments on myofilament sensit ivity to  Ca2+ sti l l  need a bigger sample size to 
provide more conclu ive results with PHLOR. QUER-3-G and DAPA. 
�) Due to shortage of t ime. patch clamp experiments testing the effects on L-type 
Ca2+ current were only conducted with DAP A rather than including PHLOR and 
QUER-3-G as v.-e l l .  Future experiments should include test ing PH LOR and 
1+ Q E R-3-G on L-type Ca- current. 
1 97 
Cha pter 7 :  Conclu ion and Futu re Direction 
7. 1 .  Conclu ion 
Col lectiv ly. al l  the tested GLT inhibitor : PHLOR. QUER-3-G and DAPA, 
produced negati,e inotropic effects. 
For PHLOR. QUER-3-G and DAPA, it can be conc luded that the negative 
inotropi m produced wa not related to changes in SR Ca2+ transport of STZ and 
Control m) ocytes. However, more evidence is needed to conclude whether they 
ignificantly affect myofilament sensitivity to Ca2+, which can be provided by 
increasing the ample size of the m ocytes tested. 
PH LOR and QUER-3-G are suggested to produce negative inotropic effects 
by reducing the AMP of the i ntracel lular Ca2+ transient. However, the exact 
mecbanismls) behind reducing intracel lular Ca2+ transient is  yet to be investigated. 
DAP A i s  suggested to produce its negative inotropic effects by blocking the L-type 
Ca2- channel .  which consequent ly decreases the intracel lular levels of Ca2+ and 
reduces myocyte shortening. 
A summary for the main findings of the study and some future directions are 
shown in Figure 7- 1 .  
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Figure 7- 1 :  Summary o f  the main findings o f  the study and some future directions 
Adapted from [26] 
SR: sarcoplasmic ret iculum ;  NCX: a+/Ca2+ exchanger: PH LOR: Phlorizin; QUER-
3-G : Quercetin-3 -0-glucoside: DAP A:  Dapagl iflozin .  Future directions are denoted 
by a question mark ( ?) .  
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7.2 .  Future Direction 
Data generated in thi stud has set the tage for several future studies. These 
might include the fol lowing: 
1 )  The sample size for the experiments of myofi lament sensitivity to Ca2
+ should be 
increa ed \vith PH LOK QUER-3-G and DAPA. 
2) The effects of PH LOR and QUER-3 -G on L-type Ca2 current should be 
inye tigated as a po sible mechanism for their observed negati e inotropic effects. 
3) DAPA was te ted on shortening at three concentrations after a 5 minute 
appl ication. FUl1her tudies could be conducted over d ifferent drug appl ication 
times on m} ocyte shortening, and at different concentrations and app l ication 
times on intracel lular Ca2+ and L-type Ca2+ current. 
.t) imi larly. PHLOR and QUER-3-G can be further studied on myocyte shortening, 
intracel lular Ca2+ and L-type Ca2+ current at d ifferent concentrations and over 
d ifferent appl ication times. 
5)  Patch c lamp experiments can be performed at d ifferent concentrations of 
'+ extracel lu lar Ca- . 
6)  The activity of the L-type Ca2+ channel is known to be modulated by several 
factors such as �- and a-adrenergic receptors. The effects of DAPA on these 
receptors can be further studied to i nvestigate whether it affects the L-type Ca2+ 
channel direct ly or indirect ly .  
7)  Other factors involved in  contro l l ing intrace l lular Ca2+ s ignal ing such as the 
mitochondria and CX can be tested with PHLOR, QUER-3-G and DAPA ( Fig .  
7- 1 ) .  
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8) Expres ion of me enger ribonucleic acid (mRNA ) and protein of GLTs and 
GL Ts can be tudied in control and d iabetic h arts using polymerase chain 
reaction ( P  R )  and western blot techniques. 
9)  Expre ion of mRNA and protein of the L-type Ca�
+ channel ,  and SGLT I and 2 
can be studi d in control and diabetic hearts. after in vivo treatment of PHLOR 
QUER-3-G and DAPA. 
1 0) more GL T inhibitor with greater selecti i ty are developed, they can also be 
u d to further characterize the effects of these medications on contraction and 
intracel lu lar Ca�+ i n  control and diabetic hearts. 
1 1 )  In the long-term. the effects of SGLT inhibitors might also be investigated in  
SGLT knockout myocytes and knockout ani mals. 
1 .  
10 1 
Chapter 8 :  Reference 
beL E. D . .  Kaulbach. H .  C . .  Tian. R .. Hopkin . 1 .  C. . ,  Duffy. J . .  
Doet chman. T. i nnemaIll1. T .  Boer . M.  E. .  Hadro. E . .  Ober te­
Berghau , c. .  Qui t. W . .  LowelL B.  B . ,  IngwalL  J .  " & Kahn. B .  B .  ( 1 999) .  
Cardiac h) pertroph with pre rved contracti le function after selective 
del tion of GL T -+ from the heart. The Journal of Clinical lnve rigation, 
1 0-1, 1 703- 1 7 1 4 . 
d r, P . .  B lOck. M . .  Pietz ch. . .  & Wolffram. . (200 1 ) . Interaction of 
quercet in glucosides with the intesti nal sodium/glucose co-transporter 
( GLT- l ) . Cancer Letters. ] 62, 1 75 - 1 80. 
3. Alu11ed. D.) Kunlar� V.� Velma. A.� Gupta. P . ..  KU111ar� H . . Dhjngra� V . �  
1 i shra. V . .  & Sharma, M .  (20 1 4 ) .  Antidiabet ic. 
renallhepatic/pancreas/cardiac protective and ant ioxidant potential of 
methanol/dichloromethane extract of Albizzia Lebbeck Benth . stem bark 
(ALEx) on treptozotocin induced diabet ic rats. BllIC Complementary and 
A lternatire Afedicine, ] -1, 243 . 
4 .  Akbar. D.  H . ,  Hagras, M .  M . .  Amin,  H .  A . .  & Khorshid, O. A (20 1 3 ) .  
Comparison between the effect of gl ibenclamide and captopri l on 
experimental ly induced diabetic nephropathy in rats. Journal of Renin­
A ngioten in-A ldosterone System, ] -1, 1 03- 1 1 5 . 
5 .  Akbarzadeh. A . .  Norouzian. D . .  Mehrabi ,  M .  R . ,  Jamshidi .  S . ,  Farhangi, A ,  
Verdi .  A A . .  Mofidian. S .  M .  A . .  & Rad. B .  L .  ( 2007) .  Induction of  diabetes 
by Streptozotocin  in rats. Indian J Clin Biochem, 22, 60-64. 
6. Al Kury. L .  T, Voitychuk. O. L Al i ,  R. M . ,  Galadari. S .. Yang. K. H .  S . ,  
H owarth, F .  C . ,  huba. Y .  M . ,  & Oz, M .  ( 20 1 4 ) .  Effects of endogenous 
call11abinoid anandamide on excitation-contraction coupl ing in rat 
ventricular myocytes. Cell Calcium, 55, 1 04- 1 1 8 . 
7 .  Alberts, B . .  Bray, D . ,  Hopkin, K . ,  Jolmson, A, Lewis. 1 . .  Raff. M. ,  Roberts, 
K . ,  & Walter. P. (20 1 3 ). Transport Across Cel l Membranes. In Essential 
Cell Biology (4 ed .. pp. 383-4 1 8 ) .  Taylor & Francis Group. 
8. American Diabetes Association (2000) .  Type 2 diabetes in chi ldren and 
adolescents. American Diabetes Association. Diabetes Care, 23, 3 8 1 -389.  
202 
9. merican Diabetes Association (2003 ) .  Peripheral Arterial Disease in 
People With Diabete . Diabele Care. 26, " 333-334 l .  
1 O. merican Diabetes Association (20 1 3 ) . Diagnosis and Classification of 
Diabete Mell itu . Diaber Care. 36, 67- 74. 
1 1 . American Diabete Assoc iation ( 20 1 3 ) .  tandards of Medical Care 111 
Diabete -20 1 3 . Diabele Care. 36, 1 1 - 66. 
1 2 . Am1strong. D. & AI- wadi, F. ( 1 99 1 ) . L ipid peroxidation and retinopathy 
in streptozotocin-induced diabetes. Free Radical Biology and AIedicine. 1 1 . 
433-436 .  
1 3 . A traZeneca ( 3 -24-20 1 4 ) .  Forx iga receives regulatory approval in Japan 
for the treatment of type 2 diabetes. 
http: ' \\"\\"\-\ .astrazeneca.com/MedialPress-releasesl Article/20 1 40324-­
forxiga-japan-appro\'al 
1 4 . A traZeneca (8 - 1 1 -20 1 4) .  Multicenter Trial to Evaluate the Effect of 
Dapagliflozin on the Incidence of Cardiovascular Events (DECLARE­
TI 1 1 58 ) .  http: lc 1 inicaltrials .gov/show CT0 1 730534 
1 5 . AstraZeneca ( 1 -22-20 1 4) .  XIGDUOTM (dapagl iflozin and metfom1in 
hydrochloride) approved in the European Union for type 2 diabetes. 
http: '!",,\w.astrazeneca.comiMediaiPress-releases/ Artic1el20 1 42 1  0 1 -­
x igduo-dapagli flozin-and-metformin-hydrochloride 
1 6. Bai ley. C .  J . .  Iqbal . N . .  TJoen. C., & List J. F .  ( 20 1 2 ) .  Dapagl iflozin 
monotherapy in drug-nai've patients with diabetes : a randomized-control led 
trial of low-dose range. Diabetes, Obesity and A1etabolism, 1 -1, 95 1 -959. 
1 7 . Baldisserotto A., Mal isard i ,  G., Scalambra, E., Andreott i ,  E., Romagnol i ,  
c. .  Vicent in i ,  C .  B . .  Manfredini ,  S . ,  & Vertuani ,  S .  ( 20 1 2) .  Synthesis, 
ant ioxidant and antimicrobial activity of a new phloridzin derivative for 
dermo-cosmetic appl ications. Molecules. , 1 7, 1 3275 - 1 3289. 
203 
1 8 . Balteau. M. ,  Taj ddine, ., de Meester. c.. Ginion, A.. De Ro iers, c. .  
Brady. . R . .  ommereyn . c. .  Honnan. . .  Vanoverschelde. J .  L. .  Gai l l )' .  
P . ,  Hue. L . .  Bertrand. L. ,  & Beauloye. C .  (20 1 1 ) . ADPH oxidase 
acti ation by hyperglycaemia in cardiomyocyte is independent of glucose 
metabol i  m but requires SGLT 1 . Cardiova cular Research. 92, 23 7-246. 
1 9. Bazan. c.. Barba. D. T.. Blomgren, P . . & Paol ini .  P .  (2009) .  I mage 
Proce ing Technique for As essing Contract i l i ty in I solated Adult Cardiac 
Myocyte . International JOllrnal oj Biomedical Imaging. 
20.  Bean, B .  P .  ( 1 984) .  i trendipine block of cardiac calc ium channels :  high­
affinit, binding to the inactivated state. Proceedings oj the alional 
Academ1' of cience . 81 ,  6388-6392. 
2 1 .  Belune. Mo o  Dupre, L Harri s, S . .  Hramiak. I . .  & Mahon, J .  ( 2003 ) .  Insulin 
Resistance in Latent Autoimmune Diabetes of Adulthood. Annals oj the 
Tel1 ' York Academy oJSciences, 1 005, 3 74-3 77 .  
_2.  Bel l .  G .  L Kayano. T . .  Buse, J .  B o o  Burant, C .  F . ,  Takeda. L Lin,  D. ,  
Fukumoto, H o o  & Seino, . ( 1 990). Molecular biology of mammal ian 
gluco e tran porters. Diabetes Care, 13, 1 98-208. 
Bel l ,  R .  M., Mocanu, M .  Moo & Yellon. D .  M .  (20 1 1 ) . Retrograde heart 
perfusion: The Langendorff teclmique of isolated heart perfusion. Journal oj 
Afolecular and Cellular Cardiology, 50, 940-950. 
24. Bennett. P .  B. ( 2006) .  Ion-chatmel drug screening galvanized. Nat Biotech, 
2-1, 4 1 5 -4 1 6 . 
25 .  Berry. G. T. ,  Mal lee, J .  J . ,  Kwon, H .  M . ,  Rim.  J .  S . ,  Mul la, W.  R . ,  Muenke. 
M . ,  & Spinner. . B. ( 1 995) .  The human osmoregulatory Na+/myo- inositol 
cotransporter gene (SLC5A3 ) :  molecular c loning and localization to 
chromosome 2 l .  Genom i cs. 25, 507- 5 1 3 .  
26. Bers. D .  M.  (2000) .  Calcium F luxes Involved in  Control o f  Cat'diac 
Myocyte Contraction. Circulation Research, 87, 2 75-28 1 .  
27 .  Bers, D.  M.  ( 2002) .  Cardiac excitation-contraction coupl ing. afure, -1 15, 
1 98-205 .  
204 
28 .  Bertrand, L . ,  Horman. . ,  Beauloye. C o o  & Vano erschelde. J. L. (2008 ) .  
In u l in ignal l ing in the heart. Cardiova clilar Research. -9. 23 8-248 .  
29 .  Bnouham, Mo o  Merhfour. F. Z . o  Ziyyat, . .  Aziz. M o o  Legs yer. A . .  & 
Mekhfi . H .  ( 20 1 0) .  Antidiabetic effect of some medicinal plants of Oriental 
Morocco in neonatal non-in u l in-dependent diabetes mell itus rats. Human & 
Experimental Toxicology, 29, 865-87 1 .  
30.  Bol lan . E . ,  Omero ic .  E . .  ven son. H . ,  Waagstein, F . ,  & Fu, M.  (2007) .  
Cardiac remodel ing rather than disturbed myocardial energy metabol ism is  
as  ociated with cardiac dysfunction in diabetic rats .  International Journal of 
Cardiology. l l ./, 1 95-20 1 . 
3 1 .  Borges, G . .  de Ol i \'e ira. M . .  algado, H . ,  & Fazan, R. ( 2006) .  Myocardial 
performance in conscious streptozotocin diabetic rats. Cardim ascular 
Diabetology. 5, 26. 
32. Bouron. A . . Potreau, D . . Besse. c., & Raymond, G. ( 1 990). An efficient 
i solation procedure of Ca-tolerant ventricular myocytes from felTet hem1 for 
appl icat ions in  electrophysiological studies. Biology of the Cell, 70, 1 2 1 -
1 27 .  
3 3 .  Boyett. M.  R .  ( 2009) .  'And the beat goes on' The cardiac conduction system :  
the wiring system of the heart . Experimental physiology, 9 {  1 03 5 - 1 049. 
34. Bracken. .. Howarth. F. C . ,  & Singh. 1. (2006) .  Effects of Streptozotocin­
I nduced Diabetes on Contraction and Calcium Transport in  Rat Ventricular 
Cardiomyocytes. Annals of {he ew York Academy of Sciences, 1 08./, 208-
222.  
35 .  Bradford. B .  ] ,  & Allen, M .  S .  (2007) .  Phlorizin Admini stration Does Not 
Attenuate Hypophagia I nduced by I ntraruminal  Propionate Infusion in 
Lactating Dairy Catt le .  The Journal of Nutrition, 1 3 7, 326-330 .  
36.  Brown, L. ,  Johnson, E . ,  & Goodman, B .  (2008) .  Making Patch-pipettes and 
Sharp Electrodes with a Prograrnmable Pul ler. e939 .  
�05 
3 7. Brov.nie. . ,  Hunter, L., Ro si ter, R. ,  H i l l . A.  P . .  Robb. W . .  & Hag-Al i .  M .  
( 20 1 4 ) .  Diabetes i n  the nited rab Emirates: the need for al id data et for 
health service planning. The Lancet Diabete & Endocrinology, 2, 535-537 .  
38 .  Bugger. H .  & beL E .  D .  ( 2009) .  Rodent models of  diabetic 
cardiomyopathy. Di eo e Model & .Mechani 111 , 2, 454-466. 
39 .  Cade, W. T. (2008 ) .  Diabete -Related Micro ascular and Macro ascular 
Di ea e in the Phy ical Therapy etting. Phy ica! Therapy, 88, 1 322- 1 3 3 5 .  
40. Cai, Q.,  L i ,  B . .  Yu, F . .  Lu, W . .  Zhang. Z . .  Yin,  M. ,  & Gao. H .  ( 20 1 3 ). 
Inve tigat ion of the Protective Effects of Phlorizin on Diabetic 
Cardiom 'opath in db/db Mice by Quantitat ive Proteornics. Journal of 
Diabete Re earch. 2013 .  
4 1 .  Cal laghan. B .  C . .  Cheng. H .  T . .  Stables. C .  L . ,  Smith. A .  L . ,  & Feldman, E .  
L .  (20 1 2) .  Diabetic neuropathy : c l inical manifestations and current 
treatments. The Lancet Neurology, 1 1 , 52 1 -534 .  
42.  Cameron, . E .  & Cotter, M.  A .  (200 1 ) . Diabetes causes an early reduction 
in autonomic gangl ion blood flow in rats. Journal of Diabetes and its 
Comp/;catio17s, 15, 1 98-202. 
43. Caniye l l .  S. & Gomis, R .  (20 1 4) .  Diagnosis and c lassification of 
autoinmmne diabetes mel l itus. A utoimmunity Reviews, 13 .  
-l4 .  Cannel l ,  M .  B . .  Cheng. H . ,  & Lederer, W. J .  Spatial non-uniformities in  
[Ca2+] i  during excitation-contraction coupling in  cardiac myocytes. 
Biophysical Journal, 6 , 1 942- 1 956. 
45. Canne l l .  M. & Thomas. M .  ( 1 994) .  Intracel lular ion measurement with 
fl uorescent indicators. In D.C.Ogden ( Ed . ), Microelecrrode techniques, The 
Plymouth -workshop handbook. (2  ed . ,  pp. 3 1 7-359) .  Cambridge. UK .  
46 .  Carbonel l .  L .  F .  S .  ( 1 987) .  Hemodynamic alterations in chronical ly 
consc ious unrestrained diabetic rats. American Journal of Physiology -
Heart and Circulatory Phy iology, 252, H900-H905 . 
206 
47. arl n, G. ,  Tou, c . .  Parikh, .. Birm ingham, B . ,  & Butler. K. ( 20 1 1 ) . 
Eyaluation of the effect of dapagl iflozin on cardiac repolarization: a 
thorough QT/QTc tudy. Diabete Ther. 2. 1 23 - 1 32 .  
48 .  Carneiro-Junior. M .  A . ,  Pellizio. M.  C .  G . ,  i lva. C .  H .  0 . .  Amorim, P. R .  
. .  i lva. K .  . .  ouza, M.  0 . , a tro, C .  A . ,  Roman-Campos, D. ,  Primo la­
Gome , T. . .  & atal i ,  A. J .  (20 1 0) .  Exercise training and detraining 
modify the morphological and mechanical properties of single cardiac 
m ocyte obtained from pontaneously hypert nsive rats. Bra:;i/ian Journal 
ofJfedicai and Biological Re earch. -13. 1 042- 1 046. 
49. Carney, S .  L . ,  Wong, . L., & Dirks, 1. H. ( 1 979). Acute effects of 
treptozotoc in diabete on rat renal function. The Journal of laboratory and 
clinical medicine. 93. 950-96 1 .  
50.  Carter, M.  & hieh, J .  C .  (20 1 0) .  Chapter 4 - Electrophysiology. In  M .Carter 
& 1 .  C.  hieh ( Eds. ) ,  Guide to  Research Techniques in  Neuroscience ( pp. 
9 1 - 1 1 8 ) .  New York : Academic Press . 
5 1 .  Ca taneda-Sceppa, C .  & Castaneda. F .  ( 20 1 1 ) . Sodium-dependent glucose 
transporter protein as a potential therapeuti c  target for improving glycemic 
control in d iabetes. 'utrition reviews, 69, 720-729. 
52. Catteral l .  W. A.  ( 20 1 1 ) . Voltage-Gated Calcium Chalmels .  Cold Spring 
Harbor Per pec/h'es in Biology. 3 . 
53 .  Cefalu, W.  T .  ( 2006) .  Animal Models of Type 2 Diabetes :  C l inical 
Presentation and Pathophysiological Relevance to the Human Condition. 
ILA R Journal, -1 7. 1 86- 1 98 .  
54 .  Cermak, R . ,  Landgraf, S . ,  & Wolffram, S .  ( 2004). Quercetin  glucosides 
i nhibi t  glucose uptake into brush-border-membrane vesic les of porcine 
j ej unum. British Journal of utritio17, 91 ,  849-855 .  
55 .  Chandar, . & Vise l l i ,  S .  ( 20 1 2) .  Glucose Transport. In Cell and !vloleeular 
Biology-Lippincott 's Illustrated Reviews Series ( Wolters K luwer Health . 
56. Chao, E .  C. & Henry, R. R.  (20 1 0) .  SGLT2 inhibit ion -a novel strategy for 
d iabetes treatment. at Re\ Drug Diseov, 9, 55 1 -559.  
�07 
57. hen. L. Q . .  Hou. B.  H., Lalonde. . .  Takanaga, H . .  Hartung. 1 .  L. .  Qu, X .  
Q . .  Guo. . L Kim. J .  G . .  ndenvood. W . .  & Chaudhuri. B .  ( 20 1 0) .  ugar 
transporters for interce l lular e. change and nutrition of path gen . Tall/re. 
-16 . 527-5 2 .  
58 .  Chen. L. Q . .  Qu. X .  Q . .  Hou, B .  H . ,  osso. D. ,  0 orio. . .  Fernie, A. R . ,  & 
Frommer. W. B. (20 1 2 ) .  ucro e efflux mediated by WEET proteins as a 
key tep for phloem tran port. Science, 335. 207-2 1 1 .  
59 .  Chen, P . ,  Zhang. W . .  Zhou, L Wang, P . .  Xiao. L . .  & Yang. M .  (2009) .  
Development of planar patch c lamp technoJog and i ts  appl ication in the 
analysi of cel lular electrophysiology. Progre s in atural Science, 1 9, 1 53-
1 60. 
60. Cben, Z. C . .  Cheng. Y.  Z . .  Cben, L .  1 . , Cheng, K. C., Li .  Y .  & Cheng. J .  
(20 1 2) .  Increa e o f  ATP-sen iti e potassium C KATP) channels in  the heart 
of type- l diabetic rats. Cardiova cular Diabetology, 1 1 , 8 .  
6 1 .  Cheng. 1 .  T., Huang, C .  C. Liu, 1 .  M. ,  Tzeng, T. F . ,  & Chang, C .  J .  (2006) .  
ovel Mechanism for Plasma Glucose-Lowering Action of Metformin in 
Streptozotocin- lnduced Diabetic Rats. Diabetes, 55, 8 1 9-825 .  
62 .  Cheung, . .  Mitchel l ,  P . ,  & Wong. T .  Y ( 20 1 0) .  Diabetic retinopathy. The 
Lancet, 3 -6, 1 24- 1 36.  
63 . Chiu. H.  K . .  Tsai ,  E .  C . ,  Juneja,  R . .  Stoever, 1 . ,  Brooks-Worrel l ,  B . ,  Goel ,  
A . .  & Palmer, J .  P .  (2007) .  Equi alent insul in resistance in latent 
autoimmune diabetes in adults ( LAD A) and type 2 diabetic pat ients. 
Diabetes Research and Clinical Practice, 77, 23 7-244. 
64 . Choi. K .  M . ,  Zhong, Y, Hoit, B.  D., Grupp, 1 .  L . ,  Hahn, H . ,  Di l ly, K .  W. ,  
Guatirnosim. S . ,  Ledere. W.  J . ,  & Matl ib, M .  A.  (2002) .  Defect ive 
intracel lu lar Ca2+ signal ing contributes to cardiomyopathy in Type 1 
diabetic rats. American Journal of Physiology - Heart and Circulatory 
Physiology, 283, H 1 398-H 1 408.  
65 .  Cobbold, P .  H .  & Rink, T. J .  ( 1 987 ) .  F luorescence and bioluminescence 
measurement of cytoplasmic free calcium. Biochemical Journal, 2-18, 3 1 3 . 
208 
66. Co yn . B . ,  Droogman . .. Hemot, ., Degai l l ier. c . .  Garbar, c . .  We)1jens. 
c . .  Roo en , B . .  choors. D . .  Lahoutte. T . .  Franken. P . •  & Van Camp. G.  
( 2008) .  Effect of treptozotocin-induced diabetes on m ocardial blood flow 
r erve a s ed b myocardial contrast echocardiography in rats. 
Cardiora. cular Diabetology, . 26. 
67 .  Co yn . B.. Droogman . . ,  Weytjens. c . ,  Lahoutte. T. .  Van Camp. G . .  
choor . D . .  & Franken. P .  (2007 ) .  Effect of streptozotocin-induced diabetes 
on left ventricular function in adult rats : an in vivo Pinhole Gated SPECT 
study. Cardiora clilar Diabetology. 6. 30. 
68.  Craig. M.  E . .  Hatter ley. A.. & Donaghue, K. C .  (2009). Definition, 
epidemiology and c Ja  sification of diabetes in children and adolescents. 
Pediatric diabete , l O, 3 - 1 2 . 
69. Cre py. V . .  prikian, 0 . . Morand. c. .  Besson. c . .  Manach. c . .  Demigne. C .  
& Remesy. c.  (200 1 ) . Bioavai labil ity of Phloret in and Phloridzin in Rats. 
The JOllrnal of 'utrWon, 131 .  3227-3230. 
70. Dai.  . .  Fraser, H . .  Yuen V .  G . .  & Mc ei l l ,  J .  H. ( 1 994). Improvement in 
cardiac function in  streptozotocin-diabet ic rats by salt loading. Can.J 
Phy iol Pharmacol, 72. 1 288 - 1 293 . 
7 1 .  Das. R . .  Burke. T . .  Van Wagoner. D .  R . ,  & Plow. E .  F .  (2009) .  L -Type 
Calcium Channel B lockers Exert an Anti inflammatory Effect by 
Suppressing E pression of Plasminogen Receptors on Macrophages. 
Circulation Research, 1 05, 1 67- 1 75 .  
72. Deeds. M .  C. Anderson. 1 .  M . .  Annstrong, A.  S . .  Gastineau, D. A . .  
H iddinga, H .  J . .  Jahangir. A . .  Eberhardt, N .  L .  & Kudva, Y .  C .  (20 1 l ) . 
S ingle dose streptozotocin-induced diabetes :  considerations for study design 
in i slet transplantation models .  Laboratory Animals, -/5 1 3 1 - 1 40. 
73 .  DeFronzo. R.  A.  (2004) .  Pathogenesis of  type 2 diabetes mel l i tus. Med CZin 
Am. 88, 787-835 .  
74. Delbridge, L. M. D .  & Roos K .  P .  ( 1 997) .  Optical Methods to Evaluate the 
Contracti le Function of Unloaded I solated Cardiac Myocytes. Journal of 
Molecular and Cellular Cardiology, 29, 1 1 -25 .  
75 .  Dokken, B .  B .  ( 2008 ) .  The Pathophysiology of Cardiovascular Disease and 
Diabete : Beyond Blood Pre sure and Lipids .  Diabefes Spectrum, 21 ,  1 60-
1 65 .  
76. Donaghue, K .  c . ,  Chiare l l i ,  F . ,  Trotta, D . .  l lgrove, L & Dahl -Jorgensen, 
K. ( 2009) .  Microvascular and macrovascular complications associated with 
diabete in chi ldr n and adolescents. Pediatric diabete , 10, 1 95-203 . 
77 .  Donnan. G .  A. .  F i  her, M. ,  Mac leod, M . .  & Davis. S .  M. ( 20 1 0) .  Stroke. The 
Lancet, 3 �1 ,  1 6 1 2- 1 623 . 
78 .  Donnel ly ,  R . ,  Emslie- mith. A .  M. ,  Gardner, 1 .  D . . & Morris. A. D. (2000) .  
ABC of arterial and venous disease: vascular complications of diabetes. 
BAfJ: British .Medical Journal, 320. 1 062. 
79. Dziuba, L Alperin. P . .  Racketa, J . , I loeje, u.. Goswami .  D . .  Hardy, E . .  
Perlstein. L Grossman. H. L. ,  & Cohen, M.  ( 20 1 4 ) .  Model ing effects of 
GLT-2 inhibitor dapagl iflozin treatment versus standard diabetes therapy 
on cardiovascular and microva cular outcomes. Diabetes, Obe ity and 
J.\felaboli /11, 1 6, 6_8-63 5 .  
80. Ehrenkranz, J .  R.  L . .  Lewis, N .  G . ,  Ronald Kahn, C . ,  & Roth, J .  (2005 ) .  
Phlorizin:  a review. Diabetes Afetabolism Research and Reriews, 2 1 ,  3 1 -38 .  
8 1 .  E isenbarth. G .  S .  (20 1 0) .  Banting Lecture 2009: An  UnfInished Journey : 
Molecular Pathogenesis to Pre ention of Type l A  Diabetes. Diabetes, 59, 
759-774.  
82. E Is: ioglu,  H.  K . .  Kabasakal. L . ,  Ozkan, . ,  C;el ikel, C; . ,  & Aanoglu-Dtilger. 
G. ( 20 1 1 ) . A study comparing the effects of rosigl itazone and/or insul in 
treatments on streptozotocin i nduced diabetic ( type I diabetes) rat aorta and 
cavernous t issues. European Journal of Pharmacology, 660, 476-484. 
83 .  E l l is .  H. (2009) .  The anatomy of the heart .  Anaesthesia & Inren ive Care 
Afedicine, 1 0, 357-359. 
2 1 0  
84. Er juwa, O. 0 . . ulaiman. . A. .  Wahab. M .  . .  i rajudeen, K. " alleh. 
1 .  . .  & Gurtu. . (20 1 l ) . Gl ibenclamide or metfonnin combined with 
honey impro e glycemic control in streptozotocin- induced diabetic rats. Inl 
J BioI. Sci, �. 244-252.  
85 .  European Medicines gency (20 1 2) .  Forxiga-dapaglijlo::in. 
86. Farmer. B. B . . Mancina, M .. Wi l l iams. E. . .  & Watanabe. A. M. ( 1 983) .  
I solation of calcium tolerant m ocytes from adult rat hearts: review of the 
lit rature and de cription of a method . Life Sci. , 33, 1 - 1 8 . 
87 .  FerraImini .  E . .  Ramos. S. J . •  Salsal i .  A . .  Tang. W . .  & List, 1 .  F.  (20 1 0) .  
Dapagliflozin Monotherap i n  Type 2 Diabetic Patients With Inadequate 
Glycemic Control by Diet aI1d Exercise: A randomized. double-blind. 
placebo-control led. phase 3 tria l .  Diabete Care, 33, 22 1 7-2224. 
88 .  Ferrannini .  E. & ol in i .  A .  (20 1 2) .  SGL T2 i nhibition in diabetes mell itus: 
rat ionale and c l inical prospects. ature Re1'ieH's Endocrinology, 8, 495-502 . 
89. Fi hler. M. G . ,  Sobie. E .  A . ,  Thakor, N .  V . ,  & Tung. L .  ( 1 996). Mechanisms 
of cardiac cel l  excitation with premature monophasic and biphasic field 
stimul i : a model study. Biophysical Journal, 70, 1 347- 1 362. 
90. Food and Drug Administration ( 1 -8-20 1 4) .  FDA approves Farxiga to treat 
type 2 diabetes. 
http: 1\\,\,,'\1\ . fda.gov ewsE\'ents ev. sroom/PressAlmouncements/ucm3808 
29.htm 
9 l . Forbes. J .  M. C .  & Cooper, M .  E. (20 1 3 ) .  Mechanisms of Diabetic 
Complications. Physiological reviews, 93, 1 3 7- 1 88 .  
92 .  Fourlanos, S . ,  Dotta, F . ,  Greenbaum, C .  1 . ,  Palmer. J .  P .  Rolandsson. 0 . , 
Colman. P .  G .. & Harrison, L .  C .  ( 2005 ) .  Latent autoinm1Une diabetes in 
adults ( LADA) should be less latent. Diabefologia, -18, 2206-22 1 2 . 
93 . Fowler. M .  1 .  (2008 ) .  Microvascular and Macrovascular Compl ications of 
Diabetes .  Clinical Diabetes, 26, 77-82. 
2 1 1 
94. Fox , K. ,  Garcia. M .  A. . .  rdi sino. D . ,  Buszman, P . .  CamicL P. G. ,  Crea, 
F . ,  Daly, c . ,  D Backer. G .. HjemdahL P . ,  Lopez- end on. L Marco. L 
Morai . J . ,  Pepper. 1 . .  echtem, u . ,  imoons. M . .  Thygesen, K. ,  Priori ,  S .  
G . .  Blanc, 1 .  J . ,  Budaj .  A. .  Carnm , J . .  Dean. V. ,  Deckers, 1 . ,  Dick tein, K . .  
Lekaki , 1 . .  McGregor. K . .  Metra. M . .  Morais. 1 . .  Osterspey, A. ,  Tamargo, 
J .. Zamorano, J .  L . ,  Zamorano, J .  L . ,  Andreotti ,  F . ,  Becher. H . ,  Dietz, R. ,  
fraser, A. ,  Gra) , H . .  Antol in, R. A.  H. ,  Huber, K. ,  Kremastinos. D. T. ,  
Maseri, A. ,  e er, H .  J . , Pasier ki ,  T . ,  igwart, u . ,  Tubaro, M. ,  & Weis. M.  
( 2006) .  Guidelines on  the management of  stable angina pectori s :  executive 
summar : The Ta k Force on the Management of Stable Angina Pectoris of 
the European ociety of Cardiology. Ellropean Heart Journal, 2 7, 1 34 1 -
1 3 8 l .  
95 .  Freeman. R.  ( 2002) .  Autonomic peripheral neuropathy. The Lancet, 365, 
1 259- 1 270.  
96.  Frode, T. . & Medei ros. Y .  S .  ( 2008) .  Animal models to test drugs with 
potential antidiabetic activity. Journal of Ethnopharmacology, 1 15, 1 73-
1 83 .  
97.  Fuj imori . Y . ,  Katsuno, K . .  akashima. 1 . ,  I shikawa-Takemura, y ' ,  Fuj ikura, 
H . . & Isaj i .  M .  ( 2008) .  Remogl iflozin Etabonate in a Novel Category of 
Selective Low-Affinity Sodium Glucose Cotransporter ( SGLT2 ) Inh ibitors, 
Exhibits Antidiabetic Efficacy in Rodent Models. Journal of Pharmacology 
and Experimental Therapeutics, 32 7, 268-276. 
98 .  Gales, c., Zan1fir. C . . Stoica, B., & echifor, M.  (20 1 3 ) .  The effect of 
piogl itazone on non-pregnant female genital tract in experimental diabetes 
mel l itus. Revista l71edico-chirurgicala a Societatii de Medici si aturalisfi 
din lasi, 1 1 7, 954-958 .  
99 .  Gardner. D .  S .  & Tai , E .  S .  ( 20 1 2) .  C l inical features and treatment of 
maturity onset diabetes of the young ( MODY). Diabetes, Metabolic 
Syndrome and Obesity, 5, 1 0 1 - 1 08 .  
1 00.  Gasparotto Junior, A . ,  Gasparotto, F .  M. ,  Boffo. M .  A. ,  Louren�o, E .  L .  B. ,  
Stefanello, M.  E.  A. ,  Salvado, M .  J . ,  Da Si lva-Santos, 1 .  E. ,  Marques, M.  C .  
A . .  & Kassuya, C .  A.  L .  ( 20 1 1 ) . Diuretic and potassium-sparing effect of 
isoquercitrin-An active flavonoid of Tropaeolum maj us L .  Journal of 
Elhnopharmacology, 134, 2 1 0-2 1 5 . 
2 1 2  
1 0 1 .  Ga parotto Junior, A. ,  Prando, T. B .  L . .  Leme. T. d. . V . ,  Ga parotto. F .  
M . .  Lourenyo. E.  L. B . ,  Rattmann. Y.  D . .  Da i lva- ante . J .  E . .  Kassuya. C .  
. L . .  & argue . M .  C.  A.  ( 20 1 2) .  echanisms underl ing the diuretic 
effect of Tropaeolurn maj us L .  e tracts and i ts main component 
i oguercitrin .  Journal of Ethnopharmacolog),. 1-11 ,  50 1 -509. 
1 02 .  Gianani .  R.  & Ei enb31ih. G .  . (2005 ). The stages of type 1 A  diabetes :  
_005 . Immunological RerieH's. 20-1, 232-249. 
1 03 .  Gi l l iam, L. K . .  Brooks-WorrelL B. M. ,  Palmer. 1. P. ,  Greenbaum, C. 1 . ,  & 
Pihoker, C .  ( 2005 ) .  utoimmunit and c l inical course in children with type 
1 .  t pe 2. and type 1 . 5 diab te . Journal of A utoimmunity, 25, 244-250. 
1 04.  G latz, 1 .  F.  C .  L . .  Luiken, J .  1 .  F. P . ,  & Bonen, A.  ( 20 1 0) .  Membr311e Fatty 
Acid Tran porters as Regulators of Lipid Metabol ism: Implications for 
1etabolic Disease. Physiological rerie,I 's, 90, 367-4 1 7 . 
1 05 .  Gomez. A. M. ,  Kerfant. B .  G . ,  & Vassort, G .  (2000) .  Microtubule 
Di ruption Modulates Ca2+ Signal ing in Rat Cardiac Myocytes. Circulation 
Research. 6. 30-36. 
1 06 .  Goona ekera. S .  A. ,  Hammer. K. ,  Auger-Messier, M. ,  Bodi .  L Chen. x..  
Zhang. H . .  Reiken, S. ,  E lrod. 1 .  W., COlTel l ,  R.  N . . York, A .  1 . ,  Sargent. M. 
A. .  Hofinann, F . ,  Moosmang. S . ,  Marks. A. R. ,  Houser, S .  R . o  Bers, D .  M.,  
& Molkentin, 1 .  D.  (20 1 2 ) .  Decreased cardiac L-type Ca2+ ch3l1llel activity 
induces hypertrophy and heart fai lure in mice. The Journal of Clinical 
Inve tigation. 122, 280-290. 
1 07 .  Gotzsche. L. B .. Rosengvist. . Gronbaek, H . ,  F lyvbjerg A. ,  & Gotzsche, 
O. ( 1 996) .  I ncreased number of myocardial voltage-gated Ca2+ channels 
and unchanged total beta-receptor number in  10ng-tem1 streptozotoc in­
diabetic  rats. Eur J Endocrinol, 13-1, 1 07- 1 1 3 . 
1 08 .  Grant, A.  O .  (2009) .  Cardiac Ion Ch3l1llels .  Circulation: Arrhythmia and 
Electrophysiology. 2, 1 85- 1 94. 
2 1 3  
] 09. Grempler, R . .  Thoma . L . .  Eckhardt, M . ,  Himmelsbach. F . .  auer. 
harp. D. E .. Bakker, R. ., ark. M .. K lein. T. .  & Eickelmann. P. ( 20 1 2 ) . 
Empagl i flozin, a novel elective odium gluco e cotran porter-2 ( GLT-2 ) 
inhibitor: haracteri ation and compari on \ ith other GLT-2 inhibitors. 
Diabete . Obe it)' and lHetabolism. 1 -1. 83-90. 
] 1 0. Gro sman. E. & Mes erl i .  F. H. (2004) .  Calcium antagonist . Progre s in 
ordiol'a cular Disea 'e . r'. 34-57.  
1 1 1 . Grund) . . M. ,  Benj amin. I .  J . .  Burke, G.  L . ,  Chait, A. ,  EckeL R. H . .  
Howard, B .  Y. .  1itch, W. ,  mith. . c . ,  & owers, 1 .  R .  ( 1 999). Diabetes 
and Cardio ascular Disease : A Statement for Healthcare Professional s From 
the American Heart A sociation. Circulation. 1 00, 1 1 34- 1 1 46 .  
1 1 2 .  Guil len, c . .  Prieto. A. .  De Buergo, M .  A. ,  Vi l la, L . ,  Rico. H . ,  Zea. A . .  
Hernandez. M .  P . .  & Alvarez-Mon, M .  ( 1 995 ) .  Isradipine. a calcium­
channel antagonist, has immuno uppre sor act ivity on T lymphocytes from 
peripheral blood and synovial fl uid from patients with autoimmune arthrit is .  
JOlirnal oflmmzll7orherap} . 18. 66-74. 
1 1 3 .  Gupta, A .. Brahmbhatt, S., & Sham1a. A .  C .  ( 2004) .  Left ventricular 
mitogen activated protein k inase signal ing fol lowing polymicrobial sepsis 
during streptozotocin-induced hyperglycemia. Biochimica et Biophysica 
A cta (BBA) - ..\folecular Basis of Disease. 1690, 42-5 3 .  
1 1 4 .  Gupta. P . .  KanwaL A . .  Putcha. U .  K . ,  Bulani .  Y . .  Soj i tra, B . .  Khatua, T .  
Kuncha. M. ,  & Banerjee .  S .  K .  (20 1 3 ) .  Cardioprotective effect of ritona lr, 
an antiviral drug, in  isoproterenol induced myocardial necrosis :  a new 
therapeutic impl ication. Journal of Tran larional Medicine, I I , 80. 
1 1 5 .  Halban, P .  A . .  Polonsky. K .  S . ,  Bowden D .  W . .  Hawkins. M .  A. ,  Ling, c . ,  
Mather. K .  1 . .  Powers, A.  c . ,  Rhodes, C .  J . ,  Sussel ,  L . ,  & Weir, G. C .  
( 20 1 4) .  B-Cell Fai lure in  Type 2 Diabetes : Postulated Mechanisms and 
Prospects for Prevention and Treatment. Diabetes Care, 3 7. 1 75 1 - 1 75 8 .  
1 1 6.  H ami l l .  O. P . .  Marty. A.. Neher. E . ,  Sakmann, B. . & S igworth. F .  1 .  ( 1 98 1 ) . 
Improved patch-clamp techniques for high-resolution current recording from 
cel ls  and cel l -free membrane patches. Pflugers A rch. 391 .  85- 1 00. 
2 1 4  
1 1 7. Hanafu a. T. & Imagawa. A .  ( 2007) .  Fulminant type 1 diabetes: a novel 
c l inical entit requiring p cial attention b _ all medical practitioner . . Vaf 
lil1 PraCf End Mel. 3, 36-45 . 
1 1 8 . Henzen, C .  ( 20 1 2 ) . Monogenic diabete mell itus due to defects in insul in 
ecret ion. \ I 'i s Med W kl)" 1 -12, w 1 3690. 
1 1 9. Hering. . .  cz_ I ,  . ,  Kraus. R. L., Berjukow. . .  triessnig, J. . & Timin .  
E .  . (1 997) .  Molecular mecharusm of use-dependent calcium channel 
block by phenylalk lamines: role of inactivation. Proceeding of the 
Natiol1al Academ)' of Science , 9-1. 1 3323- 1 3328 .  
1 20. He , P . ,  Lansman. J .  B . ,  & Tsien. R. W. ( 1 984) .  Different modes of Ca 
channel gating behaviour fa omed by dihydrop ridine Ca agonists and 
antagonists. 'all Ire, 3 l J , 538-544. 
1 2 1 .  Howarth. F. C . ,  Al- harhan. R. ,  Al-Hammadi .  A. .  & Qmeshi .  M.  A.  ( 2007). 
Effect of streptozotocin-induced diabetes on action potentials in the 
sinoatrial node compared with other regions of the rat heart . �Mol Cell 
Biochem. 300, 39-46. 
1 22 .  Howarth. F .  C. & Qureshi .  M. A.  (200 1 ) . Characterisation of Ventricular 
Myocyte horterung after Administration of Streptozotoc in ( STZ) to 
eonatal Rats. Archives of Physiology and Biochemi 11')" 1 09, 200-205 . 
1 23 .  Howarth, F .  C .  & Qureshi. M.  A.  ( 200 1 ) .  Myofilament C a  2 +  sensitivity i n  
ventricular myocytes from streptozotocin-induced diabet ic rat. Inl J 
Diabetes lvfetab, 9, 67-74. 
1 24.  Howarth, F. C .  & Qureshi. M .  A.  ( 2008) .  Myofilament sensitivity to Ca2+ 
in ventricular myocytes from the Goto-Kakizaki diabetic rat. li fo!' Cell 
Biochem. , 315, 69-74. 
1 25 .  Howarth. F .  C .. Qureshi, M. A .. & White. E. (2002) .  Effects of 
hyperosmotic shrinking on ventricular myocyte shortening and intracel lular 
Ca(2+) in streptozotocin-induced diabetic rats. Pfliigers A rch, -1-1-1. 446-45 1 .  
2 1 5  
1 26 .  Howarth. F. c . .  Qure hi .  M .  . .  obhy. Z .  H .  H . .  Parekh, K . .  Yammahi. . 
R. R. K. .  Adrian. T E. .  & deghate. E .  (20 1 1 ) . tructural lesions and 
changing pattern of expres ion of genes encoding cardiac mu cle proteins 
are a ociated with ventricular m ocyte dysfunction in type 2 diabetic Goto­
Kakizaki rat fed a high-fat diet. Experimental physiology. 96. 765-777.  
1 27. Imaga\.\ a. ., Hanafusa. T. Makino, H .. Mi agawa, 1 .  1 . ,  & Juto, P. ( 2005 ). 
High ti tre of Ig ant ibodies to enteroviru in  fulminant type- 1 diabete . 
Diabeto!ogia. -18. 290-293 . 
1 28 .  Imagawa. A. .  Hanafu a. T. Uchigata, Y . .  Kanatsuka. A . .  Kawasaki .  E . ,  
Koba, a hi .  T. .  himada, A. .  himizu, L Maruyama. T, & Makino, H .  
( 2005) .  Different contribution of  c lass I I  HLA in  fulminant and typical 
autoimmune type 1 diabetes mel l itus. Diabetologia. -18. 294-300. 
1 29 .  Imagawa. A. & Hanafusa, T ( 2006). Pathogenesis of fulminant type 1 
diabetes .  The Review of Diabetic Studies. 3, 1 69. 
1 30 .  Imagawa. A.,  Hanafusa, T .  Miyagawa. J .  i . .  & Matsuzawa. Y.  ( 2000) .  A 
novel ubtype of type 1 diabetes mel l itus characterized by a rapid onset and 
an absence of diabetes-related antibodies. ew England Journal of 
A fedicine. 3-12, 3 0 1 -307. 
1 3 1 .  I magawa. A. Hanafusa. T .  Uchigata. Y . ,  Kanatsuka, A ,  Kawasaki .  E . ,  
Kobayashi, T .  himada, A, Shimizu. L Toyoda, T. ,  & Maruyama. T. 
(2003) .  Fulminant type 1 diabetes a nationwide survey in  Japan. Diabetes 
Care, 26, 2345-2352 .  
1 32 .  I nternational Diabetes Federation (20 1 3 ) .  International Diabetes Federation 
A TLAS. 6th edn . Brussels, Belgium : International Diabetes Federation. 
1 33 .  I nternat ional Diabetes Federation (20 1 4) .  Signs and symptoms of  diabetes. 
http://wv,,'Vv" . idf. org/ si gns-and -Sympto ms-diabetes 
1 34.  Isenberg. G. ( 1 976) .  Cardiac Purkinje fibers: cesium as a tool to block 
inward rectifying potassium currents. Pjliigers Arch, 365, 99- 1 06. 
1 35 .  I senberg. G .  & Klockner, U .  ( 1 982) .  Calcium tolerant ventricular myocytes 
prepared by preincubation in a KB medium .  Pfliigers Arch, 395, 6- 1 8 . 
2 1 6  
1 36 .  I hiba h i .  T . .  Tanaka. K . .  & Taniguchi .  Y .  ( 1 98 1 ) . Platelet Aggregation and 
Coagulation in the Pathog nesis of Diabetic Retinopath in Rats. Diabete , 
30, 60 1 -606. 
1 3 7. Jackson . C. V .. McGrath.  G. M .. Tahil iani. A. G .. Vadlamudi .  R. V .. & 
c e i l l .  J .  H .  ( 1 985 ) .  A Functional and ltrastructural nalysis of 
Experimental Diabet ic Rat Myocardium :  Manifestation of a 
Cardiom, opathy. Diabete , 3-1, 876-883 .  
1 3 8 .  Ja in ki .  J .  M.  & Ei enbaI1h. G. S .  ( 2005 ) .  Insulin as  a primary autoantigen 
for type l A  diabetes. Clinical and developmental immunology, 12, 1 8 1 - 1 86. 
1 39 .  Jensen. P .  K . ,  Christiansen. 1 .  S . .  Steven. K. ,  & Parving. H .  H. ( 1 98 1 ) . Renal 
function in treptozotoc in-diabetic rats. Diabetologia, 21 ,  409-4 1 4. 
1 40. Joffe. 1 .  I . .  Travers, K.  E . .  Perreault-Micale. C .  L. .  Hampton, T. .  Katz. S .  E . .  
Morgan. J .  P . .  & Douglas. P .  S .  ( 1 999). Abnom1al cardiac function in the 
streptozotocin- induced. non-insul in-dependent diabetic rat: oninvasi e 
as essment with Doppler echocardiography and contribution of the nitric 
oxide pathv ay. Journal of the American College of Cardiology, 3-1, 2 1 1 1 -
2 1 1 9. 
1 ·+ 1 .  Jugde. H . .  guy. D . .  Mol ler. 1 . ,  Cooney, J .  M . ,  & Atkinson, R. G.  (2008 ) .  
I solation and characterization of a novel glycosyltransferase that converts 
phloretin  to phlorizin. a potent antioxidant in apple. FEBS journal, 2 75, 
3804-38 1 4. 
1 42 .  Jung. H .  ( 2002) .  The sodium/substrate symporter fami ly :  structural and 
functional features. FEBS Letters, 529, 73-77.  
I ·+] .  Junod A. ,  Lambert. A. ,  Stauffacher, W . .  & Renold, A. E .  ( 1 969). 
Diabetogenic action of streptozotocin :  relationship of dose to metabol ic  
response. The Journal of Clinical Investigation, -18, 2 1 29-2 1 39.  
1 44 .  Kahn. B .  B . ,  Shulman, G.  1 . .  DeFronzo, R.  A. ,  Cushman, S .  W . .  & Rossetti ,  
L .  ( 1 99 1 ) . Normal ization of blood glucose i n  diabetic rats with phlorizin 
treatment reverses insul in-resistant glucose transport in adipose cel ls 
without restoring glucose transporter gene expression. The Journal of 
Clinical Investigation, 87, 56 1 -570. 
1 36.  I h iba hi .  T . .  Tanaka, K . ,  & Taruguchi , Y. ( 1 98 1 ). Platelet ggregation and 
Coagulation in the Pathogene is of Diabetic Retinopathy in Rats. Diabete . 
30. 60 1 -606. 
J 3 7. Jack on. . V" McGrath. G.  M .. Tahi l iani, A. G., Vadlamudi, R.  V .. & 
Mc e i lL  J .  H .  ( 1 985) .  A Functional and ltrastructural Analy is  of 
Experimental Diabet ic Rat Myocardium: Manifestation of a 
Cardiom opathy. Diabete . 3-1, 8 76-883 .  
1 38 .  Ja insk i .  1 .  M. r Ei enbarth. G .  S .  (2005 ) .  I nsul in as a primary autoantigen 
for type 1 diabetes. Clinical and dere/opmenfal immunology. 12, 1 8 1 - 1 86 .  
1 39 .  Jensen. P .  K. ,  Clu"istian en .  J .  S . ,  Steven, K. ,  & Parving, H .  H .  ( 1 98 1 ) . Renal 
function in streptozotocin-d iabetic rats. Diabetologia. 21 ,  409-4 1 4 . 
1 40 .  JotTe. 1 .  1 . .  Travers, K. E . ,  Perreault-Micale. C .  L . .  Hampton, T . .  Katz, S .  E . ,  
Morgan. 1 .  P . .  & Douglas. P .  . ( 1 999) .  Abnormal cardiac function in  the 
treptozotocin-induced. non-insul in-dependent diabetic rat : Noninvasi e 
assessment with Doppler echocardiography and contribution of the nitric 
oxide pathway. Journal of the A merican College of Cardiology. 3-1, 2 1 1 1 -
_ 1 1 9 . 
1 4 1 . Jugde. H . .  guy. D "  Moller. 1 . .  Coone . 1 .  M. ,  & Atkinson. R. G. (2008 ) .  
I solation and characterizat ion of  a novel glycosyltransferase that converts 
phloreti n  to phlorizin. a potent antioxidant in apple. FEES journal. 2 5. 
3 804-3 8 1 4 . 
1 42 .  Jung. H .  (2002) .  The sodium/substrate symporter fami ly :  structural and 
functional features. FEES Letters, 529, 73-77.  
1 43 .  Junod, A . .  Lambert. A. ,  Stauffacher, W. ,  & Renold, A.  E .  ( 1 969) .  
Diabetogenic action of streptozotocin :  relationship of dose to metabol ic  
response. The Journal of Clinical Investigation, 48, 2 1 29-2 1 39.  
1 44 .  Kahn. B .  B . . Shulman, G .  1 . ,  DeFronzo. R.  A. ,  Cuslunan, S .  W . .  & Rossetti , 
L .  ( 1 99 1 ) . Normalization of blood glucose in  diabetic rats with phlorizin 
treatment re erses insul in-resistant glucose transport in adipose cel l s  
without restoring glucose transporter gene expression. The Journal of 
Clinical Inrestigation, 87, 56 1 -570 .  
2 1 7  
] 45 .  Kahn. . E . .  Coop r, . E . .  & Del Prato. . ( 20 1 4) .  Pathophy iology and 
treatment of t} pe 2 diabete : perspective on the pa t, present. and future . 
The Lancet. 3 3. 1 068- 1 083 .  
1 46.  Kakinuma, H . ,  Oi,  T ,  Ha rumoto-Tsuchiya, Y . .  Arai, M . .  Ka\ akita, y' ,  
Fukasawa, y ' ,  I ida. 1 . .  Hagima. . .  Takeuchi ,  H . ,  Chino, y. .  Asami. J . ,  
Okurnura-Kitaj ima. L . .  10 ,  F . .  Yamamoto, D . .  Miyata. . ,  Takahashi ,  T .  
chida, & Yamamoto, K .  (20 1 0) .  ( 1  ) - 1 ,5-Anhydro- l - [5- (4-
ethoxybenzy1 )-2-methoxy-4-rneth IphenyI J - l -thio-d-glucitol (TS-07 1 )  is a 
Potent. e lective odium-Dependent Glucose Cotransporter 2 (SGLT2) 
Inhibitor for Type :2 Diabetes Treatment. Journal of Medicinal Chemist/y, 
53. 3247-326 1 .  
1 47 .  Kaku. K . ,  Inoue, . ,  Matsuoka, 0 . , Kiyosue. A. ,  Azuma, H .  Hayashi ,  N . ,  
Tokudome. T . ,  Langki lde, A.  M . . & Parikh, S .  (20 1 3 ) . Efficacy and safety 
of dapagl iflozin as a monotherapy for type 2 diabetes mel l i tus in Japanese 
pat ient v;ith inadequate glycaemic contro l :  a phase I I  multi centre, 
randomized. double-blind. placebo-control led tria l .  Diabetes. Obe ity and 
Afetaboli m. J 5. 432-440 . 
1 48 .  Kan1ata. K . ,  Ozawa, Y . ,  Kobayashi, T. ,  & Matsumoto, T (2008 ). Effect of 
long-term streptozotocin- induced diabetes on coronary vasocon triction in 
isolated perfused rat heart. Journal 0/ Smooth Muscle Research, -1-1, 1 77-
1 88 .  
1 49. Karmaiinova, M .  & Lacinova, L .  (20 1 0 ) .  Measurement of cel lular 
excitabi l i ty by whole cel l  patch c lamp technique. Physiol Res, 59 Suppl J, 
S l -S7.  
1 50 .  Karvonen, M. ,  Pithmiemi M . .  Pitkanierni ,  J . ,  Kohtamaki, K. ,  Taj ima, N . . & 
Tuomilehto, J .  ( 1 997) .  Sex difference in the incidence of insul in-dependent 
diabetes mel l itus: an analysis of the recent epidemiological data . 
Diabetes/Metabolism Reviews, 13. 275-29 1 .  
1 5 1 .  Kasichayanula, S . .  Liu, x . ,  LaCreta, F . ,  Griffen, S .  C . ,  & Boulton, D .  W. 
( 20 1 4) .  C l inical pharmacokinetics and pharmacodynamics of dapagl iflozin, 
a selective inhibitor of sodium-glucose co-transporter type 2 .  Clinical 
pharmacokinetics, 53, 1 7-27. 
2 1 8  
1 52 .  Ka ichayanula. . .  Liu. X . .  Zhang. W. ,  Pfister. M . .  LaCreta. F .  P . .  & 
Boulton. D. W .  (_0 1 1 ) . Influence of Hepatic Impaim1ent on the 
Pharma okinetics and afety Profi le  of Dapagl i flozin :  An Open-Label .  
Paral lel -Group. ingle-Do e tudy. finical Therapeutics, 33,  1 798- 1 808.  
1 53 .  Katz. . M .  ( 1 986) .  Pharmacology and mechanisms of action of calcium­
channel blocker . Journal of clinical hyperten ion, 2, 28 
I S·+' Kawa aki. E . .  lmagawa, A.. Makino. H . ,  Uga. M. .  biru, N . . Hanafusa. T . .  
Uchigata. Y . . & Eguchi . K .  (2008 ) .  Differences in the Contribution of the 
CTLA4 Gene to u ceptibi l ity to Fulminant and Type 1 A Diabetes in 
Japan e Patients. Diabetes Care, 31 .  1 608- 1 6 1 0 . 
1 5 5 .  Kenyon. J .  L. & Gibbons. W. R. ( 1 979) .  Influence of chloride, potassium. 
and tetraethylammonium on the early outward current of sheep cardiac 
Purkinje  fibers. The Journal of General Phy iology, 3. 1 1 7- 1 3 8 .  
1 56 .  Kim. J .  D . .  Kang. . M . . Seo, B .  1 . .  Choi ,  H .  Y . ,  Choi. H .  S . . & Ku, S .  K .  
( 2006) .  Anti-diabet ic Activity o f  SMKOO l .  a Poly Herbal Formula in 
Streptozotocin Induced Diabet ic Rats: Therapeutic StUdy. Biological and 
Pharmaceutical Bulletin. 29. 477-482 . 
1 5 7 .  Kim. Y .  W.,  Kim. 1 .  Y . ,  & Lee, S .  K .  ( 1 995) .  Effects of phlorizin and 
acipimox on insul in resistance in STZ-diabetic rats. Journal of Korean 
medical cience. 1 0, 24. 
1 5 8 .  Kim. Y. & Babu, A.  R .  ( 20 1 2 ) .  Cl inical potential of sodium-glucose 
cotran porter 2 inhibitors in the management of type 2 diabetes. Diabetes. 
metabolic syndrome and obesity: targets and therapy, 5, 3 1 3 .  
1 59.  King. A.  1.  (20 1 2) .  The use of animal models in  diabetes research .  Briti h 
Journal of Phannacology, 1 66, 87 7-894. 
1 60. Kintoko, K., Wen, Q . .  Lin. x.. Zheng, N . ,  Xu. x.. & Huang. R.  (20 1 4) .  
Diabetogenic Activity of Streptozotoc in on Kunming Strain Mice as Animal 
Model of Diabetes Mel l itus. IOSR Journal of Pharmacy and Biological 
Science . 
:2 1 9  
1 6 1 .  Kiran, G . .  andini .  C .  D . .  Ran1esh. H .  P . .  & alimath. P. V. ( 20 1 1 ) .  
Progre ion of earl pha e diabetic nephropath in treptozotocin-induced 
diabetic rat : Eval uat ion of \ arious kidne -related parameters. Indian 
Journal of Experimental Biology, 50, 1 33- 1 40. 
1 62 .  K i  ei Pharmaceutical ( 7-3 -2009) .  Discontinuation of the development of 
"Remogliflozin" b GlaxoSmithKl ine. 
http: \\'W\\ .k i  ei .co .jp/e contents/relationI2009/20090703.html .  
1 63 .  K Jauke, N . . mith,  G .  L . ,  & Cooper. 1 .  (2003 ) .  t imulation of Single 
Isolated Adult Ventricular Myocytes within a Low Volume Using a Planar 
Microelectrode Array. Biophy ical Journal, 85, 1 766- 1 774. 
1 6  .. 1-. Komoroski. B . ,  Vachharajani ,  . .  Boulton. D . ,  Kornhauser, D . .  Geraldes, 
M .. L i .  L . ,  & Pfister. M. ( 2009) .  Dapagl iflozin. a Novel SGLT2 Inhibitor, 
Induces Do e-Dependent Glucosuria in Healthy SUbjects. Clin Pharnwcol 
The,., 5, 520-526. 
1 65 .  Kong. H . .  Jones P . ,  Koop, A. .  Zhang. L . ,  Duff. H., & Chen, S .  (2008) .  
Caffeine induces Ca2+ release by reducing the threshold for luminal Ca2+ 
activation of the ryanodine receptor. Biochem.J. ,/ 1 ,/, 44 1 -452 .  
1 66 .  Kornreich, B .  G .  ( 2007) .  The patch c lamp technique: Principles and 
technical considerations. Journal o/ Veterinary Cardiology, 9, 25-3 7. 
1 67 .  Kotan i .  R . ,  agata. M . .  Imagawa. A . •  Moriyama. H.. Yasuda, H . .  
M iyagawa, 1 . ,  Hanafusa, T. ,  & Yokono. K. ( 2004) .  T lymphocyte response 
against pancreatic beta cel l antigens in fulminant type 1 diabetes. 
Diabetologia . .f , 1 285- 1 29 1 . 
1 68 .  Kotsanas, G . .  Delbridge, L .  M . ,  & Wendt, 1 .  R. (2000) . Stimulus interval ­
dependent d i fferences in  Ca2+ transients and contracti le responses of 
diabetic rat cardiomyocytes. Cardiovascular Research, ./6, 450-462 . 
1 69 .  Kumar. S . ,  Singh, R .. Vasudeva. . , & Sharma, S. ( 20 1 2) .  Acute and 
chronic animal models for the evaluation of anti -diabetic agents. 
Cardiovascular Diabefology, I I , 9.  
210 
1 70. K) se10va. z.,  Garcia. . 1 . . Gajdo ikova. " Gajdosik. .. & tefek. 1. 
( 2005 ) .  Temp ral relationship between len protein oxidation and cataract 
development in treptozotocin-induced diabetic rats. Phy iol Re , 5-1, 49-56. 
1 7 1 .  Lee. C .  W . .  Lee. H. . ,  Chao Y. 1 . .  100. W. H . .  Kang, D. O . .  & Moon, 1 .  Y. 
( 20 1 3 ) .  In vivo 1 m  e t igation of anti-diabetic properties of ripe onion j uice in  
normal and streptozotocin-induced diabetic rat . Preventive nuh-irion and 
food cience, J . 1 69. 
1 72 .  Leveen. H .  H . .  Le een. R. F. ,  & LeVeen, E.  G. ( 8-4- 1 987) .  Treatment of 
cancer \',1th phlorizin and its derivatives. Google Patents. 
1 73 .  Lev i .  A. L Hanco. , 1 .  c . .  Howarth, F. c . .  Croker, 1 . ,  & Vinn icombe. 1 .  
( 1 996). A method for making rapid changes o f  superfusate whi l st 
maintaining temperature at 37  degrees C .  Pflugers Arch, -132, 930-93 7. 
1 74 .  L i ,  Y .  Q . .  Zhou, F .  C . ,  Gao, F . ,  Bian, 1 .  S . ,  & Shan, F .  ( 2009) .  Comparat ive 
Evaluation of Quercetin. Isoquercetin and Rutin as Inhibitors of a­
Glucosidase. Journal of Agricultural and Food Chemi fly. 5 7, 1 1 463-
1 1 468 .  
1 75 .  L iao. R . .  Podesser. B .  K . ,  & Lim, C .  C .  ( 20 1 2 ) .  The continuing evolution of 
the Langendorff and ejecting murine herui : new advances in  cardiac 
phenotyping. American Journal of Physiology - Hearl and Circulatory 
Physiology, 303. H 1 56-H 1 67 .  
1 76. L i fe Technologies ( 20 1 1 ) . Fluorescent Ca { 2+ }  Indicators Excited with UV 
L ight Section 1 9 .2 .  Retrieved from : 
http://v.rw\lv .b2b. invitrogen.comisite/us/en/homelReferenceslMolecular­
Probes-The-H andbookllndicators-for-Ca2-Mg2-Zn2-and-Other-Metal-
Ions, F luorescent -Ca? -Indicators-Exc ited-with-UV -Light.html#head 1 
1 77 .  L in . ! .  W. ,  Sosso. D . .  Chen, L .  Q . .  Gase, K . ,  Kim,  S .  G . .  Kessler, D . .  
K l inkenberg, P .  M. ,  Gorder, M. K. ,  Hou, B .  H. ,  Qu, X .  Q . ,  Carter, C .  1 . ,  
Baldwin, 1 .  T. .  & Frommer, W .  B .  (20 1 4 ). Nectar secretion requires sucrose 
phosphate synthases and the sugar transporter SWEET9. alure, 508, 546-
549. 
22 1 
1 78 .  Li ato. G . .  Cu in, 1 . .  Tiengo. " Del Prato. .. & leanrenaud. B .  ( 1 99_) .  The 
contribution of h) p rgl caemia and h poin ulinaemia to the insulin 
re istance of treptozotoc in-diabetic rat . Diabel% gia. 35, 3 1 0-3 1 5 . 
1 79 .  Li t, l .  F .. Woo. Y .. Morales, E . ,  Tang, W. ,  & Fiedorek, F .  T .  ( 2009) .  
odium-Glu 0 e otransport Inhibition With Dapagl i flozin in Type 2 
Diabete . Diab tes are, 32, 650-657 .  
1 80. Liu. I .  M . .  Chang. C .  K . .  luang. . W .. Kou. D. H .. Tong, Y. c . ,  Cheng. K.  
c . ,  & Cheng. l .  T. ( 2008) .  Role of hypergJycaemia in the pathogenesis of 
h)  potension ob erved in  type- l diabetic rats. International Journal of 
Experimental Pathology, 89, 292-300. 
1 8 1 .  Lj ubisavijevic. M.  (2007) .  Effects of voluntary exercise on heart function in  
streptozotoc in ( STZ)-induced diabetic rat. 1m J Diabetes & lvietabolism, 15, 
32-37 .  
1 82 .  Ljubojevic. S . ,  Walther, . .  Asgarzoei. M . .  Sedej ,  S . ,  Pieske, B . ,  & 
Kockskamper, 1 .  (20 1 1 ) . I n  Situ Cal ibration of ucleoplasmic versus 
Cytoplasmic Ca2+ Concentration in Adult Cardiomyocytes. Biophysical 
Journal. 1 00, 2356-2366. 
1 83 .  Louch. W.  E . ,  Sheehan. K. A . .  & Wolska. B .  M. (20 1 1 ) . Methods in 
cardiomyocyte isolation. culture, and gene transfer. Journal of Molecular 
and Cellular Cardiology, 5 1 ,  288-298. 
1 84.  Lu. H. L Tzeng. T .  F . .  Liou, S .  S . .  Da Lin,  S. ,  Wu. M.  C., & Liu 1 .  M. 
(20 1 4) .  Ruscogenin amel iorates diabetic nephropathy by its anti ­
inflammatory and anti -fibrotic effects in  streptozotocin-induced diabetic rat. 
BlviC ComplementCIIY and A lternative Medicine, 1 ,/  1 1 0. 
1 85 .  Luippold. G. ,  Klein. T . .  Mark, M . ,  & Grempler, R.  (20 1 2 ) .  Empagl iflozin. a 
novel potent and selective SGLT -2 i nhibitor, improves glycaemic control 
alone and in combination with insu l in in streptozotocin-induced diabetic 
rats. a model of type 1 diabetes mell itus. Diabetes, Obesity and Metabolism. 
1 '/, 60 1 -607 .  
1 86. Lukaefnova, A. , Hubkova, B . ,  Racz, 0 . .  & Nistiar. F .  (20 1 3 ) . Animal 
Models  for Study of Diabetes Mel l i tus. In (pp. 229-254) .  
1 8 7.  MacDougal L D. . & Calaghan. . ( 20 1 3 ) . novel approach to the 
Langendorff techniqu : preparation of i olated cardiom ocytes and 
myocard ial ample from the arne rat heart . Experimental phy iology. 98. 
1 295- 1 300. 
1 88 .  Mahadevan. V .  (20 1 2 ) .  Anatom) of the heart. Surgery (Oxford), 30. 5-8 .  
1 89. 1alhotra. " PenpargkuL " Fein, F .  . .  onnenblick. E .  H . . & Scheuer. 1 .  
( 1 98 1 ) . The e1Tect o f  streptozotocin-induced diabete i n  rats on cardiac 
contracti le protein . Circulation Research, -19. 1 243- 1 250.  
1 90. Malik. M . .  Bakir, A. .  aab, B .  A. ,  Roglic.  G . ,  & King, H .  ( 2005).  Glucose 
intolerance and a soc iated factors in the multi -ethnic population of the 
nited Arab Emirates : results of a national survey. Diabetes Research and 
finical Practice, 69, 1 8 8 - 1 95 .  
1 9 l .  Mather, A.  & Pol lock. C .  ( 20 1 0 ) .  Renal glucose transporters: novel targets 
for hyperglycemia management. a/ Rev Nephrol, 6, 307-3 1 1 .  
1 92.  McCauley, R.  A.  & Wang, X.  ( 20 1 1 ) . Fulminant type 1 diabetes rnel l i tus­
l ike presentat ion in a H ispanic woman in the United States. Diabetes & 
j\1etaboli m, ] ", 3 56-3 5 8 .  
1 93 .  McDonald. T .  F . ,  Pelzer, S . ,  Trautwein, W . . & Pelzer, D.  J .  ( 1 994) .  
Regulation and modulation of calc ium channels in cardiac, skeletal ,  and 
smooth mu c 1e cel ls .  PhYSiological reviews, 74, 365-507.  
1 94 .  McEvoy. R .  c.,  Andersson. L Sandler, S . .  & Hellerstrom. C .  ( 1 984) .  
Multiple low-dose streptozotoc in-induced diabetes in  the mouse. Evidence 
for stimulation of a cytotoxic cel lu lar immune response against an insul in­
producing beta cel l  l ine. The Journal of Clinical Investigation, 7-1, 7 1 5-722 . 
I T '" - - -' 
1 95 .  eng. W. ,  E l l  worth. B .  A. .  irschl ,  A.  . ,  McCann. P .  1 . .  Patel ,  M . .  
Girotra. R. . .  Wu, G . .  her. P .  " Morri on. E .  P . .  Bi l ler. . A . .  Zahler. R . .  
Deshpande. P .  P . .  Pullockaran. A. ,  Hagan, D. L . .  Morgan. ., Taylor. 1. R . .  
Obermeier, M .  T.. Humphreys, W. G . .  Khanna, A . ,  Discenza, L . .  Robertson, 
J. G . ,  Wang. ., Han, . .  Wetterau. J .  R . .  Jano itz, E. B . ,  F l int O. P .. 
Whale '. 1 .  M.,  & Wa hburn, W. . ( 2008 ). Discovery of Dapagliflozin :  A 
Potent elective Renal odium-Dependent Glucose Cotransporter 2 
( GLT2 ) Inh ibitor for the Treatment of Type 2 Diabetes. Journal of 
jiedicinal hemistl}" 5 1 ,  1 1 45- 1 1 49. 
1 96. Miethke. H., Wittig. B. .  ath, A. ,  & Jungennalm, K.  ( 1 986) .  
Gluconeogenic-glycolytic capacities and metabol ic zonation in  l iver of rats 
with streptozotocin. non-ketotic as compared to al loxan. ketotic diabetes. 
Hisrochemi try. 85, 483-489. 
1 97 .  Miki. T . .  Hoh, T. . unaga, D .. & Miura, T. ( 20 1 2 ) .  Effects of diabetes on 
myocardial infarct size and cardioprotection by preconditioning and 
postconditioning. Cardio1'Q cular Diabetolog)'. 1 1 . 67. 
1 98 .  Mittendorfer, B. & Klein, S .  (20 1 4) .  Absence of leptin triggers type 1 
diabetes. Nat A1ed, 20. 705-706. 
1 99. Monckton. G. & Pehowich, E. ( 1 980) .  Autonomic neuropathy in  the 
streptozotocin diabetic rat. The Canadian journal of neurological 
sciences. Le journal canadien de ciences neurologiques. 7. 1 35- 1 42.  
200.  Montessuit C .  & Lerch. R. N. ( 20 1 3 ) . Regulation and dysregulation of 
glucose transport in  cardiomyocytes. Biochimica el Biophysica Acta (BBA) -
Aiolecl/lar Cell Research. 1833, 848-856. 
20 1 .  Montessuit c.,  Rosenblatt-Velin, N., Papageorgiou, 1 .  fL Campos, L . , 
Pel l ieux, c . .  Palma, T. ,  & Lerch, R. N.  ( 2004) .  Regulation of glucose 
transporter expression in  cardiac myocytes :  p3 8 MAPK is  a strong inducer 
of GLUT4. Cardiovascular Research. 6-1. 94- 1 04. 
202. Moreau, c.,  Drui , D. ,  Amault-Ouary, G., Charbonnel B . .  Chai l lous. L. ,  & 
Cariou, B .  (2008) .  Fulminant type 1 diabetes in  Caucasians: A report of 
three cases. Diabetes & Metabolism, 3-1. 529-532 .  
203 . Mova at 1 .  & Portha. B. ( 1 999). Beta-cel l grov.1h in the neonatal Goto­
Kaki aki rat and regenerat ion after treatment with streptozotocin at birth. 
Diabetologia. -12. 1 098- 1 1 06.  
204.  Mueckler. . ( 1 994) .  Faci l i tati e glucose transporters. European Journal of 
Biochemi. fly. 2 1 9. 7 1 3-725 .  
205 . Mueckler. M. & Thoren , B .  (20 1 3 ) .  The LC2 (GLUT) fami l  of 
membrane tran porters. Afolecl/lar aspect of medicine. 3-1.  1 2 1 - 1 3 8 .  
206. Mythi l i ,  M .  D. ,  V as. R . .  Akila. G . ,  & Gunasekaran. S .  (2004 ). Effect of  
streptozotoc in on  the ultrastructure of  rat pancreatic islets. Aficroscopy 
Re earch and Technique. 63, 274-28 1 .  
207. abeebaccus, A. & Shah, A .  M. (20 1 4 ) .  Biochemistry and physiology of 
cardiac muscle .  fedicine, -12, 4 1 3-4 1 7 . 
208 . Tagata. M . ,  Moriyama, H . ,  Kotani ,  R . ,  Yasuda H . , K ishi, M . ,  Kurohara, M. ,  
Hara. K . .  & Y okono, K .  ( 2007) .  Immunological aspects of  'fulminant type 1 
diabetes' . Diabetes Research and Clinical Practice, 7 , S99-S 1 03 .  
209. aik, R .  G., Brooks-Worre l l ,  B .  M., & Palmer. J. P. ( 2009) .  Latent 
Autoimmune Diabetes in Adults. The Journal of Clinical Endocrinology & 
J.\fe lab 0 liS177. 9-1, 463 5-4644 . 
2 1 0 . atal i ,  A .  L Turner, D .  L . ,  Harrison, S .  M . ,  & White. E .  (200 1 ) . Regional 
effects of voluntary exercise on cell size and contraction-frequency 
responses in rat cardiac myocytes. Journal of Experimental Biology, 20-1, 
1 1 9 1 - 1 1 99. 
2 1 1 .  erbonne, J .  M. K .  & Kass, R.  S .  (2005 ) .  Molecular Physiology of Cardiac 
Repolarization. Physiological reviews, 85, 1 205- 1 253 .  
2 1 2 . olan, C .  1 . .  Danun, P . ,  & Prentk i ,  M.  (2009) .  Type 2 diabetes across 
generations: from pathophysiology to prevention and management. The 
Lancet. 3 8, 1 69- 1 8 1 . 
225 
2 1 3 . omura. . ,  akamaki, . ,  Hongu. M., Ka\ anisru. E .. Koga. Y . .  akamoto. 
T. .  Yamamoto. Y . .  tao K .. Kimata. H . .  akayama. K .. & Tsuda­
T ukimoto, . (20 1 0 ) .  Disco er of Canagliflozin. a ovel C-Glucoside 
\.\ ith Thiophene Ring. as od ium-Dependent Glucose Cotransporter 2 
Inhibitor for the Treatment of Type 2 Diabetes Mell itu ( 1 ) . Journal of 
jfedfcinal Chemi '11'.1' ,  53 . 6355-6360. 
2 J  4. ygren. A .. 01 on, M.  L . .  Chen, K. Y .. Emmett. T.. Kargacin. G .. & 
himoni. Y. (2007). Propagation of the cardiac impulse in  the diabetic rat 
heart : reduced conduction reserve. The Journal of Ph), fology, 580, 543-560. 
2 1 5 . Ogden. D .  & tanfield. P .  ( 1 994) .  Patch c lamp techniques for single channel 
and whole-cel l  recording. In In A1icroelectrode technique : the Plymouth 
H 'orkshop handbook (2 ed .. pp. 53 -78 ). 
2 1 6. Olson. M. L . .  Kargacin. M.  E . .  Ward, C. A.. & Kargacin, G. 1. ( 2007). 
Effects of Phloretin and Phloridzin on Ca2+ Handl ing. the Action Potential .  
and Ion CUlTent i n  Rat Ventricular Myocytes. Journal of Pharmacology 
and Experimental Therapeutics, 32 1 , 92 1 -929. 
2 1 7 . 0 hiro, K . ,  Murakami ,  K . ,  Sunagawa, R., & Mimura. G. ( 1 99 1 ) . Chronic 
effects of tolbutamide on myocardial tension during ischemia and 
reperfusion in  perfused hearts i solated from insul in  dependent and non 
insul in dependent diabetic rats. Jpn. Heart 1, 32, 347-36 1 . 
2 1 8 . Palmer. B .  M .  & Moore. R. L .  (2000) .  Excitation wavelengths for fura 2 
pro ide a l inear relationship between [Ca2+] and fluorescence ratio. 
A merican Journal of Physiology - Cell Physiology, 2 79, C I 278-C 1 284. 
2 1 9 . Panda, S .  & Kar. A.  ( 2007) .  Antidiabetic and antioxidative effects of 
Annona squamosa leaves are possibly mediated through quercetin-3-0-
glucoside . BioFacfOrs, 31 , 20 1 -2 1 0 . 
220. Pandya, K.  G. ,  Patel ,  M. R., & Lau-Cam, C .  A. ( 20 1 0) .  Comparative study 
of the binding characteristics to and inhibitory potencies towards PARP and 
in vivo anti diabetogenic potencies of taurine, 3 -aminobenzamide and 
nicotinamide. J Biomed. Sci, 1 7  Suppl 1 ,  S 1 6 . 
226 
22 1 .  Papa, G .. Degano, c . .  Iurato. .. Licciardel lo. C . ,  Maiorana. R .. & 
Finocchiaro. C .  (20 1 3 ) .  Macro a cular complication phenotype in type 2 
diabet ic pat ient . ardiora cu/ar Diabetolog)', 12, 20. 
222. Pa lovic D. ,  McLatchie. L .  M., & hattock, M.  J .  (20 1 0) .  The rate of loss 
of T-tubule in  cultured adult ventricular myocytes is specie dependent. 
Experimental phy iolog)" 95, 5 1 8-527.  
PinnelL J . ,  Tumer. S . ,  & Howel l ,  (2007). Cardiac muscle physiology. 
Continuing Education in A naesthesia, ritical Care & Pain, 7, 85-88 .  
224. Poucheret, P., Gro . R . ,  Cadene, A .  Manteguetti ,  M . ,  Serrano. J .  J . ,  Ribes, 
G .. & Cro . G. ( 1 995) .  Long-term correction of STZ-diabetic rats after 
short-tem1 i .p. YO 04 treatment : Persistence of insulin secret ing capacities 
a essed by isolated pancreas studies. Aiol Cell Biochem, 1 53 1 97-204.  
2_5 .  Pozzi l l i ,  P .  & Buzzetti, R.  (2007) .  A new expression of diabetes: double 
diabete . Trends in Endocrinology & Aielabolis111, 18, 52-57 .  
226.  Ramanadhan1. S . ,  Decker. P . .  & Telmer, T. E . ,  Jr .  ( 1 983) .  Effect of i nsulin 
replacem nt on streptozotocin-induced effects in the rat heart. Life Sci, 33, 
289-296. 
227.  Ramanadham. . & Tenner, J .  ( 1 983) .  Alterations in  Cardiac Performance in 
Experin1ental ly- Induced Diabetes .  Pharmacology, 2 7, 1 3 0- 1 39.  
228 .  Raza i .  S . ,  Zahri, S . .  Zarrini ,  G . .  azemiyeh, H.,  & Mohammadi ,  S .  ( 2009) .  
B io logical act ivity of quercetin-3 -0-g1ucoside, a known plant flavonoid. 
Ru J Bioorg Chem. 35, 3 76-3 78 .  
229. Rees. D .  A & Alcolado. J .  C .  (2005) .  Animal models of diabetes mell itus. 
Diabetic Afedicine, 22, 359-370. 
230.  Reinehr, T . ,  Schober, E. ,  Wiegand, S . , Thon, A, & Hol l ,  R.  (2006) .  B-cel l  
autoantibodies in  chi ldren with type 2 diabetes mel l itus: subgroup or 
misc lassification? Archives of Disease in Childhood, 91 ,  473-477.  
23 1 .  Rithalia, A . ,  Qure hi ,  M.  . .  Howarth. F. C . . & Harri on, . M .  (2004) .  
Effect of halothane on contract ion and intracellular calc ium in ventricular 
myocyte [rom treptozotocin-induced diabetic rats. British journal of 
anae the ia, 92, 246-253 .  
232 .  Robin on, 1 .  A. ,  Jenkins, . . ,  Holman. . A . .  Roberts-Thomson. . J . .  & 
Monteith. G .  R. (2004) .  Ratiometric and nomatiometric Ca2+ indicators for 
the a se sment of intracel lular free Ca2+ in a breast cancer cell l ine using a 
fluore cence microplate reader. Journal of Biochemical and Biophysical 
,\fethod , 5 . _27-237 .  
233 .  Roe. M.  W . .  Lemasters, J .  1 . ,  & Herman, B .  ( 1 990) .  Assessment of  Fura-2 
for measurements of cytosol ic free calcium .  Cell Calcium, 1 1 . 63 -73 . 
23-+. Roese. 101m H .  (20 1 3 ) .  Laboratory rats: injection sites. Retrieved from : 
http: \\ \\ \\ . lssu .ed ulfacultv/j roese/Animal Care/rat inj ections.htm 
235 .  Rossett i .  L .  & Lauglin, M .  R. ( 1 989).  Correction of  chronic hyperglycemia 
with vanadate, but not with phlorizin. nom1alizes in  vivo glycogen repletion 
and in vitro glycogen ynthase activit in diabetic skeletal musc le. The 
Journal of Clinical Inve tigation, 8./. 892-899. 
236. Rossetti, L.. Smith. D. .  bulman. G .  1 . .  Papachristou, D . ,  & DeFronzo. R.  A.  
( 1 987) .  Correction of hyperglycemia \ i th  phlorizin normalizes tissue 
sensitivi ty to insul in  in diabetic rats. Journal of Clinical investigation. '""'9, 
1 5 1 0. 
237 .  Rossin i .  A .  A . .  L ike. A.  A . ,  Chick. W.  L . ,  Appel ,  M.  C . ,  & Cahi l l ,  G .  F. 
( 1 977) .  Studies of streptozotocin-induced insul i t is and diabetes. Proceedings 
of the arional Academy of Sciences. 7-1. 2485-2489. 
238 .  Rubio-Cabezas. O. & El lard. S .  ( 20 1 3 ) .  Diabetes Mel l i tus in eonates and 
Infants: Genet ic Heterogeneity, C l inical Approach to Diagnosis. and 
Therapeutic Options. Hormone Research in Paediatrics, 80, 1 3 7- 1 46.  
228 
2 " 9. aadi ,  H . .  Carruthers, . G. .  agelkerke, l-Ma kari . F . .  Afandi, B . .  
Reed, R . .  Lukic. M.. ichol ls. M.  G . .  Kazam. E. ,  Algawi . K . ,  l -Kaabi . 1 . .  
Leduc. C . .  abri. . ,  E l - adig, M . .  E lkhumaidi .  S . .  Agarwal . M. ,  & 
Benedict. . (2007) .  Prevalence of d iabete mel l itus and its compl ication in  
a population-based ample in l Ain, nited Arab Emirates. Diabeles 
Re.· arch and Clinical Practice, 7 , 369-3 77 .  
_40. abino- i lva. R. .  Mori. R. c., Da id- i lva, . ,  Okamoto, M. M . .  Freitas, H . 
. .  & Machado. . F. (20 1 0) .  The a+/glucose cotransporter : from genes 
to therapy. Bra:::ilian Journal of Medical and Biological Research, ./3, 1 0 1 9-
1 026. 
2..+ 1 .  anlbrano. G .  R . .  Fraser. 1 . ,  Han, H . .  Ni, Y ,  O'COlmel l ,  T . ,  Yan, Z. ,  & Stul l .  
J .  T.  (2002) .  avigating the signall ing network in  mouse cardiac m ocytes. 
Talure, La, 7 1 2-7 1 4 . 
242. alHer, R . ,  Schneppenheim,  R. ,  Dombrowski, A . ,  Gotze, H . ,  Steinmann, B . ,  
& chaub. J .  ( 1 997) .  Mutations in GLUT2, the gene for the l iver-type 
gluco e tran porter, in patients with Fancoru-Bickel syndrome. al Genet, 
] �, 324-326. 
243 .  Santos. . c..  Figueira-Coelho, 1. ,  Martins-Si lva, 1 . .  & Saldanha, C. ( 2003 ) .  
Mult idiscipl inary uti l ization of d imethyl sul foxide: pharmacological, 
cel lular. and molecular aspects. Biochemical Pharmacology, 65, 1 035- 1 04 1 . 
24"+. Schaan. B .  D . ,  Dall 'Ago, P .. Maeda. C .  Y . ,  Ferl in .  E . .  Femandes, T. G. , 
Schmid. H . ,  & Ir igoyen. M. C .  ( 2004) .  Relationship between cardiovascular 
dysfunction and hyperglycemia in streptozotocin-induced diabetes in rats. 
Bra:::i/;an Journal of Medical and Biological Research. 3 , 1 895- 1 902. 
245 .  Scheepers, A., Joost, H. G., & Schurmarm, A.  ( 2004) .  The glucose 
transporter fami l ies SGLT and GLUT: molecular basis of normal and 
aberrant function. Journal of Parenteral and Enteral utrilion, 28, 364-3 7 1 .  
246. Schwartz, S .  L . ,  Akinlade, B . ,  Klasen, S . ,  Kowalski ,  D . .  Zhang, W . ,  & 
Wilpshaar, W. ( 20 1 1 ) . Safety, pharmacokinet ic ,  and pharmacodynamic 
profiles of ipragl iflozin (ASP 1 94 l ) .  a novel and selective i nhibitor of 
sodium-dependent glucose co-transporter 2 ,  in patients with type 2 diabetes 
mel l i  tus. Diabetes Techno!. Ther, 1 3, 1 2 1 9- 1 227. 
229 
247. el leck Chemical (20 1 3 ). Dapagliflozin :  Catalog o. 1 5-+8 .  
http: W\\ \\ . el leckchem.com/product IDapagliflozin .html 
2-+8. e\ er , . 1 . (2000) .  The cardiac muscle cel l .  Bioe aJ' . 22. 1 88- 1 99. 
250. 
25 1 .  
252 .  
hao. C .  H . ,  Capek, H .  L . ,  PateL K. P . .  Wang, M. ,  Tang, K . .  DeSouza. c . .  
agai. R. ,  ayhan. W . ,  Periasamy, M. ,  & Bidasee, K. R .  (20 1 1 ). 
Carbonylation Contribute to ERCA2a Activity Loss and Diastol ic 
D function in a Rat Model of Type 1 Diabetes. Diabetes. 60. 947-959. 
hibazaki ,  T., Tomae. M. ,  Ishikawa-Takemura. Y., Fushimi .  N . ,  Itoh, F . ,  
Yamada. M . ,  & I saj i , M .  ( 20 1 2 ) . KGA-2727, a 0 el Selective I nhibitor of 
a H igh- ffinity odi tilll Glucose Cotransporter ( GLT 1 ), Exhibits 
ntidiabetic Efficacy in Rodent Models. Journal of Pharmacology and 
Experimental Therapeutic , 34-. 288-296. 
i lYerthom. D. 0.,  Johnson. B .  R. ,  Ober, W.  c . .  Ganison, C. W., & 
i l\'erthom, A.  C .  ( 20 1 3 ). Human Physiology : An Integrated Approach. In  
(6  ed. ,  pp. 462-507) .  Pearson Education. 
i ngh. J . .  Chonkar, A., Bracken, . ,  Adeghate, E . .  Latt, Z., & Hussain, M. 
( 2006) .  Effect of treptozotocin-Induced Type 1 Diabetes Mel l itus on 
Contraction, Calcium Transient. and Cation Contents in the I solated Rat 
Heart. Annal of the ell' York Academy of Sciences, 1 0  -I, 1 78- 1 90. 
Skrzypiec-Spring. M . .  Grotthus, B. ,  Szelag, A. ,  & chulz, R.  (2007 ). Isolated 
heart perfusion according to Langendorff - Sti l l  viable in the new 
mi lleruuum. Journal of Pharmacological and Toxicological Alethods. 55. 
1 1 3 - 1 26. 
254. S l ingerland. A. S .  (2006) .  Monogenic diabetes in  chi ldren and young adults :  
Chal lenges for researcher, c l in ic ian and patient. Rev Endocr A-letab Disord, 
7. 1 7 1 - 1 85 .  
2 5 5 .  Smith, P .  A . ,  Aschroft, F .  M . ,  & FewtrelL C .  M.  ( 1 993) .  Pemleation and 
gating properties of the L-type calcium channel in mouse pancreatic beta 
cel ls .  The Journal of General Physiology. 101 , 767-797. 
230 
256.  obeL B .  E .  & chneider. D .  J .  ( 2005 ) .  Cardiovascular compl ications in  
diabete mel l itus. Current Opinion in Pharmacology, 5 ,  1 43 - 1 48 .  
257 .  purgeon, H .  . ,  duBelL W. I-L tern, M .  D. ,  ol lott, . 1 . .  Ziman. B .  D . ,  
i l \'erman, H. . .  Capogro si ,  M .  c . ,  Talo, . . & Lakatta, E .  G. ( 1 992) .  
Cytosol ic calcium and myofi laments in ingle rat cardiac myocy1es achieve 
a dynan1ic equi l ibrium during twitch rela ation. The Journal of Physiology, 
-I· r, 83- 1 02 .  
258 .  quadrito. F . ,  Trimarchi ,  G .  R. ,  Lupica, S . ,  Magri , V . .  Costa, G . ,  Brezenoff, 
H .  E . ,  & Caputi ,  . P .  ( 1 986) .  Cerebral cholinergic control of rat arterial 
blood pre ure in treptozotocin-induced diabetes. Pharmacol Res 
Commlln. , 18, 95 1 -965 .  
259 .  riniva an, K. & Ran1arao, P. (2007) .  Animal models in  type 2 diabetes 
research:  an over iew. Indian J Afed Res, 125, 45 1 -472. 
260. teadman, B .  W., Moore, K .  B. ,  Spitzer. K .  W., & Bridge, J .  H. B .  ( 1 988 ) .  
A video ystem for measuring motion in contracting heart cel ls .  Biomedical 
Engineering, IEEE Transactions on, 35, 264-272 . 
26 1 .  StUmpel .  F . .  Burcel in, R . .  Jungermann, K . .  & Thorens, B .  (200 1 ) . ormal 
kinetics of intestinal glucose absorption in the absence of GLUT2 : Evidence 
for a transport pathway requiring glucose phosphorylation and transfer into 
the endoplasmic ret iculum. Proceedings of Ihe arional Academy of 
Sciences, 98, 1 1 330- 1 1 33 5 .  
262 .  Stum 011 ,  M . .  Gold tein, B .  J . , & van Haeften, T .  W .  ( 2009) .  Type 2 
diabetes: principles of pathogene is  and therapy. The Lancel, 365, 1 333 -
1 346. 
263 . Sun. Q. ,  Ma. Y . ,  Zhang, L. .  Zhao, Y .  F., Zang, W.  1. .  & Chen. C .  ( 20 1 0) .  
Effects of GH secretagogues on  contracti l ity and Ca2+ homeostasis of  
i solated adul t  rat ventricular myocytes. Endocrinology, 151 ,  4446-4454.  
264. Sunagawa, R . .  Nagamine. F., Murakami ,  K., Mirnura, G . ,  & Sakanashi, M .  
( 1 989) . Effects of  dobutamine and acetylchol ine on  perfused hearts isolated 
from streptozocin-induced diabetic rats . Arzneimille(forschung. , 39, 470-
474. 
265. uzuki .  M . .  Honda. K . .  Fukazawa. M . .  Ozawa. K. .  Hagita. H . .  Kawai. T. 
Takeda. M . .  Yata. T .  Kawai . M . .  Fukuzawa. T. Kobaya hi .  T. ato. T .  
Kawabe. Y . . & Ikeda. . ( 20 1 2) .  Tofogl iflozin. a Potent and Highly pecific 
odium/Gluco e Cotransporter 2 Inhibitor. Improves Glycemic Control in 
Diabetic Rat and Mice. Journal of Pharmacology and Experimental 
Therapeutic , 3-11 ,  692-70 l .  
266. zkudel ki .  T (_00 1 ). The mechanism of al loxan and streptozotocin action 
in B cel l  of the rat pancrea . Ph),siol Re , 50, 53 7-546. 
267.  Szkudel ki .  T (20 1 2 ) .  treptozotoc in-nicotinamide-induced diabetes in the 
rat. Characteri t ics of the experimental model .  Experimental Biology and 
Medicine, 23 , 48 1 -490. 
268. Tabibiazar. R. & Edelman. S. V. (2003 ) .  Si lent Ischemia in People With 
Diabetes: A Condition That Must Be Heard. Clinical Diabetes, 21 ,  5-9. 
269. Tahara. A.. Kurosaki .  E., Yokono, M . . Yamaj uku. D . .  Kihara. R.. 
Haya hizaki .  Y . .  Takasu. T. Imamura, M . ,  Li. Q.. Tomiyama. H . .  
Kobayashi. Y . .  oda. A . .  Sasamata. M . .  & Shibasaki .  M.  (20 1 4) .  Effects of 
sodium-glucose cotransporter 2 selective inhibitor ipragl iflozin on 
hyperglycaemia. ox idative stress. inflammation and l iver injury in  
streptozotocin-induced type 1 diabetic rats. Journal of Pharmacy and 
Pharmacology, 66, 975-987 .  
:270 .  Tahrani .  A .  A . .  Barnett. A.  H . .  & Bailey. C .  J .  (20 1 3 ) . SGL T inhibitors in 
management of diabetes. The Lancet Diabetes & Endocrinology, 1 ,  1 40-
1 5 1 .  
27 1 .  Takahashi. A . .  Can1acho, P . ,  Lechleiter, 1 .  D . .  & Herman, B .  ( 1 999). 
Measurement of intracel lular calcium. Physiological reviews, 79. 
272.  TAKI I .  H. , MATSUMOTO, K . .  KOMETANI .  T .  O KADA, S . .  & 
FUSHIKl ,  T. ( 1 997) .  Lowering Effect of Phenol ic  Glycosides on the Rise in 
Postprandial Glucose in Mice. Bioscience, Biotechnolog) , and Biochemistry, 
61 ,  1 53 1 - 1 53 5 .  
273 . the D ECODA Study Group (2003 ) .  Age- and Sex-Specific Pre alence of 
Diabetes and Impai red Glucose Regulation in 1 1  Asian Cohorts. Diabetes 
Care, 26, 1 770- 1 780. 
" ') - -' -
274.  The DECODE tudy Group ( 2003 ) .  ge- and ex- pecific Prevalences of 
Diab tes and Impaired Gluco e Regulation in 1 3  European Cohorts 1 .  
Diabetes Care, 26. 6 1 -69. 
275 .  The DI MO D Project Group (2006) .  Incidence and trends of childhood 
Type- l diabete \ orldwide 1 990- 1 999. Diabetic JvJedicine. 23, 85 7-866. 
276 .  Therapeutic Good Administration (20 1 3 ). Au tralian Public Assessment 
Reportfor Dapaglijlo::.in propanediol monohydrate . 
277.  Thorens. B .  & MueckJer. M .  (20 1 0) .  Glucose transp0l1ers in the 2 1 st 
Century.  American Journal of Phy iology-Endocrinology and AJetabolism. 
_ 9  . E I 4 1 -E I 45 .  
278 .  Thyge en. K. ,  Alpert, 1 .  S . .  Jaffe, A.  S . ,  Simoons, M .  L. ,  Chaitman, B .  R . ,  & 
White, H .  D .  ( 20 1 2 ) .  Third Universal Definition of Myocardial Infarction. 
Circl/lation. J 26. 2020-2035 .  
279 .  Tomlinson. K .  C . .  Gardiner, S .  M. ,  Hebden, R.  A. ,  & Bennett. T .  ( 1 992) .  
Functional consequences of streptozotocin- induced diabetes mell itus, with 
particular reference to the cardiovascular system. Pharmacological Reviews. 
-1-1. 1 03 - 1 50. 
280. Tsuj ihara. K . .  Hongu. M . .  aito, K . ,  I namasu, M . ,  Arakawa. K . .  Oku, A . ,  & 
Matsumoto. M .  ( 1 996). Na (+  )-glucose cotransporter inhibitors as 
antidiabetics. I .  Synthesis and pharmacological properties of 4'­
dehydroxyphlorizin derivatives based on a new concept. Chemical & 
pharmaceutical bulletin, -1-1. 1 1 74- 1 1 80 .  
28 1 .  Tsutsumi ,  c . .  Imagawa, A. ,  Ikegami.  H . ,  Makino, H . ,  Kobayashi ,  T . ,  
Hanafusa, T. ,  & on behalf of the Japan Diabetes Society Committee on Type 
( 20 1 2 ) .  Class I I  H LA genotype in fulminant type 1 diabetes: A nationwide 
SUT\'ey with reference to glutamic acid decarboxylase antibodies. Journal of 
Diabetes Investigation, 3. 62-69. 
282 .  Tucker. M iriam E. ( 1 -8-20 1 4 ) .  FDA Approves Dapagl iflozin ( Farxiga) for 
Type 2 Diabetes Treatment. http://www .medscape.com/viewarticle/8 1 8858 
233 
283 . Tung. L .  & Borderi . J .  R.  ( 1 992 ). nalysi of electric field timulation of 
ingle cardiac mu cle ce l ls .  Biophy iced Journal. 63. 3 7 1 -386. 
284. Tuomi .  T . .  antoro. . .  Caprio. . .  Cai. M . .  Weng. L & Groop. L .  ( 20 1 3 ). 
The many face of diabete : a disea e ith increasing heterogeneity. The 
Lancet. 
285 .  Tuomilehto. L Rastenyte. D .. BirkenhJger. W.  H . .  Thij s. L.. Antikainen. 
R.. Bulpitt. C. J . ,  Fletcher. A.  E . .  Forette. F .  L Goldhaber. A.. Palatini ,  P . .  
art i .  c . .  tae en. J .  A. ,  & Fagard. R .  ( 1 999). Effects of  Calcium-Channel 
B lockade in Older Pat ients with Diabetes and ystol ic  Hypertension. e11' 
England Journal o/.Hedicine, 3-10. 677-684 . 
286. Ushigome. E . .  Fukui, M., Hamaguchi .  M., Tanaka. T. .  Atsuta. H. ,  Ohnishi . 
M . .  Oda. Y . ,  Yanlazaki .  M. ,  Hasegawa, G . ,  & Nakamura. N .  ( 20 1 3 ). 
Beneficial effect of calc ium channel blockers on home blood pressure 
variabi l i t  in the morning in patients with typej::2 diabetes. Journal 0/ 
Diabetes im'e ligation, -I. 399-404. 
287 .  Vadlamudi .  R.  V . ,  Rodgers, R. L . .  & Me e i l l ,  J. H .  ( 1 982) .  The effect of 
chronic al loxan- and streptozotoc in-induced diabetes on isolated rat heart 
perfornlance. Can J Physiol Pharmacol. 60, 902-9 1 1 .  
288 .  Valentine. V .  ( 20 1 2) .  The Role of the Kidney and Sodium-Glucose 
Cotransporter-2 I nhibition in Diabetes Management. Clinical Diabetes, 30, 
1 5 1 - 1 55 .  
289.  Valentova, K . ,  Vrba. 1 . .  B ancfro va. M . .  lrichova, J . ,  Kr .  & , V .  ( 20 1 4) .  
I soquercitrin :  Pharmacology, toxicology, and metabolism. Food and 
Chemical Toxicology, 68, 267-282. 
290. V igl ietta. V . .  Kent. S .  C . .  Orban, T. ,  & Hafler. D .  A. (2002) .  GAD6S­
reactive T cel ls  are activated in  patients with autoimmune type l a  diabetes. 
The Journal o/Clinical investigation, J 09, 895-903 . 
29 1 .  V itor, R. F . .  Mota-Fi l ipe, H . ,  Teixeira, G . ,  Borges. C . ,  Rodrigues. A. 1 . ,  
Teixeira. A . ,  & Paulo, A.  ( 2004) .  Flavonoids o f  an extract o f  Pterospartum 
tridentatum showing endothel ial protection against oxidative inj ury. Journal 
0/ Efhnopharmacology, 93. 363-3 70. 
292. Wang. D. W. K. ( 1 99 � ) . bnormalit ies of K+ and Ca2, currents in  
entricular myocyt from rats with chronic diabetes. American Journal oj 
Phy iology - Hearl and ircuiator).' Phy iology, 269. H I 288-H I 296. 
293 . Wang. 1. G.. tae n. 1. A . .  Gong. L . .  & Liu. L .  (2000). Chinese trial on 
i olated ystolic h perten ion in the elderly .  ArcMves oj internal medicine, 
1 60, 2 1 1 -220. 
294. Wang. J . .  un. G. x., Yu. L.. Wu. F .  A. ,  & Guo. X .  J. (20 1 3 ) . Enhancement 
of the selective enzymatic biotransformation of rutin to isoquercitrin using 
an ionic l iquid as a co-solvent . Biore ource Technology, 1 2  , ] 56- 1 63 .  
295 . Wang. R .  . .  Bouwens, L . .  & KlOppel. G .  ( 1 994) .  Beta-cel l  prol iferation i n  
normal and streptozotocin-treated ne\\"born rat : site. dynamics and capacity. 
Diabetologia, 3 �, 1 088- 1 096. 
296. Wang. R. . . Bouwens.  L . .  & KlOppel .  G .  ( 1 996). Beta-cel l  growth in 
adolescent and adult rats treated with streptozotocin during the neonatal 
period. Diabetologia. 39. 548-5 57. 
297. Warner I nstrlm1ents (20 1 4) .  Perfusion Chamber with Field Stimulation ( RC-
49MF ) .  http ://w\\w.warneronl ine.comiproduct info.cfm?id=73 1 
298. Wei. M . .  Ong. L . .  Smith. M .  T . .  Ross. F .  B . .  Schmid. K . .  Hoe . A. J . ,  
Burstow. D . .  & Brown. L .  (2003 ) .  The streptozotocin-diabetic rat as  a model 
of the chrome complications of human diabetes. Heart, lung and circulation. 
1 2, 4-+-50.  
299.  Wei l .  R . .  ozawa. M. ,  Koss, M . , Weber. c..  Reemtsma. K . ,  & McIntosh. R. 
( 1 976). The kidney in streptozotoc in diabetic rats . Morphologic, 
u ltrastructural .  and function studies. Archives oj pathology & laboratory 
medicine, 1 00, 3 7-49. 
300. Whitaker. R.  H. ( 20 1 4) .  Anatomy of the heart . Medicine. -12, 406-408 .  
3 0 1 . Wi1cken, D .  E .  L .  (20 1 4) .  Physiology of the n01111al heart . . Medicine, -12, 
409-4 1 2 . 
235 
302. Wood. C o o  i l l iam . c . .  & Waldron, G .  1 .  (2004) .  Patch clamping by 
numbers. Drug Di co\'ery Today, 9 .  434-44 1 .  
303 .  Wood. I .  . & Trayhum. P. ( 2003 ) .  Gluco e transporters (GLUT and 
GL T) :  expanded fami l ies of sugar transport proteins. Briti h JOZll'l1al of 
Nutrition, 9, 3-9. 
304.  oodcock, E .  A.  & Matkovich, . 1 .  (2005) .  Cardiomyocytes structure, 
function and as ociated pathologies. The Infernational Journal o{ 
Biochemi try & Cell Biology, ]':, 1 746- ] 75 1 .  
305 .  orld Health Organization ( 1 999). Definition, Diagnosis and C lassification 
of Diabetes Mell itus and its Complications. Part 1 :  Diagnosis and 
CIa sification of Diabetes Mel l i tus. Genem: World Health Organi::ation .  
306. World Health Organization (2006). Definition and diagnosis of diabetes 
mel litu and intermediate hyperglycemia: report of a WHO/I DF 
consultation. Genera: World Healfh Organi::atiol1, 1 -50. 
307. World Health Organization (20 ] 1 ) . Use of glycated haemoglobin (HbA l c ) 
i n  the diagnosis of diabetes mel l i tus: abbreviated report of a WHO 
consultation. Geneva: T f  orld Health Organi::ation.  
308 .  World Health Organization (20 1 1 ) . Global status report on 
noncommunicable diseases 20 1 0. Genew: World Health Organization. 
309. Wright E .  M .  ( 1 998) .  1 .  Glucose Galactose Malabsorption. American 
Journal of Physiology - Gasfrointestinal and Liver Phy iology, 2 75, G879-
G882.  
3 1 0 . Wright E .  M .  (20 1 3 ) . Glucose transport fanl i l ies SLC5 and SLC50. 
Alolecular aspects of medicine, 3-1, 1 83- 1 96.  
3 1 1 .  Xu, Y . ,  Tao, Y.,  Cheung, L .  S . ,  Fan, C. ,  Chen, L .  Q. ,  Xu, S . ,  Perry, K. ,  
Frommer, W.  B . ,  & Feng, L .  ( 20 1 4) .  Structures of bacterial homologues of 
SWEET transporters in two distinct confomlations. Nature, advance online 
publication . 
236 
3 1 2 . uan. Y .  H.. Hu. Y. BOo Chen. L. Q.. 0 o. DOo Ducat. D.  c. .  Hou. B.  HOo & 
Frommer, W.  B. (20 1 3 ) . Functional role of oligomerization for bacterial and 
plant EET ugar tran porter fami l  . Pro eedings of (he National 
Academy ofScien e . 1 1 0, E3685- 3694 . 
3 1 3 . Yara . . .  Ugur. M O o  Ozdemir. O o  GurdaL H .. Pural i .  N . .  Lacampagne. A .  
Va sort. G O o  & Turan. B.  (2005 ) .  Effects of Diabetes on  Ryanodine Receptor 
Ca Relea e Channel ( RyR2 )  and Ca2+ Homeostasis in Rat Heart. Diabete , 
5-1. 3082-3088 .  
3 1 4 . Yin .  D . ,  Tao. L Lee, D.  D . .  hen, J . .  Hara. M . .  Lopez, J . ,  Kuznetsov, A .  
Phil ip on, L. H . .  & Chong. A . ( 2006) .  Recovery of Is let B-Cel J  Function 
in  treptozotocin- Induced Diabetic Mice: An Indirect Role for the Spleen . 
Diabete , 55, 3256-3263 . 
3 1 5 . Yoo. K. H .  (2006 . MATERIALS AND M ETHODS. In  Contractile 
Behavior of Field Stimulated Left J 'entricular Afyocytes from Biop y 
Sample o/the Anterior and Remote Regions of the Swine Heart (pp. 48-64). 
tate n i\'ersity of ew York at Buffalo .  
3 1 6 . Young. L . .  Coven, D. ,  & Russel l ,  R. ( 2000) .  Cel lular and molecular 
regulation of cardiac glucose transport. J ue! Cardiol, 7, 267-276. 
3 l 7 . Young. M .  E . .  Wi lson. C .  R . .  Razeghi. P . ,  Guthrie, P. H .. & Taegtmeyer. H .  
(2002). Alterations o f  the Circadian C lock in the Heart by Streptozotoc in­
induced Diabetes. Journal of Afolecular and Cellular Cardiology, 3-1, 223-
23 l .  
3 1 8 . Zahradnik, r . .  Minarovic. I . . & Zahradnfkova, A .  (2008 ). Inh ibition of the 
Cardiac L-Type Calcium Channel Current by Antidepressant Dmgs. Journal 
of Pharmacology and Experimental Therapeutics, 32-1, 977-984. 
3 1 9 . Zambrowicz, B . .  Freiman, L Brown, P .  M., Frazier, K .  S., Turnage, A . ,  
Bronner, L Ruff. D . ,  Shadoan, M O o  Banks, P . ,  Mseeh, F . ,  Rawlins, D .  B . ,  
Goodvvin, N .  c . ,  Mabon, R . ,  Harrison, B .  A ,  Wilson. A ,  Sands, A . .  & 
Powel l ,  D .  R. ( 20 1 2 ) .  L X42 1 L a Dual SGLT l ISGLT2 I nhibitor. Improved 
Glycemic Control  in Patients With Type 2 Diabetes in a Randomized, 
Placebo-Control led Trial . Clin Pharmacol Ther, 92, 1 5 8- 1 69. 
237 
320. Zhang. B .  I .  & annaju 1. F. ( 2000) .  Diurnal rhythms of blood pressure. 
heart rat . and locomotor acti ity in adult and old male Wistar rats. 
Ph), ;olog)' & Behavior, -0. 375-380.  
32 1 .  Zhang, J . ,  Liang, R . .  Wang. L . .  Yan, R. ,  Hou, R. ,  Gao. . . & Yang. B .  
(20 1 3 ) .  Effect of an  aqueous extract of Crataegus pinnatifida Bge .  var. 
major .E .Br. fru it on experimental atherosc lerosis in rats. J01lrnal of 
Elhnopharmac% gy, 1-1  . 563 -569. 
", _2.  Zhang, X.-Q. . & J ianl iang Carl. L .  (2002) .  Effects of sprint training on 
contracti l ity and [Ca2+ J i  transients in adult rat myocytes. Journal of Applied 
Ph), i% g)" 93, 1 3 1 0- 1 3 1 7 . 
323 .  Zhao, F.  Q. & Keating. A.  F .  (2007).  Functional propert ies and genomics of  
glucose transporters. Curren! genol17ics. 8, 1 1 3 .  
"' 24.  Zhao. Y. ,  Inayat. S . .  Dikin, D .  A. .  Singer, 1 .  H..  Ruoff, R. S . ,  & Troy. 1 .  B. 
(2008) .  Patch c lamp technique: Review of the current state of the art and 
potential contributions from nanoengineering. Proceedings of the In tilulion 
of '\fechanica/ Engineer , Part : Journal of Tanoengineering and 
Nanos), tem , 222, 1 - 1 1 .  
325 .  Zhao. Y ,  Xu, J . ,  Gong, J . .  & Qian, L .  (2009) .  L -type calcium channel 
current up-regUlation by chronic stress is associated with increased alpha- I  c 
subunit expression in  rat ventricular myocytes. Cell Stress and Chaperones, 
1 -1. 33 -4 1 . 
326. Zheng. M . .  Hou. R. ,  & Xiao. R. P. (2004) .  Acidosis- induced p38 MAPK 
activation and its implication in  regulation of cardiac contracti l ity. Acta 
PharmacoI. Sin. . 25, 1 299- 1 305 .  
327 .  Zhou. L . ,  Cryan. E .  V . ,  D'Andrea, M .  R . ,  Belkowski ,  S . ,  Conway. B .  R . .  & 
Demarest. K .  T .  (2003 ) .  Human cardiomyocytes express high level of 
a+/glucose cotransporter 1 (SGL T 1 ). Journal of cellular biochemistry, 90, 
339-346. 
328. Zimmer. H. G .  ( 1 998) .  The Isolated Perfused Heart and Its Pioneers. 
Physiology, 1 3, 203-2 1 0 . 
238 
Cha pter 9 :  Conference Pre entat ions and Journal  Pub l ication 
9. 1 .  Conference Pre entat ion 
Hamouda . .  Qure hi M. . .  Sydorenko Y . .  Howarth F.  C.  (20 1 4 ) .  odium-
gluco e co-tran pOl1er inhibitor reduce the ampl itude of shortening and Ca2+ 
tran ient in \ entricular myocyte from treptozotoc in-induced diabetic rat. Physiology 
20 1 4. London. England. 
9.2. Journa l  Pu bl icat ion 
Hamouda, " ydorenko. Y. ,  Qureshi .  M.  A. ,  Alkaabi .  J .  M . ,  Oz. M . .  & Howarth. 
F. c. (20 1 4) .  Dapagl iflozin reduce the amplitude of shortening and Ca2+ transient in  
ventricular myoC)1es from streptozotocin-induced diabetic rats. Molecular and 
Cellular Biochemistry. 1 - 1 2  .
H amouda. . .  Qure hi. M. A . .  Alkaabi,  1. M. ,  Oz. M . •  & Howarth. F.  C. (20 1 4) .  
Reduction In  the ampl i tude of shortening and Ca2+ transient by  Phlorizin and 
Quercetin-3-0-Glucoside In entricular myocytes from streptozotocin-induced 
diabetic rats [ I n  process] . 
